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0.0 Abbreviations
Table 0.1 Abbreviations
BASE Bovine atypical spongiform encephalopathy
BSE Bovine spongiform encephalopathy
CJD Creutzfeldt-Jakob disease
CNS Central nervous system
CSF Cerebrospinal fluid
CT Computed tomography
CWD Chronic wasting disease
EEG Electro-encephalogram
DLB Dementia with Lewy Bodies
FFI Fatal familial insomnia
FHx Family history
FLAIR Fluid attenuated inverse recovery
gCJD Genetic Creutzfeldt-Jakob disease
gPD Genetic prion disease
GSSS Gerstmann-Straussler-Scheinker syndrome
gTSE Genetic transmissible spongiform encephalopathy
iCJD Iatrogenic Creutzfeldt-Jakob disease
IHC Immunohistochemistry
MBM Meat and bone meal
MM Methionine homozygosity encoded by codon 129 of
PRNP
MRI Magnetic resonance imaging
MV Methionine / valine heterozygosity encoded by codon 129
ofPRNP
NA Not applicable
NCJDRSU National Creutzfeldt-Jakob disease research and
surveillance unit
OPRI Octapeptide repeat insertion
PM Post-mortem
PRNP Prion protein gene
PrPc The normal cellular isoform of the prion protein
PrpKes The protease-resistant core fragment of PrP c
PrPSc The misfolded, pathogenic form of the prion protein
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Table 0.1 (continued) Abbreviations
pTau Phosphorylated tau protein
sCJD Sporadic Creutzfeldt-Jakob disease
SFI Sporadic fatal insomnia
SNP Single nucleotide polymorphism
TME Transmissible mink encephalopathy
TSE Transmissible spongiform encephalopathy
vCJD Variant Creutzfeldt-Jakob disease
VPSP Variably protease sensitive prionopathy
vv Valine homozygosity encoded by codon 129 of PRNP
Table 0.2 Definitions
Term Definition
Mutation A genetic change (insertion or point mutation) not seen in
healthy populations (excluding relatives of those with
genetic prion disease) and causative of disease.
Polymorphism A genetic locus at which variation is seen in normal




Complete sequencing of the PRNP gene to seek any
genetic polymorphisms or mutations (as opposed to




Human prion diseases are progressive, fatal neurological conditions linked to
conformational changes in the structure of the prion protein. Prion diseases may be
sporadic (sporadic Creutzfeldt-Jakob disease or sCJD, Sporadic Fatal Insomnia),
acquired (variant CJD, iatrogenic CJD, kuru) or genetic (genetic prion disease, gPD).
gPD is due to a disease-specific point or octapeptide repeat insertion (OPRI)
mutation in the prion protein gene (PRNP). Numerous different PRNP mutations
have been described. In some cases of gPD the phenotype may closely resemble that
of sCJD, and it can be impossible to distinguish sporadic from genetic cases without
genetic screening. The clinico-pathological phenotype of gPD is highly variable,
both between different mutations and even within families carrying the same
mutation. This variability can be partly explained by a polymorphism at codon 129
of PRNP. Codon 129 encodes either methionine or valine, and the status of both the
mutated and wild-type alleles may influence disease susceptibility and phenotype.
Codon 129 may also affect the manifestations of sporadic and acquired prion
disease. Homozygosity for methionine at codon 129 is over-represented in both
sporadic CJD (sCJD) and variant CJD (vCJD); indeed all definite or probable clinical
cases of vCJD seen to date have been homozygous for methionine. Other
polymorphisms ofPRNP have been found in a small number of patients with
sporadic and variant CJD. The significance of these polymorphisms has not been
fully investigated. It is likely that other, as yet unidentified, genetic factors also play
a role in influencing susceptibility to prion diseases and the clinico-pathological
phenotype. A recent genome wide association study of vCJD patients found codon
129 to be the main genetic risk factor for vCJD, but did identify other candidate loci
that may contribute to disease susceptibility. Work is in progress to carry out
genomic screens for other, novel polymorphisms in 309 patients with sCJD and 118
patients with vCJD.
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Aims of this MD Thesis
The aims of the work described in this MD thesis are:
1) To review all cases of gPD on the database of the National Creutzfeldt-Jakob
Disease Research and Surveillance Unit. The clinico-pathological phenotype,
investigative findings and family history will be reviewed in detail. The findings will
be compared with those cases of gPD previously described, in particular with cases
seen in other European countries. The incidence and prevalence of these diseases in
the UK will also be assessed.
2) To review cases of sCJD and vCJD with novel PRNP polymorphisms of
uncertain significance. The clinico-pathological phenotype will be reviewed in detail




159 cases of gPD were identified between 1970 and 2009, representing 7.8%
of the prion disease (of any type) cases referred to the NCJDRSU over this time
period. 17 different PRNP haplotypes were identified: P102L-129M, P105L-129V,
A117V-129V, S132I-129M, Y163X, D167G-129M, D178N-129M, D178N-129V,
E200K-129M, D202N-129V, V210I-129M, Q212P-129M, 2-OPRI, 4-OPRI, 5-
OPRI, 6-OPRI, 7-OPRI. The clinicopathological phenotypes were highly variable
and often difficult to distinguish from sCJD. The highest number of cases was caused
by the 6-OPRI, most of which belonged to a single kindred.
Several cases in the 4-OPRI group were found to share an additional risk
allele, rsl029273C. In may be that this mutation is not pathogenic unless this risk
allele is also present. This raises the possibility that other as yet unidentified genetic
risk factors exist which influence gPD susceptibility and clinicopathological
phenotype.
Overall 61.4% of cases tested had a positive cerebrospinal fluid (CSF)
14-3-3, 90.0% an elevated SI00b, 23.1% had Magnetic Resonance Imaging (MRI) of
the brain showing basal ganglia or cortical high signal, and 18.1% had an
electroencephalogram (EEG) showing triphasic periodic complexes. A positive
family history of prion disease was present in 57.9% of cases.
Discussion
The range of point mutations and OPRI seen in the UK is considerable, but
the majority of cases were due to 6-OPRI, E200K, or PI 02L. The UK differs from
the rest of the world in that E200K is not the commonest mutation, due to the
presence of a large British kindred with the 6-OPRI. Even within the larger kindreds,
the clinicopathological phenotype remained very variable. Some distinctive features
which may act as pointers towards gPD were found, such as a linear pattern of PrPSc
deposition in the cerebellum seen in E200K-129M cases. Analysing the data in the
smaller groups should be done with caution, and further large international studies
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are needed in order to truly determine the influence of factors such as codon 129
status.
As with other forms of prion disease, there is an excess of individuals with
methionine homozygosity at codon 129. It is unclear whether or not PRNP mutations
in cis with valine at codon 129 will result in prion disease at an older age or with a
different phenotype, or if these are not actually pathogenic in this genetic context. In
the case of 4-OPRI, it appears that an additional risk allele is required for the
development of disease, and it remains to be seen if other additional genetic factors
will be found to influence disease susceptibility and phenotype.
A relatively small percentage of cases had EEGs showing periodic triphasic
waves, or basal ganglia or cortical high signal on MRI. CSF SI00b was more
sensitive than 14-3-3, the reverse of the pattern seen in sCJD. A pattern of a negative
14-3-3 and a very high SI00b should lead to suspicions of gPD.
The current diagnostic criteria for gPD are relatively strict, and may exclude
some individuals who have neuropathologically confirmed prion disease (without
PRNP genotyping) and several second degree relatives with gPD. This is a potential
problem, especially as the neuropathological appearances cannot be relied upon to
distinguish sporadic from genetic disease. Particular attention should be paid to the
family history and any subtle unusual neuropathological appearances to try and
reduce the risk of gPD cases being missed. In conclusion, gPD remains a difficult
condition to diagnose and study. Large systematic collaborative studies are essential





I.I A Historical Overview of Prion Disease
Prion diseases are a group of neurodegenerative diseases affecting various
mammalian species. They are also known as Transmissible Spongiform
Encephalopathies (TSE). Many prion diseases have now been experimentally
transmitted to various animal species but the host range of naturally occurring
diseases is more constrained"0. Species affected outwith the laboratory include
humans, sheep, mink, elk, mule deer and, in recent decades, cattle343,201. It is now
thought that acquired prion diseases are caused by an infectious agent known as a
prion (for 'proteinaceous infectious particle')313 , but the exact nature of prions
remains unclear.
Prion diseases are unusual for two reasons. First, prions appear to lack any
nucleic acid but are able to replicate, and second prion diseases can be sporadic or
hereditary but also retain infectious properties110. Prion diseases have been spread by
both medical and veterinary procedures, and epidemics have arisen via the
107 42 378
cannibalistic consumption of infectious material in both humans and cattle ' '
Unfortunately in the latter case we have witnessed the ability ofprions to cross
barriers between species; consumption ofmeat from cattle infected with Bovine
Spongiform Encephalopathy (BSE) gave rise the new zoonosis known as 'variant
CJD' (vCJD) in humans387.
Genetic prion diseases were first described almost a hundred years ago, when
neurodegenerative illness characterised by ataxia and dementia was observed to
afflict families across multiple generations. It is now known that this was due to
mutations of the gene which encodes for the normal cellular isoform of the prion
protein (PRNP); although typically autosomal dominant, cases of gPD frequently
occur in the absence of any history of affected relatives.
Here I will briefly summarise developments in prion disease research from
the 18th century to the present day, concentrating on human and in particular genetic
forms of disease.
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I.II Scrapie: The Prototypic Prion Disease
In the mid 18lh century, descriptions emerged from Britain and continental
Europe of a new, fatal disease of sheep, which caused animals to bite and scratch
themselves and to develop gait abnormalities. These symptoms were the source of
the several different disease names: 'scrapie' in England; 'tremblante' ('trembling') in
France;'traberkrankheit' ('trotting disease') in Germany and 'ridd ('tremor') in
Iceland 334. Wool was a vital part of the British economy at the time and the financial
impact of scrapie was so severe that the topic was debated in the House of
36Commons . However scrapie was not viewed as a threat to human health. The
description of Leopoldt in 1750 neatly summarises the clinical manifestations:
'Occasionally, some sheep contract scrapie, an illness recognizable in the
recumbency of the animal. It nibbles at its claws andfeet and scratches its back
against posts. It ceases to prosper, looses appetite andfinally gets weary. They drag
themselves for a long time, are consumed more and more, and in the end, they are
doomed to death. Animals that fall ill with this distemper won't recover. Therefore
the very best a shepherd can do who has caught sight ofan animal that hasfallen ill
with scrapie, is to cull the animal and slaughter itfor the nobleman's servants. Thus,
it is advisable for a shepherd to immediately separate such an animalfrom the
healthy life-stock, as this disease is contagious and can cause great damage to the
flock.'
Leopoldt 1750; translated in 334.
Scrapie is primarily a disease of sheep, but may also spread to goats and
moufflon394. It is highly contagious and once introduced into a flock frequently
becomes endemic, resulting in an extensive geographical range418'85.
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I.III Creutzfeldt and Jakob
The archetypal human prion disease is CJD, named after the European
neurologists responsible for the earliest known descriptions of the disease.
Hans Gerhard Creutzfeldt was a German physician with expertise in
neuropathology, neurology and psychiatry. He also earned the Iron Cross (First and
Second class) for his services as Staff Surgeon of the German Naval Reserve during
the First World War. In 1939 he became the professor and director of the Kiel
University psychiatric and neurological department, where he continued to work
until his retirement in 1953 when he moved to Munich to pursue scientific research;
his time there was however most notable for his denunciation of the war criminal
Werner Heyde, director of the medical division of the T4 program, who was
practicing in Munich under a pseudonym. (Creutzfeldt was probably aware of his
true identity for several years but alerted the authorities after becoming embroiled in
a dispute with him over a medicolegal forensic report). In 1955 Creutzfeldt became
an Honorary Senator of the Christian Albrecht University; in 1959 the Kiel Faculty
commemorated the Golden Jubilee of his doctorate. Creutzfeldt died in Munich on
the 30th of December 1964 393.
Alfons Maria Jakob trained in psychiatry under such luminaries as Kraepelin,
Nissl and Alzheimer, before habituating in neurology at the University of Hamburg.
Jakob contributed extensively to many areas of neurology and neuropathology,
producing monologues on the cerebellum and extrapyramidal system. He also
studied neurosyphilis and the effects ofmalaria therapy, a cutting edge treatment at
the time. He died at the age of 47 years having developed staphylococcal septicaemia
as a consequence of chronic osteomyelitis 332.
I.IV Creutzfeldt-Jakoh Disease
In 1913 Creutzfeldt first met Bertha E, the patient who would be the subject
of his seminal 1920 publication. Bertha E. was described as having symptoms of a
'noticeably awkward gait', 'childish and stubborn nature' and motor spasms and
hyperalgesia, with onset at age 16 years followed by a progressive decline to a state
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of severe dementia accompanied by mutism, muscular twitches, spasticity and
seizures. She died in status epilepticus at 22 years of age. On neuropathological
examination there was parenchymal disintegration with vascular involvement,
neuronophagy and glial and vascular proliferation and diffuse nerve tissue
degeneration. There was a family history ofmental impairment in 2 siblings.
Creutzfeldt concluded that the aetiology of the condition was obscure 76-24().
In 1921 Alfons Jakob published 3 cases ofwhat he termed 'spastic
pseudosclerosis'; he subsequently added a further 2 cases to the literature179'178. Jakob
described a fatal illness characterized by early personality change followed by
cognitive decline and hallucinations, accompanied by a progressive decline in
mobility, speech impairment and involuntary movements. Pathological changes of
'encephalomyelopathy with disseminated foci of degeneration' were seen240. Jakob
linked his cases to the earlier description of Bertha E. by Creutzfeldt and the term
'Creutzfeldt-Jakob disease' entered the literature shortly afterwards. However it was
to be some decades before the detailed phenotypical and pathological characteristics
of CJD were fully delineated.
I.V Early Descriptions of Familial Prion Diseases
In the early years of the 20th century there was considerable interest in
hereditary diseases, in particular familial forms of neurological and psychiatric
illness. At the 1912 meeting of the Viennese Neurological and Psychiatric
Association a report of a family afflicted by a hereditary neurodegenerative disease
was presented. This family was subsequently reported in greater clinico-pathological
detail first by Gerstmann in 1928 and then by Gerstmann, Straussler and Scheinker in
861936 . Affected individuals developed a progressive cerebellar syndrome
accompanied by cognitive decline, with a mean age of onset of 46 years and a mean
disease duration of 6 years. Pathologically degeneration of the spinocerebellar and
corticospinal tracts was seen, with 'peculiar inclusions of a foreign substance'
described as being roughly sphererical inclusions of a bluish-green colour when
viewed after Nissl staining241. An eponymous label of Gerstmann-Straussler-
Scheinker syndrome (GSSS) was appended and numerous further case reports
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appeared in various countries. As early as 1940 links were made with CJD on clinical
grounds although the pathology was recognized as being distinct241.
Reports of familial CJD also appeared in the literature around the same time.
196 2^8
The 'Backer' family of Kirschbaum and Meggendorf is the earliest example ' ; the
importance of such families as being affected by a disease that is distinct from sCJD
was not appreciated for some decades.
It was not until the molecular biology breakthroughs ofWatson and Crick37"
and the subsequent explosion of knowledge regarding the intricacies of genetics and
PRNP in particular, that GSSS and familial CJD were linked to genetic mutations.
Whether or not these mutations are actually pathogenic in nature or give rise to a
susceptibility to an external agent remains highly controversial.
I.VI The Transmissible Nature of Prion Diseases
In the early 1930s brain tissue from sheep with scrapie was shown to be
infectious; this was demonstrated both intentionally in the laboratory and
unintentionally in the field. A vaccine for the ovine disease louping-ill was
developed in the 1930s using the brain, spinal cord and spleen of donor sheep. After
4 years of trials the vaccine was released for general use; unfortunately 2 and a half
years later animals which had received one particular batch began to develop scrapie.
In some cases scrapie appeared in breeds of sheep which had hitherto never appeared
to be susceptible to the disease. Subsequent investigations revealed that scrapie had
also appeared in flocks from which donor sheep had been taken; it was concluded
that some donor animals had been incubating scrapie during vaccine production. This
was then confirmed experimentally, with both brain and spinal cord being shown to
be infectious, with long incubation times. Intracerebral inoculation was a more
efficient and faster route of transmission that the subcutaneous one. The agent was
noted to be small in size and resistant to formalin140. At the same time Cuille and
Chelle had been conducting the experimental inoculation of sheep with central
nervous system (CNS) tissue from animals with scrapie and successfully transmitted
the disease78'77'79- The louping-ill incident demonstrated the formalin resistance of the
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infectious agent and is the first known case of'iatrogenic' transmission of prion
disease.
I.VII Defining A Disease
During the first half of the 20th century the debate over the definition and
indeed the very existence ofCJD continued. Various competing terminologies were
in use at the time, and many of the early case reports ofCJD would not be classified
as such using modern criteria. Jakob himself used the term 'spastic pseudo-sclerosis',
whilst others favoured 'disseminated encephalomyelopathy' or 'cortico-pallido-spinal
m so o/in •
degeneration' >s ■ . There was considerable debate as to whether or not CJD was
'a pathological entity, or ... a heterogeneous collection of presenile cerebral
degenerations' 43. The classic clinical triad of dementia, myoclonus and increasing
immobility and the neuropathological triad of spongiform change, neuronal loss and
astrocytosis were first described by Nevin et al. in I960275. The term 'sporadic CJD'
is used to describe cases ofCJD occurring spontaneously, with no underlying
iatrogenic or genetic cause. The distinctive clinical subtypes of sCJD are
eponymously known by their earliest descriptors, Heidenhain, Brownell and
Oppenheimer. Heidenhain's syndrome refers to those presenting with cortical
blindness 263-158 whilst Brownell-Oppenheimer syndrome describes those with a
predominantly cerebellar onset43 .
I.VIII Kuru: The Missing Link?
The description of kuru on the island of Papua New Guinea in 1957 by
Gajdusek and Zigas heralded a resurgence of interest in the spongiform
encephalopathies107'112'7'6. Kuru is characterised by progressive cerebellar ataxia,
• • 11*7 11K 1 11 1G8
with dementia being conspicuous by its late onset or absence ' ' ' . Amyloid
plaques containing abnormal prion protein (PrPSc) are seen in the cerebellum,
accompanied by cerebellar atrophy, generalised astrocytosis and neuronal
degeneration, with relatively mild spongiform change 200-372.
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Kuru affected the Fore tribe, who believed that the soul of a deceased person
could only pass to the afterlife if the body was entirely consumed by female relatives
(with male children occasionally and adult males rarely participating) . These
mortuary feasts resulted in a prion disease epidemic, thought to have originated in an
individual who died of sCJD; this theory is supported by molecular and biological
similarities between kuru and sCJD372. The incidence of kuru rapidly declined after
the outlawing ofmortuary feasts in 1950. The last known patient died in 2005287.
Polymorphisms of PRNP have been shown to exert an influence on kuru
susceptibility. Women who participated in multiple mortuary feasts but did not
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develop kuru are usually heterozygotes at codon 129 ; as were most of the patients
who developed kuru after incubation periods of several decades70. Recently another
PRNP locus, codon 127, has also been shown to influence susceptibility.
In 1959 similarities in the neuropathological appearances of kuru and scrapie
were identified147'148, leading to increased efforts to transmit kuru to experimental
animals, with researchers crucially allowing for much longer incubation times. In
1966 the first successful transmission of kuru to chimpanzees was reported109 "1'22.
This was quickly followed by the transmission of sCJD, gCJD and GSSS to
primates129'110,128. These findings contributed a new, defining characteristic to CJD,
GSSS, kuru and scrapie: not only are they spongiform encephalopathies but they are
potentially transmissible, clearly differentiating them from other neurodegenerative
diseases.
I.IX Emerging Animal Prion Diseases
Transmissible mink encephalopathy (TME) first appeared in fur farms in
Wisconsin and Minnesota in 194745'154 154>239 jt ^as nQW been rep0rted in Canada,
Finland, Germany and Russia395. Animals display an insidious onset of behavioural
change with increased aggression and hyperaesthesia, followed by hind limb ataxia,
self-mutilation, terminal blindness and coma154'239. TME is highly contagious and an
outbreak usually results in the death of all the animals on a farm. Neuronal
degeneration and astrocytosis occur, accompanied by extensive neuropil
vacuolation91'343. The origins and routes of transmission of TME are unclear; feed
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containing prion-contaminated animal offal is considered to be the most likely
culprit45'238'343'239'321. Disease control concentrates on the avoidance of high-risk
offal; given the paucity of recent outbreaks this approach appears to be effective.
Chronic wasting disease (CWD) is a fatal disease of farmed and wild
Cervidae first identified in Colorado in 19673 '342'391. Behavioural change occurs
followed by weight loss, teeth grinding, excessive salivation, polydipsia and
polyuria. Widespread spongiform change is seen accompanied by astrocytosis,
neuronal degeneration and intracytoplasmic vacuolation, with lesion distribution
varying between species144'145.Extensive PrPSc is found in the CNS and extraneural
tissues; the distribution differs between species, as does the influence of various
codons of PRNP342. Transmission routes are unclear, but CWD is certainly
contagious and impossible to eradicate even if all animals in an affected area are
culled and the land decontaminated264. There has been no evidence of transmission to
humans 247 but research continues to assess CWD's zoonotic potential1'204.
Prion disease in cattle is discussed later in the introduction.
I.X The Unconventional Nature of the Infectious Agent
Although Leopoldt referred to scrapie as being a contagious disease in 1750
the infectious nature of scrapie was not widely accepted by the scientific
establishment until the transmission studies ofGordon and Chelle140'80. They noted
the infectious agent to be small, filterable and also resistant to treatment with
formalin. It was concluded at the time that a virus was responsible; later the concept
of a 'slow virus' was introduced to highlight the long incubation periods. This term
was then modified to 'unconventional virus' to reflect the agent's extreme resistance
to radiation, heat and formalin140'4'5'130. The fact that infectivity persisted following
procedures which would be expected to degrade nucleic acid led to further
speculation regarding the nature of the infectious agent.
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I.XI Purifying Prions
Early work attempting to isolate and characterize the infectious agent was
hampered by difficulties in purification and the long incubation periods encountered
when transmitting scrapie to mice. The use of Syrian Golden hamsters proved to be a
significant development because of the shorter incubation periods of scrapie in them.
Prusiner and Bolton speeded up laboratory experiments even further by developing a
incubation time assay which greatly reduced the number of experimental animals
32 •needed for a single experiment . This paved the way for the purification of a protein
associated with scrapie infectivity of 27,000 to 30,000 Daltons molecular weight,
which was present only in the brains of animals infected with scrapie and was
resistant to digestion with proteinase K32"315.
I.XII The Prion Protein Hypothesis
Prusiner hypothesised that the scrapie agent was not a virus but was a 'novel
infectious entity' based on its aforementioned resistance to procedures which
inactivate nucleic acids and its small size. He coined the acronym 'prion' to
demonstrate the /iroteinaceous and infectious nature of the agent313. The prion
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protein was subsequently found to be encoded by a host cellular gene , on the short
arm of chromosome 20 in humans (PRNP)347. Genetic variation at PRNP is very
important. In this thesis the term 'polymorphism' is used to refer to a genetic locus at
which normal individuals display genetic variation, which may influence disease
susceptibility or phenotype, but does not cause disease. The term 'mutation' is used to
refer to genetic abnormalities which are thought to be causative of genetic disease,
and not found in healthy populations.
The primary structure of the prion protein is believed to remain unchanged in
health and disease; its pathogenic properties arise from a change in the three
dimensional structure. The normal cellular isoform of the prion protein (PrP ) is
mostly an alpha-helical structure. This undergoes a conformational change to a
structure rich in beta-sheets (the pathogenic prion protein PrPSc) which is deposited
extracellularly as amyloid plaques or concentrated intracellularly290'35 . This
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transition from a-helical to P-sheet appears to be a central event in prion propagation
and pathogenesis. The exact mechanism by which it occurs remains obscure. There is
still controversy as to whether prions are purely proteins, or whether they include
some hitherto undetectable nucleic acid. Similarly the pathogenesis of gPD causes
argument; are these solely due to additional mutations ofPRNP or are there more
complex gene-environmental factors?
I.XIII Sporadic CJD
The majority of cases of human prion disease fall into the category of sCJD,
which has a worldwide annual mortality of 0.5 to 1.5 cases per million population
-jQr
per year . Despite large scale epidemiological studies the aetiology remains
obscure. The encoding of methionine or valine at codon 129 ofPRNP appears to
have a major influence on disease susceptibility and phenotype.
The mean age at onset is 65 years, with an extensive range from 14 to 92
years. From symptom onset the median disease duration is short, 4.5 months, with a
mean of 8 months, although 4 percent of patients live for more than 2 years395.
sCJD is typified by a triad of rapidly progressive dementia, myoclonus and
periodic triphasic complexes on the electro-encephalogram (EEG). The commonest
presenting complaint is of cognitive decline. Less frequently there is a purely
cerebellar43 or visual onsetl:>8, or, rarely, presentation with other features such as
stroke-like illness. Occasionally there are non-specific prodromal symptoms.
Personality and behavioural change are often seen, as are psychiatric features such as
depression and anxiety. Visual symptoms include visual blurring or loss, diplopia or
field defects, and may progress to cortical blindness. Visual hallucinations and
misperceptions are common. As the disease progresses dementia becomes a universal
finding, and 80% develop myoclonus395.
Frequent examination findings are pyramidal, extrapyramidal and cerebellar
signs, paratonic rigidity, primitive reflexes and cortical blindness. Myoclonus and a
startle response may occur in response to auditory, tactile or visual stimuli.
Terminally the patient becomes akinetic and mute and often cortically blind.
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Aspiration pneumonia due to dysphagia is a common occurrence. Cheyne-Stokes
respiration may be seen.
The diagnosis of prion disease is frequently difficult, especially in the early
stages of the illness. The differential is wide and includes conditions ranging from
Alzheimer's disease and vascular dementia to metabolic encephalopathies. The most
useful tests when investigating a potential case of sCJD are brain magnetic resonance
imaging (MRI), EEG and cerebrospinal fluid (CSF) analysis.
sCJD is classically associated with an EEG finding of periodic triphasic
complexes with a frequency of 1Hz, but these may not develop until late on in the
disease. Their sensitivity and specificity are approximately 66 and 74%
respectively415. Periodic complexes are seen in a number of other conditions, some of
which may clinically resemble sCJD. Whilst it is estimated that between 60 to 80%
of patients will develop these EEG changes at some point, sometimes only non-
395
specific slow wave abnormalities are recorded '.
MRI findings of bilateral, symmetric high signal intensities in the basal
ganglia are highly sensitive and specific for sCJD. Typically the putamen and
caudate are involved1 ''335, less often the corpus striatum, anterior putamen,
cerebral or cerebellar cortex are affected.
Routine CSF analysis is usually normal; the total protein may be modestly
elevated but is rarely greater than 1 gram per litre. Neuronal proteins such as 14-3-3,
SI 00b and tau have been found to be present at elevated levels in the CSF of patients
with prion disease. These are non-specific markers of neuronal damage and may be
present in conditions such as recent infarction or seizure, so some interpretive
caution is required. Flowever in the context of a patient who is suspected of having
sCJD on clinical grounds they have a high sensitivity and specificity63'301.
sCJD cases can show considerable clinical and pathological heterogeneity.
Work is on-going to try to sub-classify patients at the molecular level, and tie this in
to distinct clinicopathological phenotypes. Two major techniques used are the
identification of the prion protein type, and the pattern of PrPSL glycosylation. Partial
digestion of PrPSc by protease K results in 2 types fragments of different molecular
weights. Type 1 has a relative electrophoretic mobility of 21 kilodaltons, and Type 2
is 19 kilodaltons. It was originally thought that the majority of patients have only
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Type 1 or Type 2 PrPSc, but recent work involving the sampling ofmultiple brain
regions suggests that many individuals may have both types present409'156- It als0
appears that there may be further sub-types of PrPSc distinguishable by highly
sensitive gel electrophoresis, and also truncated prion protein fragments in various
forms have been reported by several authors.
An additional method for analysing differences between PrP subtypes is by
looking at the glycosylation at residues 181 and 197. At these points PrP may
undergo post-translational modification by glycosylation. Thus PrPSc (and PrPc) may
be unglycosylated, monoglycosylated or diglycosylated. The relative prevalence of
the different forms is termed the glycoform ratio153. For convenience a predominance
ofmonoglycosylated PrPSc is known as type A, whilst if diglycosylation prevails this
is termed type B. This classification is probably an over-simplification, as variable
glycosylation ratios have been reported in the different brain regions in the same
individual. Some types ofmutant PrP associated with PRNP mutations may also
show distinct glycosylation ratios, which may be helpful in the neuropathological
• 53
diagnosis .
The codon 129 status is also used to classify cases into those with methionine
homozygosity (MM); valine homozygosity (VV); or heterozygosity (MV) at this
locus. For example, the 'classical' sCJD phenotype of rapidly progressive dementia
with myoclonus and ataxia is seen in MM or MV individuals with PrPRes type 1
(sCJD-MMl or sCJD-MVl), whilst sCJD-VV2 patients have a cerebellar variant293.
The neuropathological features provide additional classification criteria, as to
whether findings affect predominantly cortical or thalamic areas, or display plaques
similar to those seen in kuru.
At neuropathology, spongiform change, astrocytosis and neuronal loss are
seen, with amyloid plaques present in a minority. Typically the cerebral cortex,
putamen, caudate nucleus, thalamus and molecular layer of the cerebellar cortex are
involved, but the severity and distribution of neuropathological changes is highly
variable.
Overall the molecular classification of sCJD (and other forms of prion
disease) is very much still evolving, and it is likely that the current system will be
expanded and become more complex over time. The following tables summarise the
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key subtypes and their clinical and neuropathological characteristics. The
mechanisms underlying links between particular molecular and clinical findings also
remain to be elucidated.
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I.XIV The Molecular Classification of Sporadic GD
(adapted from Parchi 2011296)
Table 1.1 Molecular subtypes ofsOD: disease duration and ape at onset





MM1 or MV1 40 70.1 (48-86) 4 (1-24)
VV2 15 64.5 (45-83) 6.3 (3-18)
MV 2 kuru 8 65.4 (48-81) 15.8(5-48)
MM/MV 2 cortical 1 (approximately) 67.8 (61-75) 20 (12-36)
MM2 - thalamic 1 (approximately) 52.3 (36-71) 15.5 (8-24)
VV 1 1 (approximately) 39.3 (24-49) 15.3 (14-16)
MM/MV 1 + 2 cortical 28 68.6 (42-89) 4.0(1-26)
MV2 kuru + 2 cortical 3 (approximately) NA NA
VV 2 + 1 3 (approximately) 69.3 (59-85) 6.5 (3.5-13)
Table 1.2 Clinical features of the sOD subtypes
sCJD Subtype Clinical features
MM1 or MV1
Rapidly progressive dementia and myoclonus. Ataxia at onset in half and
visual impairment in a third.
VV2 Often ataxia present at onset with dementia appearing later.
MV 2 Kuru Dementia and ataxia. Duration may exceed 2 years.
MM/MV 2 cortical Dementia, myoclonus and pyramidal signs. Ataxia uncommon.
MM2 - thalamic
Usually insomnia and psychomotor hyperactivity, accompanied by ataxia
and other motor signs (Sporadic Fatal Insomnia)
VV 1 Progressive dementia followed by myoclonus and pyramidal signs.
MM/MV 1 +2
cortical
Usually similar to MM/MV 1; influenced by the relative predominance of
PrPSctype 1 or 2.
MV2 Kuru + 2
cortical
NA
VV 2 + 1 Similar to VV2
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Table 1.3 Neuropatholoaical features of the subtypes ofsCJD
sCJD Subtype Neuropathologieal features
MMl or MV1
Spongiform change of the neocortex (particularly the occipital cortex),
striatum, thalamus. Sparing of hippocampus and brainstem.
Focal changes in the molecular layer of the cerebellum.
Synaptic and sometimes punctate PrPSc deposition.
VV2
Microvacuolar spongiform change in the deep layers of the neocortex.
Involvement of the subcortex and hippocampus and cerebellum.
Plaque-like and perineuronal PrPSc deposits.
MV 2 Kuru Kuru type plaques in the cerebellum. Plaque-like deposits (similar to VV2).
MM/MV 2 cortical
Cerebral cortex severely affected with widespread, often confluent vacuoles.
Basal ganglia and thalamus less severely affected; hippocampus and
cerebellum usually spared.
MM2 - thalamic
Marked atrophy of the thalamus and inferior olive.
Focal spongiform change, usually limited to the cerebral cortex.
VV 1
Severe spongiform change in the cerebral cortex and striatum.
Sparing of the brain stem and cerebellum. Faint synaptic PrPSc deposition.
MM/MV 1 +2
cortical
Similar to MM/MV 1. Also similar findings to MM 2 cortical (large
confluent vacuoles, perivacuolar and focal PrPSc staining).
MV2 kuru + 2 cortical
Similar to MV 2 kuru with additional large confluent vacuoles.
Mixed kuru plaques and cortical PrPSc deposition.
Perivacuolar and coarse focal PrPSc.
VV 2 + 1 Similar to VV2
I.XV Iatrogenic Human Prion Diseases
The earliest report of iatrogenic transmission ofCJD came from the USA in
1974, when a 55 year old woman died of neuropathologically confirmed CJD 18
months after a corneal transplant; upon review of the donor's records it was found
that she too had died of neuropathologically confirmed CJD90. 3 years later CJD was
transmitted by depth electrodes, which were first implanted into the brain of a
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woman who subsequently died of neuropathologically confirmed CJD . The
electrodes were cleaned with benzene, ethanol and formaldehyde and reused twice;
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both patients subsequently died of CJD. 28 months after the original event the
electrodes were experimentally implanted into the frontal lobe of a chimpanzee; the
animal also contracted CJD126.
The majority of cases of iCJD have occurred following exposure to either
cadaveric derived dura mater grafts or growth hormone. Nearly 200 cases of dura
mater graft related CJD had been reported, 142 of which occurred in Japan, where
the use of such grafts during neurosurgery was particularly common. In most cases
the Lyodura brand was implicated, probably due to the practice of pooling dura from
multiple donors14'37.
The use of cadaveric growth hormone to treat growth hormone deficiency
was widespread from the late 1950s to the 1980s, with little or no screening of
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donors and the pooling of up to two thousand glands during hormone extraction
31°. In Australia cadaveric gonadotropin was used as fertility treatment, and this too
has been linked with CJD transmission, albeit in only a handful of cases65'37.
Three cases of secondary transmission of symptomatic vCJD via blood
transfusion have occurred234'162'300. In one additional case blood from a donor who
later developed vCJD was transfused into a man who later died of an aneurysm; at
post-mortem (PM) PrPSc was found in his spleen, but not in the CNS. This is
considered to be a case of sub-clinical vCJD, and it is unclear if this PRNP codon
129 heterozygous individual would have developed a clinical illness if he had lived
longer. One further pre-symptomatic individual was identified as part of a study of
neurologically asymptomatic patients with haemophilia who were thought to be at
high risk of vCJD299. This individual had severe haemophilia and as a result has
received large amounts of Factor VIII, 2 batches ofwhich included a donation from a
single donor who subsequently died of vCJD. The recipient died of a thrombosed
iliac artery aneurysm, with no clinical evidence of neurological illness. PrPSc (with a
glycoform ratio consistent with vCJD) was found in his spleen but not in other
tissues (including brain) tested9.
As with other types of human prion disease the PRNP codon 129 status may
influence the risk of developing certain forms of iCJD, with homozygous individuals
being at increased risk. There are now rigorous mechanisms in place to minimise the
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risks of iatrogenic transmission via known routes; however the spectre of further
cases transmitted via a novel route remains.
I.XVI Bovine Spongiform Encephalopathy
On the twenty second of December, 1984, a veterinary surgeon was called to
a farm in Sussex to examine a cow with unexplained weight loss and an arched
back236; this was the first known case of BSE236'378'384'383. BSE is characterized by
behavioural change, hyperaesthesia to touch and sound, ataxia, tremors, decreased
milk yield and progressive weight loss. Illness duration is usually between one and
two months382'18. There is spongiform change of the grey matter with neuronal
vacuolation, neuronal loss and astrocytosis. PrPSc is widely found, and scrapie
associated fibrils are also seen380'165.
Epidemiological evidence points towards the epidemic being due to an
extended common source, with the onset of exposure being 1980 or 198 1 384 383 jt
was quickly recognized that the most likely source of the epidemic was the use of
meat and bone meal (MBM) as cattle feed407'384'383 The original source of the
infectious material is has been postulated to be scrapie sheep, but the possibility of a
novel bovine prion disease having arisen spontaneously cannot be excluded98'168. The
recycling of animals which died of BSE into the food chain may have helped to
lower the 'species barrier' and favoured the propagation of the disease strain with the
highest level of infectivity and shortest incubation time194.
The compulsory notification and slaughter of cases of BSE, and a ban on the
use ofMBM were effective in controlling the epidemic, which peaked in January
236 3791993 ' . Novel prion diseases later appeared in felines and exotic zoological
animals, probably due to infected bovine material being used as animal
feed195'357397"379"162. In all nearly two hundred thousand cases of BSE have occurred
in the UK to date405'39". Atypical forms of BSE have subsequently been identified
during active surveillance, which appear to occur sporadically in animals over 8
years of age, which may show little or no signs of disease73'54'29. These can be further
subdivided based on the molecular mass of the PrPRes fragment seen on Western blot
after partial protease digestion - those with the lower molecular mass are termed L-
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type and those with a higher weight H-type177. It has been proposed that the classical
BSE may have arisen due to animals with sporadic spongiform encephalopathy being
rendered into MBM, but this is controversial.
I.XVII Variant CJD
Although it was first thought that BSE did not pose a threat to human
health127, the potential for prion strains to alter their characteristics after cross-
species passaging was recognised, and led to a robust system of surveillance being
put in place in the UK. Some years later several cases of young adults affected by
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prion disease were identified' ' ' . Not only were these patients much younger than
those typically affected by sCJD, but their presentation, disease duration and
neuropathological findings were also distinct. From the outset this 'new variant' of
CJD (vCJD) and BSE were thought to be causally linked, and there is now strong
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evidence to support this view .
The mean age at onset in vCJD is 28 years (range 12 to 74 years) with a
median disease duration of 14 months. At onset there are typically psychiatric or
behavioural symptoms, and many patients also experience painful sensory
symptoms412. Psychiatric features are usually the sole manifestation for several
months; later clinical features such as cognitive decline, myoclonus, cerebellar,
pyramidal and extrapyramidal signs appear. Terminally there is akinetic mutism414.
To date with only one exception all definite or probable cases have been
methionine homozygous at PRNP codon 129. Routine investigations (such as full
blood count, metabolic and vasculitis screens, autoantibodies and CT brain imaging)
are usually normal. The EEG typically shows non-specifically slow-wave
abnormalities or is normal413. Routine CSF analysis may show a modestly elevated
CSF protein. CSF 14-3-3 analysis is of less utility in vCJD, being less sensitive. MRI
characteristically shows symmetrical hyperintensity of the pulvinar nucleus of the
thalamus, changes which in the correct clinical context are highly sensitive and
specific for vCJD.
On neuropathological examination widespread florid amyloid plaques are
found, typically surrounded by an area of spongiform change. The cerebral and
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cerebellar grey matter are particularly severely affected. Clusters of multiple smaller
plaques lacking a halo of spongiform change are also found in the cerebral and
cerebellar cortex. PrPSc is detectable within these plaques, and also around neurons
and blood vessels in the cerebral and cerebellar cortex. A distinct isoform of the
prion protein is found, with a glycosylation ratio not typically seen in sCJD173. PrPRes
can be detected outwith the CNS, with lymphoid tissues such as the tonsils, lymph
nodes, appendix and spleen being involved.
The current statistics record 176 cases of vCJD in the UK, and an additional
47 cases elsewhere. The yearly incidence of vCJD in the UK seems to be falling;
there are concerns over the possibility of a 'second wave' of cases occurring, but
calculations indicate that this is unlikely to affect a large number of individuals119.
I.XIII Sporadic Fatal Insomnia
Cases of Sporadic Fatal Insomnia (SFI) have a phenotype indistinguishable
from that of the gPD Fatal Familial Insomnia (FFI) but there are no detectable PRNP
mutations. To date only 13 cases have been described, all with methionine
homozygosity at codon 129292'245-333>303>260>50>31U93^
Most patients initially developed decreased vigilance, altered sleep-wake
cycles and behavioural change, followed by pyramidal signs, dysarthria, dysmetria,
impaired short-term memory and decreased spontaneous speech. As with FFI,
dysautonomia and a loss of normal regulation of Cortisol and norepinephrine are
seen, whereas dementia is not. The EEG shows abnormal slow wave activity, and
neuroimaging shows atrophy. Polysomnography has demonstrated severe disruption
to normal sleep patterns, with loss ofREM sleep, lack of sleep spindles and slow
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wave sleep .
The pathological changes are comparable to those of FFI, with spongiform
change of the thalamus, caudate nucleus and inferior olivary nucleus. Mild
spongiosis of the cerebral cortex with mild neuronal loss and gliosis has been seen in
some cases, as has cell loss in the cerebellum. PrPSc deposition is most marked in the
basal ganglia, with a finely granular, synaptic pattern seen. Type 2 PrPSc is usually
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seen, with the unglycosylated form being under-represented. This last finding
distinguishes SFI from FFI.
Although the SFI phenotype tends to be consistent between cases, there are
several exceptions. The patient described by Priano et al. had similar clinical and
pathological features but with the presence of type 1 PrPSc, which the authors
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speculated could possibly be related to neurosurgery 21 years prior to onset . Of
interest is a case report of an individual with SFI who was related to a confirmed FFI
kindred. This individual's PRNP genotype was normal, as was her father's. However
there were several paternal relatives with confirmed FFI due to the D178N-129M
mutatiom0. Non-paternity was considered but excluded, and the proband was lacking
in the unglycosylated form of PrPRes on immunohistochemistry (IHC), a finding
typical of SFI. The only explanations are coincidence (the authors calculated the
probability of an SFI case occurring in an FFI family by chance to be 0.000078 to
0.000156) or that somatic mosacism was in some way involved. Another case exists
with pathological and genetic findings consistent with SFI, but with a cerebellar
onset . SFI is now classified as being part of the spectrum of sCJD (sCJD MM
thalamic), and there is evidence from transmission studies that SFI and FFI share the
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same prion strain .
1.XIX Variably Protease Sensitive Prionopathy
Recently a small number of cases of a novel human prion disease have been
reported114'157, with low levels of variably protease sensitive PrPSc (VPSP). Whilst
the first reported cases were all valine homozygous at PRNP codon 129, further
affected individuals with heterozygosity or methionine homozygosity have now been
reported155'117. Whilst VPSP is described as being a sporadic disease and none have
been found to have mutations ofPRNP, a significant number of the cases identified
to date had a strong family history of dementia419. This suggests that the condition
could be linked to genetic factors other than PRNP-
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I.XX PRNPh the Significance of Codon 129
The prevalence and characteristics of human and animal prion diseases are
known to be intricately linked to host and donor genetic factors. In humans a
particular polymorphic residue ofPRNP at codon 129 has a major impact upon
disease susceptibility and phenotype69'115. Individuals may be homozygous for
methionine or valine, or heterozygous, at codon 129. In the British population the
majority (47%) are heterozygous, with the remainder being homozygous for either
methionine (42%) or valine (11%)281. However in those afflicted by prion disease,
these proportions change. Methionine homozygosity appears to confer a greater risk
of developing sporadic and variant CJD296. Codon 129 status is also a major
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determinant of clinical phenotype amongst sCJD patients . In iCJD homozygosity
at codon 129 (either valine or methionine) is over-represented. There are interactions
between codon 129 and mutations of PRNP; for example FFI occurs when an
individual has both the D178N mutation and methionine at codon 129 of the mutated
allele; if the mutated allele carries valine the disease phenotype is radically altered to
one resembling gPD116.
In non-Caucasian populations the normal distribution of codon 129 differs,
with Far Eastern groups having a predominance of methionine homozygotes.
However, this does not seem to lead to differences in the incidence ofprion disease.
For example in Japan the distribution of codon 129 in the normal population is MM
92%, MV 8% and VV 0%, but the incidence of sCJD is the same as that of
Caucasian populations281.
In animals, equivalent genes to PRNP have been found and again these play
an important role89'316. The genetics of sheep in this regard are far more complex than
those of people, with different breeds of animals having multiple different risk
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alleles, with some of these behaving differently in different breeds ' . When disease
is transmitted from one species to another, genetic factors influence the disease
characteristics seen". It is possible that BSE only came into existence because a cow
of a particular genotype was exposed to a particular strain of scrapie in a particular
breed of sheep of a particular genotype.
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It has been speculated that genetic factors other than PRNP codon 129 status
may influence human susceptibility to prion disease. Modern genome wide
association techniques allow this hypothesis to be tested, by comparing the genomes
of large groups of individuals affected by sporadic, iatrogenic or variant CJD or kuru
with control groups. In those with vCJD a genome wide association study found (as
expected) a strong association with PRNP codon 129, and also several promising
new SNPs which may be related to diseases susceptibility2"^4. In particular a
polymorphism of the cathepsin D gene (CTSD) has been found to be associated with
an increased risk of vCJD30. However it does not appear to influence the risk of
developing sCJD or gPD21'. When kuru was investigated, those who lived through
the epidemic and participated in mortuary feasts but did not develop kuru were found
to be highly likely to be heterozygous at codon 127 of PRNP (G127V). This
haplotype was not seen in samples from kuru victims or from control individuals
living in areas of Papua New Guinea which were not affected by kuru"" .
I.XXI Polymorphisms of PRNP
PRNP has been extensively studied in human populations, with a bias in
studies towards Caucasian subjects. At least 65 pathogenic mutations and 23
polymorphisms have been identified, with interactions between mutations and
polymorphisms occurring in some instances. In some cases there is uncertainty as to
whether or not a mutation is pathogenic or not. Not all polymorphisms result in a
change of the amino acid encoded for. A summary is given in table 1.4.
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P39P Proline Proline Beck 2010"
G54S Glycine Serine Beck 201025
P68P Proline Proline Windl 1999392
A117A Alanine Alanine Hsiao 1989l6y
G124G Glycine Glycine Prusiner 1997314
Y128Y Tyrosine Tyrosine Beck 201025
G127V Glycine Valine Beck 2010"
Ml 29V Methionine Valine Owen 1990284
I138M Isoleucine Methionine httD://www.mad-cow.ore/prion point mutations
G142S Glycine Serine http://www.mad-cow.or2/prion point mutations
Y150Y Tyrosine Tyrosine Beck 20 1 025
V161V Valine Valine Prusiner 1997314
N171S Asparagine Serine Samaia 1997331
N173N Asparagine Asparagine http://www.mad-cow.ore/prion point mutations
H177H Histidine Histidine Ripoll 1993 320
T188T Threonine Threonine http://www.mad-cow.ore/prion point mutations
D202D Aspartic acid Aspartic acid http://www.mad-cow.ore/prion point mutations
R208R Arginine Arginine http://www.mad-cow.ore/orion point mutations
Q212Q Glutamine Glutamine Windl 1999392
E219K Glutamic acid Lysine Furukawa 1995104
R228R Arginine Arginine Windl 1999392
S230S Serine Serine Windl 1999392
1-Octapeptide Repeat Insertion Yu 2009408
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I.XXII Prion Diseases Associated with Mutations of PRNP
As previously discussed, the occurrence of familial human prion diseases was
recognised at the beginning of the 20th century.
The first mutation of the PRNP gene to be discovered was the 6 octapeptide
repeat insertion (6-OPRI) 286. This was rapidly followed by the identification of
numerous other insertional and point mutations as familial groups were genotyped.
New mutations are still being found, and to date the total comprises 65 pathogenic
PRNP mutations, with additional 'silent' polymorphisms However only a handful of
mutations are responsible for the majority of gPD cases.
The clinicopathological phenotype varies considerably, and can differ even
between patients from the same family with the same mutation. As with sCJD, PRNP
codon 129 may exert a major influence upon the manifestations of the disease, which
can result in a distinct disease phenotype arising. A strict division into gCJD and
GSSS phenotypes is not always possible (or indeed meaningful) and therefore
inherited prion diseases are now often classified according to the haplotype of the
pathogenic mutation and the codon 129 status of the mutated allele. GSSS may also
be diagnosed by its characteristic neuropathological appearances. In addition there
are several instances of novel PRNP mutations associated with dementia or
psychiatric illness, without any patients having confirmed prion disease. The current
list of known pathogenic mutations and a brief resume of their geographical range
and clinical manifestations are given in tables 1.5 and 1.6.
The incidence of gCJD, FFI and GSSS varies across the world; given the
difficulties in diagnosing prion disease, the similarities between some genetic and
sporadic cases, and the ethical issues surrounding genotyping it is not surprising that
comprehensive figures can be difficult to obtain. It is once again a case of'you find
what you look for', and it would be wise to assume that a lack of reported cases does
not necessarily equate to a lack of disease, and may in fact indicate a lack of
surveillance. Where adequate surveillance is performed, considerable variation in the
incidence of different mutations is found. In some cases this is due to a mutation
arising in an isolated population and being perpetuated by inbreeding, and in others
the statistics for an entire country are skewed by the presence of one large (well
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studied) family. The EuroCJD study findings are summarised in table 1.7; overall an
incidence of 0.17 cases permillion population per year was found, with 10.2 % of all
• • • •••210
cases of human prion disease having a genetic origin
32
Table 1.5. AH known PRNP point mutations
Haplotype Epidemiology
S97-129M China; single case
P102L-129M Extensive range worldwide
P102L-129M, 219K Japan; single family
PI 021.-l 29V USA/Italian; 2 cases
P105L-129V Japan; rare
P105S-129V N. America; single family
P105T-129M E. India; 2 families
P105T-129V 1 family
G114V-129M Uruguay, China, S. India
A117V-129V N. Europe & N. America
G131V-129M America, Holland; 2 cases
Y145X-129M Japan; single case
R148H-129M Germany, N. America; 2 cases
Q160X-129M Austria, N. America; 2 families
D167N-129M Turkey; single case
N171S-129V Brazil; single family
1)178N I29M Europe, N. America, Australia
D178N-129V Europe, N. America, Israel
DI78N-129V&N171S-129V Single African-American family
VI80I-129M Japan, S. Korea, France, N. America
V1801—129 & M232R-129M Japan; single case
T183A-129M Germany, Brazil; 2 families
H187R-129V N. America; single family
T188A-129M Australia; single case
T188K-129M Austria, Germany; 4 cases
T188R-129V Germany, N. America; 2 cases
T193I-129M Greece; single case
E196K-129M Germany; 3 cases
E196K-129V Germany; 1 case
P198S-129V N. America; large kindred
F198V-129M China; single case
E200K-129M Commonest cause of gPD worldwide
E200K-129V Europe; rare
D202G-129V Germany; single case
D202N-129V Canada, 1 family; England, 1 case
V203I-129M Italy; 2 cases
V203I-129V Korea; single case
R208H-129M China, Europe, N.America; 4 cases
R208H-129V France; single case
R208C-129M China; single case
Continued on nextpage
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Tabjej^.s fcontinued) AH Known PRNP Point Mutations
Haplotype Epidemiology
V210I-129M China, Europe, Japan, N.America
E211Q-129M France, Italy
Q212P-129M Ireland, N. America; 2 cases
Q217R-129V N. America
Y218N Spain; single case
M232R-129M China, Japan, Korea
M232T Poland; single case
Y226X 129V Holland; single case
Q227X-129V Holland; single case
P238S Germany; single case
Table 1.6 PRNP deletions & insertions
Haplotype Epidemiology
del 24 base pair 129M Europe; 2 cases
24 nucleotide insertion Canada; 1 case
1-OPRI 129M France, Italy; 3 cases
2-OPRI 129V N. America, Holland; 2 families
4-OPRI 129IVI Britain, Italy, Japan
4-OPR1 129V France; single case
5-OPRI 129M Britain, N. America, Ukraine, Germany
5-OPRI 129V N. America, Germany
6-OPRI 129M Europe, Japan, N. America
6-OPR1 129V France; single case
7-OPRI 129M N. America (single family) & Japan (single case)
7-OPRI 129V Holland
8-OPR1 129M France; single family
8-OPRI 129V France, Holland
9-OPR1 129M England, Germany, 2 families
12-OPR1 N. America; single family
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I.XXIII The Worldwide Incidence of Genetic Prion Disease
Table 1.7 The worldwide incidence ofgenetic prion disease
Adapted from Kovacs et ai. 2005210 with additional information from other
sources.
Country Genetic prion disease cases
(% of all prion disease cases)
Incidence
(per million population per year)
Australia 210 10.2 0.14
Austria 210 14.4 0.28
Canada 210 8.5 0.12
China118 7.8 -
France 210 9.0 0.18
Germany 210 7.6 0.13
Italy210 17.4 0.30
Netherlands 2111 2.1 0.02
Slovakia 210 69.5 1.07
Spain 210 10.3 0.23






Japan 270 15.90 -
Chile 113 45.00 -
Belgium 289 4.00 -
Sweden 235 0.92 -
Finland 214 27.27 -
Total210 10.2 0.17
2
Reports from those undertaking prion disease surveillance in Kenya ,
r\f\l • 9SQ
Mexico , and India are negative for genetic cases; however in these countries no
PRNP genotyping has been carried out so there is an absence of evidence rather than
evidence of absence. Surveys found a case of GSSS in Poland due to the novel
T232T mutation34, whilst in Ireland a case of FFI due to D178N 129M was detected
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between 1980 and 2002167; in Sweden 1 case ofGSSS was found between 1985 and
199623-\ All of the reported cases of gPD in Finland are from the same kindred and
attributed to the D178N mutation214.
I.XXIV Rationale for the Current Study
The clinicopathological phenotype of different human gPD is still not fully
understood, largely due to the rarity of these conditions and the ethical difficulties
surrounding genetic testing for unbeatable, fatal disorders. The primary aim of this
thesis therefore, is to systematically review cases of gPD in the UK over a substantial
time period in order to gain insights into the manifestations of these mutations, and
how their distribution in the UK compares with that reported elsewhere.
The PRNP codon 129 polymorphism is thought to play a major role in
determining disease susceptibility and phenotype, but the effect of other
polymorphisms is less clear. A second aim is to investigate the influence exerted by
other PRNP polymorphisms found in cases of sporadic and variant CJD.
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CHAPTER TWO
LITERATURE REVIEW OF INDIVIDUAL
PRNPMUTATIONS
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2.1 Introduction to Literature Review
A large number ofPRNP mutations and polymorphisms have now been
described worldwide. All are rare, and some have only been reported in one
individual. Fully characterising their clinicopathological phenotype is therefore
difficult, compounded by interactions with other genetic factors such as the
polymorphic residue at codon 129 ofPRNP. The purpose of this literature review is
to summarise the status quo of the gPD literature, and to provide a basis for
comparisons with the finding of the present study of gPD in the UK. Figure 1 shows
the mutations reviewed in this chapter. The prion protein gene consists of 2 exons
with the open reading frame being within the second exon. There are 253 amino
acids. Normally the nucleotide sequence from codons 51 to 91 codes for a
nonapeptide followed in tandem by four identical octapeptide repeats which are also
almost identical to the nonapeptide (except for the omission of a glycine). This area



































2.II Literature Review Methodology
A comprehensive search of Medline and Pubmed databases was undertaken,
using multiple relevant keywords selected to be as inclusive as possible. Keywords
used included: 'prion disease'; 'genetic prion disease'; 'familial prion disease';
'hereditary prion disease'; 'transmissible spongiform encephalopathy'; 'genetic
transmissible spongiform encephalopathy'; 'FFI'; 'fatal familial insomnia'; 'Indiana
kindred'. Multiple variants on these terms were also used as search terms, as were the
individual mutations and halotypes. Key authors in the field were identified and
searched for to obtain a full list of publications by them. The abstracts of publications
identified were reviewed to assess their relevance. Any potentially useful
publications were obtained and reviewed in full. A small number of references were
not available in full (primarily those not published in English). The references cited
in these papers were also reviewed for relevance. Further references were obtained
from existing reviews such Kong et al. and Kovacs et al. This process was repeated
and results cross-referenced until no further relevant publications were found.
Data regarding age at onset, clinical features and investigative findings,
disease duration, neuropathological and immunohistochemical analysis were
extracted. Details of the ethnic origin of individuals and their families, the pattern of
inheritance and genetic studies were recorded.
Where possible the available data was summarised into tables. These were
sub-divided as appropriate, in order to collate patients or families of the same
haplotype, and to identify those with additional PRNP polymorphisms which could
influence the phenotype. In the OPRI cases, those with a known insertion sequence
are sub-divided according to the exact sequence. This information was not always
available, and this is stated in the text.
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2.Ill P102L-129 M
The P102L-129 M mutation is the commonest cause of GSSS worldwide,
and has been identified in at least 31
families328'88,138'169'218'139'225'149'406'83'220'374'132'297'62. The mutation has been reported in
Austria, Canada, China, Denmark, France, Germany, Hungary, Israel, Italy, Japan,
Korea, Mexico, Poland, the UK and the USA. Linkage between the mutation and the
disease has been demonstrated348. There is evidence that the mutation has occurred
on multiple occasions, and it has a high penetrance376. There is considerable
phenotypic heterogeneity both between and within families. Several different clinical
phenotypes have been described, which are not completely explained by differences
at codon 129. The mean age at onset has been found to be younger in methionine
homozygous patients, although the disease duration is not affected376. PrPRcs of a
type similar to type 1 has been described, but the glycoform ratio is distinct, with a
predominance of the diglycosylated form of PrPRes 294. There is speculation that
differences in the propagation ofwild-type and mutant prion protein may explain
some of the phenotypic heterogeneity371. P102L was one of the earliest prion
diseases to be transmitted to experimental animals, where it often closely resembles
experimentally transmitted sCJD and lacks the amyloid deposition seen in
humans241'19.
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Table 2.1 P102L-129M Clinical phenotvpe, investigative and
neuropathologies/ findings




MM 47.3 +/- 10.2 49
+1-26MV 54.0 +/- 5.7
Clinical features FHx
Slowly progressive cerebellar ataxia & late onset dementia; occasional myoclonus
Prominent cognitive & psychiatric features; few other neurological features








Multicentric PrPSc positive plaques
Fibrillar & non-fibrillar PrPSc in the cerebral & cerebellar parenchyma
Variable spongiform change; more severe if disease duration shorter
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2.IV P102L-129M, 219K
One Japanese family has been described with the P102L mutation and lysine
at residue 219, in conjunction with methionine at codon 129. E219K is a normal
polymorphism and was not found on the mutated allele of 20 other (unrelated) P102L
cases screened. Of the 4 family members reported, 2 had dementia without other
neurological features, 1 had cerebellar signs alone, and 1 had a cerebellar onset with
the later appearance of dysarthria, dystonia and apraxia. These findings are in
contrast to the typical P102L-129M phenotype of a cerebellar onset followed by late
cognitive decline. The pathological findings were also distinct (but this finding
should be interpreted with caution as only 1 individual with P102L-129M, 219K has
undergone neuropathological examination).
Table 2.2 P102L-129M, 219K Clinical phenotype, investigative and
neuropathoioaicai findings




MM Lysine (segregating with the
P102L mutated allele)
44 4 to > 5
Clinical features FHx
Cerebellar signs without dementia; or dementia alone Positive
EEG Neuroimaging 14-3-3
Not typical Atrophy Not reported
Neuropathological findings
A few PrPSc positive plaques in the cerebrum, cerebellar cortex & basal ganglia
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2.V P102L-129V
Two cases of GSSS due to the P102L mutation coupled with valine at codon
129 have been reported361'405. Brain homogenate from the first reported case was
used to successfully transmit disease to humanised transgenic mice; however, no
details are available other than that this individual was valine homozygous at codon
129 and ofNorth American origin358. Details of other case are given below.
Table 2.3 P102L-129V Clinical ohenotype, investigative and
neurepathoioaicai findings
Sex Origin Onset Duration Codon
(years) (years) 129
M Italian American 33 12 VV
Onset Clinical features FHx
Seizures Progressive sensory loss & weakness, gait disturbance,
bilateral hearing loss, dysarthria, dysphagia, epilepsy
Positive
Neuropathological Findings
PrPSc positive amyloid plaques in the cerebral & cerebellar cortex, basal ganglia &
hippocampus
Degeneration of the corticospinal, spinocerebellar & gracile tracts
Punctate PrPSc deposition in the substantia gelatinosa
No evidence of spongiform change
The clinical and pathological findings were distinct from those typically seen
with P102L-129M. The disease duration was longer, with seizures being a prominent
feature, and no evidence of dementia. The spinal cord was affected and there was a
lack of spongiform change. A maternal cousin of the proband was also thought to be
affected, but no further data regarding this individual is available.
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P105L-129V
Five unrelated Japanese families have been reported with prion disease due to
the P105L (CCA to CTA) mutation, coupled with valine on the mutated
allele13'362'198'398'273'399. The majority of patients had an illness characterised by a
spastic paraparesis and dementia, however in 2 cases gait apraxia was present rather
than spasticity. The neuropathological findings have also been variable, with 2 cases
showing numerous neurofibrillary tangles. This finding was absent from the other
reported cases. All cases have had a positive family history, with an apparently
autosomal dominant pattern of inheritance. Overall the clinicopathological phenotype
resembles that of GSSS.








(38 to 57 years)
5 to 12 years MV
Clinical features FHx
Dementia, dysarthria, spastic paraparesis, pyramidal signs, ataxia.
Tremor in 2 cases
Positive
EEG Neuroimaging 14-3-3
No periodic complexes Atrophy Not reported
Neuropathological findings
Atrophy, neuronal loss & gliosis
PrPSc positive amyloid plaques, predominantly in the cerebral cortex
Pyramidal tract degeneration. Sparing of the cerebellum
Neurofibrillary tangles in 2 cases
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2.VII P105S-129V
One family with prion disease due to the PI 05S mutation has been described.
Details of the proband are given below364. The mutation was also found in a parent,
who was described as being unaffected. There was a limited FHx, but no clear
history of neurological illness in any other members.
Table 2.5 P105S-129V Clinical phenotvpe, investigative and
neuropathological findings






F N. America 30 10 MV*
Onset Clinical features FHx
Cognitive decline, behavioural
change & dysphasia









Spongiform change, neuronal loss, astrocytosis
Multicentric & punctate plaques
* The P105S segregated with valine at codon 129. The other allele carried a 1-OPRI
deletion, a normal polymorphism.
The glycosylation ratio was also analysed, and the abnormal prion protein
was found to contain unglycosylated and monoglycosylated fragments, with the
monoglycosylated being predominant. This pattern is unusual for GSSS, and




This haplotype has been described in 2 families; only very limited
information is available about the first family, which was reported on the website
http://www.mad-cow.oru/prion point mutations.html. The father apparently died of
CJD at the age of 42 years, and his son subsequently developed symptoms at the age
of 30 years. The P105T mutation was found in the son, with heterozygosity at codon
129. Details of the other family326 are shown below.
Table 2.6 P105T-129M Clinical ohenotvoe, investigative and






East India 13 to 40 Approximately 2 to 3 MM & MV
Onset Clinical features FHx
Psychiatric symptoms or
behavioural and gait problems




Normal or diffuse slowing White matter high signal (1 case) Negative
The clinical phenotype seen in the family reported by Roagaeva et al. was
variable, with some individuals primarily having dementia, pyramidal signs and
ataxia in their 30s, whilst the proband initially developed psychiatric features at the
age of 13 years followed by pyramidal and cerebellar signs but without dementia.
These differences may be related to the proband being heterozygous at codon 129
whilst other family members were homozygous for methionine.
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2.IX P105T-129V
One family has been described with the P105T mutation in conjunction with
308valine at codon 129V . Three members were affected, all ofwhom developed
progressive cognitive decline followed by a cerebellar syndrome with gait ataxia.
The clinical details are given below.








Not stated 41 4 years and 8 months VV
Onset Clinical features FHx









Spongiform change and neuronal loss throughout cerebral cortex (cerebellum mildly affected)
Synaptic PrPScdeposition in all cortical layers
Some plaque-like deposits and unicentric PrPSc plaques
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2.X G114V-129M
Two families have been reported with prion disease due to a glycine to valine
change at codon 114 of the PRNP gene, with an autosomal dominant pattern of
inheritance233'322'403'339. In addition 1 affected South Indian male and a female
25Turkish patient have been described . In the small number of cases reported the
codon 129 status of the wild type allele did not obviously influence the clinical
phenotype. In the families reported by Rodriguez et al.322 and Liu et al.233 methionine
was present at codon 129 of the mutated allele. Unaffected mutation carriers who
were older than the affected individuals were found in both families, implying
incomplete penetrance. The mutation has not been found in control populations.
Table 2.8 G114V clinical phenotvpe (1)




Rodriguez M & F Uruguay mean 23.4




Liu233 M & F China 32 to 45 2 to 3 years MM
Beck25 M S. India 75 6 months MV
Table 2.9 G114V clinical phenotvpe f2)
Reference Onset Clinical features FHx
Rodriguez322 Personality & behavioural
change
Dementia, extrapyramidal &
pyramidal signs, myoclonus, mild
cerebellar features.
Positive









apraxia, well preserved cognition
Negative
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Table 2.10 G114V investigative findings




Liu233 Non-specific slowing Bilateral caudate nuclei and putaminal
high signal & atrophy (1 case)
Negative (1 case)
Beck25 Non-specific slowing Basal ganglia high signal Negative
Table 2.11 G114V neuropathoiopicai findings
Reference Neuropathological Findings
Rodriguez722* Spongiosis, gliosis & neuronal loss (2 cases)
Amyloid plaques & synaptic PrPSc deposition (1 case)
Liu233 Neuronal loss, spongiform change and astrocytosis in the cortex.
Synaptic PrPSc deposition. Type 1 PrPRes
Beck25 Not done
* The neuropathological data comes from frontal brain biopsies of 2 cases.
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2.XI A117V-129V
Nine families have been reported with prion disease due to this mutation;
there are 2 base changes at codon 117, firstly an A to G substitution at the third base
(a normal finding in 10% of the population), and secondly a C to T substitution at the
second base. The second substitution causes a coding change from alanine to valine.
The affected families are variously of French, German, British, Irish and North
American origin88,280'171,363'243'l60-237-209^ pattern 0f inheritance is autosomal
dominant, with high penetrance.
The clinical phenotype varies both between and within reported families.
Dementia may be the dominant problem, or there may be dementia and a cerebellar
syndrome. Other cases have marked extra-pyramidal and pyramidal features and
myoclonus, or present with neuropsychiatric problems. 1 case with prominent lower
motor neurone signs and spinocerebellar tract degeneration has been described209.
Patients frequently have a background of behavioural and personality change prior to
the onset of overt neurological problems, often being reported as being aggressive
and antisocial.
There are usually widespread PrPSc amyloid plaques in the cerebral cortex,
hippocampus, basal ganglia and thalamus. The cerebellum is usually spared, however
in a minority it is severely affected. Spongiform change, neuronal loss and
neurofibrillary tangles have also been found in some cases.
Valine homozygous and heterozygous individuals have been described; it is
not clear if the codon 129 status significantly affects the clinico-pathological
phenotype. Valine homozygosity may possibly be associated with a younger age at
onset237.
A transgenic mouse model ofA117V has been created. These animals
develop a disease with a longer duration than is seen in mouse models of sCJD, and
have more prominent ataxia402. Neuropathologically there were PrPSc positive
plaques present. As with the human cases, the neuropathological features seen varied
between individuals, with differences in plaques distribution.
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Various Second to seventh decade 1 to 11 MV& VV
EEG Neuroimaging 14-3-3
Slow or non-specifically abnormal Atrophy Not reported
Clinical features FHx
Dementia in isolation or associated with a cerebellar syndrome;
possibly other findings such as pyramidal or extrapyramidal signs
Positive
Neuropathological findings PrPSc type
Classically widespread PrPSc amyloid plaques; the cerebellum is often spared.




G131V-129M is a rare mutation which has been reported in association with
a GSSS-type phenotype. Both of the published cases had a similar age at onset,
clinical and pathological features although one was codon 129 heterozygous and the
other homozygous. Neurofibrillary tangles were seen in the Australian case and tau
positivity in the Dutch patient. This pattern of findings has been seen with other
pathogenic PRNP mutations, and raises questions regarding whether these findings
are causally linked or coincidence.
Table 2.13 G131V-129M clinicopatholoaical phenotvoe of the patient
reported bv Panegyre5291
Origin Sex Onset (years) Duration Codon 129
Australia Male 42 9 years MM
Clinical features FHx
Behavioural change, dementia, anxiety, apraxia, gegenhalten, hyper-reflexia Negative
EEG Neuroimaging 14-3-3
No periodic complexes Generalised atrophy Unknown
Neuropathological Findings
Abundant PrP c positive amyloid plaques in the cerebellum.
Molecular layer particularly affected
Occasional neurofibrillary tangles
Protease resistant PrP. No spongiform change.
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Table 2.14 G131V-129M clinicopatholoaical Dhenotvoe of the patient
reported bv Jansen181
Origin Sex Onset (years) Duration Codon129
Holland Male 36 Not reported MV
Onset Clinical features FHx
Slowly progressive dementia Ataxia, parkinsonism Positive
Neuropathological Findings
Numerous PrP c amyloid plaques in the cerebellum
Tau positive amyloid deposits in the cerebral cortex, striatum, hippocampus & midbrain
2 distinct PrP types: 8 kDa unglycosylated fragment & a detergent-insoluble but protease-sensitive
form of PrPSc. No spongiform change
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2.XIII Y145X-129M
One Japanese patient with a stop mutation at codon 145 has been described.
This patient died after a prolonged illness, and on PM did not have spongiform
change. No transmission studies have been published from this patient, and her
illness is currently termed 'PrP cerebral amyloid angiopathy'. The authors report that
the neuropathological changes seen resembled the findings in scrapie124'199.
Table 2.15 Y145X-129M Clinical ohenotvpe. investigative and
neuropathoioaicai findings
Sex Origin Onset Duration Codon 129
(years) (years)
F Japan 38 21 MM
Onset Clinical features FHx
Memory problems & disorientation Dementia Negative
EEC Neuroimaging 14-3-3
Normal Severe atrophy Not done
Neuropathological findings
Cerebral atrophy
Extensive PrP c amyloid deposition in cerebral blood vessels
Neurofibrillary lesions in cerebral gray matter
Severe neuronal loss and gliosis
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2.XIV R148H-129M
Two patients with prion disease due to a histidine to arginine substitution
(CGT to CAT) at codon 148 of the PRNP gene have been described298'217. The
clinical features are summarised below.
Table 2.16 R148H-129M Clinical ohenotvpe. investigative and






F German 82 6 MM
Onset Clinical features FHx




Periodic complexes Small subcortical & peri-ventricular high signal lesions Positive
Tau elevated
Neuropathological findings PrPRes Type
Slight atrophy




Table 2.17 R148H-129M Clinical phenotvpe, investigative and









Onset Clinical features FHx
Hearing loss &
difficulty driving
Fatigue, sleep disturbance, balance & gait problems,




Neuropathoiogicai findings PrPRes Type
Spongiform change, neuronal loss & gliosis
Kuru plaques in the granular & Purkinje layers of the cerebellum
PrPSc positivity in plaques & in a synaptic fashion
2
* The mutation was also found in the proband's 2 sisters, who were well at the ages
of 66 and 70 years.
The methionine homozygous case closely resembled the clinicopathological
phenotype of sCJDMM2, whilst the heterozygous case resembled sCJDMV2.
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2.XV Q160X-129M
Two families with probable prion disease and the Q160X-129M mutation
have been identified. Only limited clinical information is available for the first
family95'96. In the second family a mother and daughter were affected. Both had an
Alzheimer's type presentation and neuropathology, but with PrPSc positivity186.
However there was no spongiform change at PM so the possibility remains that these
individuals were affected by familial Alzheimer's disease rather than their illness
being linked to the Q160X mutation. There is also speculation that PRNP stop
mutations as a group may tend to give rise to neurofibrillary tangles and ncuritic
plaques.
Table 2.18 Q160X-129M Clinical phenotvpe, investigative and








M Austria 32 Dementia MM Positive
M Austria 48 Dementia MV Positive
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Table 2.19 Q160X-129M Clinical phenotvpe, investigative and








39 & 59 years 8 MV&MM
Onset Clinical features FHx
Cognitive decline Slowly progressive dementia Positive
EEG Neuroimaging
'unremarkable' (sic) 'unremarkable' (sic)
Neuropathological findings
Extensive neurofibrillary tangles and neuritic plaques.
Tau and PrPSc positive
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2.XVI D167N-129M
One individual with a D167N mutation has been reported; it is unclear if this
mutation is pathogenic or not, especially as the patient's mother is a carrier, and
reported to be unaffected at the age of 65 years. 25Clinical details of the proband are
given below. It has not been identified in normal populations.






M Turkey 33 2 MM
Onset Clinical features FHx
Forgetful, emotional
lability, aggression




Generalised slowing Moderate frontotemporal cortical atrophy Not done
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2.XVII N171S-129V
One Brazilian family has been identified with an adenine to guanine
substitution at codon 171, resulting in an asparagine to serine change. This mutation
was found in 6 family members, 4 of whom had a history of psychiatric illness, with
auditory hallucinations, persecutory delusions, depression and aggression. 1 affected
relative had a 7 year history of behavioural change, gait disturbance and dementia,
and a further relative carried the mutation but was asymptomatic in their 5th decade.
The proband had a 10 year history of psychiatric illness, whilst his mother had a 35
year history of psychiatric illness, and now has dementia at the age of 76 years. No
investigative findings or pathological data are available. It is therefore unclear if this
family is affected by prion disease or not; of note is the fact that a sibling of the
proband had bipolar disorder but had no mutations ofPRNP3} 1.
2.XVIII D178N
The D178N mutation is one of the commonest causes of gPD worldwide, and
is one of the most intriguing mutations. Two distinct clinicopathological phenotypes
can arise, depending on the codon 129 status of the mutated allele. If methionine is
encoded, then FFI occurs; if valine is present then a sCJD-like phenotype is seen l37.
The phenotype is further modified by codon 129 of the wild-type allele271. These
rules are not absolute, with a sCJD-like phenotype being reported in individuals with
D178N-129M41'. However no cases of FFI due to the D178N-129V haplotype have
been reported. The mechanisms responsible for the different phenotypes are not well
understood. D178N-129M is much more widely reported than D178N-codon 129V,
and haplotype analysis indicates that many European FFI cases can be linked to one
of two common founders323. Of particular interest is a recently reported patient with
somatic mosacism ofD178N-129V; this was a de novo mutation (not being present
in either parent) and presumed to be post-zygotic as wild type D178-129M, D178-
• • 12129V and mutated D178N-129V were all detectable in blood and brain tissue .
The existence of SFI further confuses the issue; as previously discussed, SFI
has an almost identical phenotype to FFI. The only difference (excepting the lack of
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a mutation on PRNP genotyping) is the glycosylation ratio292. This raises interesting
speculation as to whether or not mutations elsewhere in the genome could be
contributing to these diseases, or if SFI in fact belongs to the sCJD phenotypic
spectrum.
2.XIX D178N-129M (FFI)
FFI has been reported in at multiple families and individuals from various
European countries (including Germany, Austria, Spain, Italy, the UK, France and
Finland), Australia, N. America, Japan, China and Korea312. Haplotype analysis of
European cases suggests that that two historical independent mutational events may
be responsible for many current cases323. The codon 129 status of the wild type allele
influences the disease phenotype; there is a tendency for the age at onset to be
younger in homozygous patients, but this is not statistically significant, whereas the
mean disease duration does significantly differ between homozygous and
971
heterozygous cases . Patients do not seem to develop dementia, but display
progressive confusion with decreased vigilance, working memory and attention.
Details of the phenotype are given below.
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Table 2.21 D178N-129MM Clinical phenotype, investigative and
neuropathoioQicai findings
Onset (years) Duration (months)
49 (range 20 to 72) 11 +1-4 (range 5 to 21)
Onset Clinical features FHx
Sleep-wake cycle disturbance &
decreased vigilance
Insomnia, autonomic dysfunction, confusion,
motor symptoms, terminal akinetic mutism
Positive
EEG Neuroimaging 14-3-3
Non-specific slow wave activity Hypometabolism in the thalamus, basal




Severe neuronal loss & astrogliosis of the thalamus
Minor spongiform change in the cerebral cortex*
Often negative
Occasional PrPSc deposition in the
molecular layer of the cerebellum;
Type 2 PrPRes
• • • 183* Tau deposition reported in one case
Table 2.22 D178N-129MVClinical phenotvpe, investigative and
neuropathoiopicai findings
Onset (years) Duration (months)
49 (range 20 to 72) 23 +/- 18 (range 7 to 84)
Onset Clinical features FHx
Ataxia & dysarthria Later onset of sleep-wake disturbance; more motor




in some long duration cases
Mild atrophy
More widespread hypometabolism
Positive in around 50%
Neuropathological findings Immunohistochemistry
Similar to D178N-129MM but more severe cerebral
cortical involvement
Often negative
Occasional PrPSc deposition in the
molecular layer of the cerebellum;
Type 2 PrPRes
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The distinction between homozygous and heterozygous cases does not always
hold; homozygous cases with normal sleep patterns and a sCJD-like clinical
phenotype have been reported330'411'354. An increasing number of reports describe
considerable phenotypic variation within families, and some authors postulate that
there is a spectrum of disease ranging from classical FFI to a sCJDMMl-like
phenotype 14 \ In one case an ataxic phenotype resembling GSSS was seen352.
Variations in the amount and type of abnormal prion protein found may possibly
correlate with the phenotypic type. The disease has been transmitted by the
inoculation of humanised transgenic mice, which go on to display prominent
thalamic pathology. However unlike the donor cases, the mice display PrPRes type 1;
the reason for this difference between donor and recipient is not fully understood359.
Animals genetically modified to have a PRNP mutation homologous to D178N-
129M also develop spontaneous prion disease, and like their human counterparts
they display abnormalities of the sleep-wake cycle and EEG176'89.
2.XX D178N-129V
The D178N mutation with valine on the mutated allele gives rise to a sCJD-
like clinicopathological phenotype; no cases with this mutation and features akin to
FFI have been reported. Both codon 129 heterozygous and valine homozygous
individuals have been described, which appears to significantly influence the age at
onset and disease duration; however the clinical features and pathological
appearances are homologous in the 2 groups (although the number of cases reported
in detail with known codon 129 status is somewhat limited). Twelve families have
been described from N. America, France, Finland, Germany (the original Backer
family first described in 1920), and Israel312. Of the N. American kindreds one is of
Hungarian-Romanian, one ofDutch and one of French-Canadian origin. Brain tissue
has been used to successfully transmit disease to squirrel monkeys but not to
39 359
transgenic mice ' .
65
Table 2.23 D178N-129V Clinical phenotvoe, investigative and
neuroDattioioaicai findings
Codon 129 Mean Onset (years; range)* Mean Duration (months; range) *'
VV 39 +/- 8 (26 to 47) 14+/-4 (9 to 18)
MV 49 +/- 4 (45 to 56) 27+/- 14 (7 to 51)
Onset Clinical features FHx
Cognitive decline, behavioural change
& psychiatric features
Ataxia, dysarthria, aphasia, tremor,
myoclonus
Positive





Spongiosis, severe gliosis, variable neuronal loss. Possibly ballooned or enlarged neurons
Widespread changes especially in the frontal & occipital cortex, putamen & caudate nucleus,
subiculunt & entorhinal cortex. Cerebellum spared
Immunohistochemistry
Punctate PrP c deposition (associated with spongiosis)
Minimal PrPSc in cerebellum
Type 1 PrP es; unglycosylated form under represented
*
p < 0.01 ; ** p < 0.05; figures from Kong et al in Prion Biology and Diseases312 .
# Neuroimaging results and CSF analysis findings have only been reported for a very
small number of cases.
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2.XXI D178N-129V & N171S-129V
An African-American family has recently been reported with both the D178N
mutation and the N171S mutation, with valine on the mutated allele16. N171S has
been linked to psychiatric disturbance, and all of the affected family members with
D178N and N171S presented with depression and anxiety. Further details of the
proband are given below. The later clinical features were similar to those of FFI.
Table 2.24 D178N-129V& N171S-129VClinical ohenotvpe and
investigative finding^6
Onset (years) Duration (months) Codon 129
52 52 MV
Onset Clinical features FHx
Psychiatric disturbance Insomnia, pyramidal, cerebellar and visual disturbance,




Slow Basal ganglia & cortical high signal Not done
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2.XXII V180I-129M
The V1801 mutation has been reported in a small number of Japanese patients
and individuals from the USA, France and South Korea. In addition 1 Japanese
patient was found to have both the VI801 and the M232R mutation (discussed in
'Single cases' section)401'404'164,197'351'189 In codon 129 MV cases amyloid
angiopathy and neurofibrillary tangles were found alongside severe spongiform
change351. Five patients were methionine homozygous and 6 heterozygous at codon
129 (the status of the American patient was not reported). The age at onset was
slightly younger in the homozygous cases (mean age at onset 70.3 years vs. 74.8
years). Only very subtle PrPSc deposition was found, although there was widespread
spongiform change. In the codon 129 heterozygous cases kuru plaques were also
found351'60'279.
Table 2.25 V180I-129M Clinical phenotvpe, investigative and
neuropathoiogicai findings of the Japanese cases
Onset (years) Duration (years) Codon 129
66 to 81 1 to 2 MM & MV cases
Onset Clinical features FHx




Slow; no periodic complexes Extensive cortical high signal Raised (2 out of 3 cases)
Neuropathological findings
MM cases Widespread spongiform change, astrogliosis & neuronal loss
Subtle synaptic PrPSc deposition
Cerebellum relatively spared
MV case Spongiform change & kuru plaques in the cerebral cortex
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Table 2.26 V180I-129M Clinical phenotvpe, investigative and
neuropathoiogicai findings of the French case
Onset (years) Duration (months) Codon 129
66 54 MM
Onset Clinical features FHx
Cognitive decline & dysphasia Mutism, myoclonus, rigidity, dystonia Negative
Neuropathoiogicai findings
Severe spongiosis & gliosis of the cerebral cortex, striatum & entorhinal cortex
Moderate neuronal loss & gliosis of the thalamus
Synaptic PrPSc deposition
Cerebellum spared; no plaques in any brain region
Western blotting demonstrated mono- and unglycosylated PrPRl!'
2.XXIII T183A-129M
Two families with prion disease due to the T183A-129M mutation have been
described278,277'95'141. In the Brazilian family278 individuals with methionine
homozygosity and heterozygosity at codon 129 were identified; this possibly
influenced the disease duration. The proband was heterozygous at codon 129 and had
a disease duration of 9 years, whereas his mother was methionine homozygous and
died within 2 years of onset. However the age at onset did not seem to be affected by
the codon 129 status.
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Table 2.27 T183A-129M Clinical phenotype, investigative and
neuropatholoaical findings of the family reported bv Nitrini278
Origin Onset (years) Duration (years) Codon 129
Brazil 44.8 4.2 MM & MV
Clinical features FHx
Personality change, frontotemporal features, dementia Positive
EEG Neuroimaging 14-3-3
Slow Severe atrophy or
striatal & cortical high signal
Negative
Neuropathological findings
Severe spongiform change & neuronal loss in the deep cortical layers & the putamen,
with minimal gliosis.
PrPSc immunoreactivity in the putamen & cerebellum only.
Table 2.28 T183A-129M Clinical ohenotvpe. investigative and
neuropatholoaical findings of the family reported bv
Grasbon-Frodi141
Origin Onset (years) Duration (months)
Germany 40 4
Clinical features FHx
Dementia, cerebellar ataxia Positive
EEG Neuroimaging 14-3-3
Normal Global atrophy NA
Neuropathological findings
Severe spongiform change, particularly in the molecular layer of the cerebellum. Neuronal loss




The HI 87R mutation has been described in 2 large multi-generational
kindreds, both in North America151,46'56'72. The codon 129 status is only known for
one family, where the mutation was in sine with valine46. Both MV and VV
individuals have been reported, and the codon 129 status of the wild type allele may
influence the neuropathological manifestations. The clinical phenotype in this family
was one of dementia, ataxia, myoclonus and seizures, with a median age at onset of
42 years and disease duration of 12 years. 9 affected individuals of both sexes have
been identified, with an autosomal dominant pattern of inheritance. A possibly
unique type of'curly' PrP deposition was seen in one VV patient72. Further details
are given in the tables below.
The family reported by Hall et al. was also large, with 12 affected individuals
over 4 generations151. A high level of childhood psychiatric disorders was reported in
affected individuals, one ofwhom had neurological problems from birth with
language and motor development. Further details of the clinico-pathological
phenotype are given in the table; overall the clinical features after the onset of
dementia were similar to those reported by Butefisch et al, as was the lack of
spongiform change, plaques or significant astrocytosis. However the 'curly' PrP
found by Butefisch et al. was not seen.
Interpreting the significance of early psychiatric problems is difficult. In this
particular pedigree, 2 individuals in one generation had early psychiatric problems,
and each subsequently had children with early psychiatric problems. Does this
indicate neurodevelopmental problems caused by the PRNP mutation? Were these
symptoms actually the onset of clinical prion disease? Or are they coincidental and
due to environmental or independent genetic factors? Transgenic mice models of this
mutation would be helpful, as this would allow the study of early behaviour in a
controlled social and genetic environment, and for the serial examination of
neuropathological tissue at different ages to determine if behavioural changes were
linked to pathological prion disease.
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Table 2.29 H187R-129V Clinical phenotype, investigative and
neuropathological findings of the MV cases reported by
Butefisch46
Mean Onset (years)* Mean Duration (months)*
36 13
Onset Clinical features
Dementia, behavioural change Dementia, gait disturbance, dysarthria, pyramidal signs,
myoclonus, seizures, cerebellar signs
EEG Neuroimaging 14-3-3
Slow Diffuse atrophy Negative
Table 2.30 H187R-129V Clinical ohenotvoe, investigative and
neuropathological findings of the W cases reported bv
Butefisch46





Dementia, gait disturbance, pyramidal signs, myoclonus,
seizures.
EEG Neuroimaging 14-3-3
Slow Diffuse atrophy Negative
Neuropathological findings*
'curly' prion protein deposits with a laminar distribution in the cerebellar cortex.
Minimal astrocytosis
No plaques or spongiosis
*The only neuropathology details known are from a brain biopsy performed on a VV
individual.
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Table 2.31 H187R Clinical phenotvpe, investigative and neuropatholoaical
findings of the cases reported bv Hall151
Mean Onset of Dementia (years)* Disease duration (years)
32 9 to 28
Onset Clinical features
Childhood psychiatric disorders in 4 patients.
Later onset of dementia
Dementia in all cases. Extra-pyramidal & cerebellar
signs common, seizures in 50% of cases
EEG Neuroimaging
Bursts of sharp, slow activity or generalized
slowing.
Mild to moderate diffuse cortical atrophy
Neuropathological findings*
Moderate to severe atrophy in frontal, temporal and parietal regions. Mild gliosis and reactive
astrocytosis. No spongiform change or plaques. Scattered tau positive staining in 1 case.
Immunohistochemistry
2 cases tested: negative in 1, positive in the other with intermediate resistance to protease K digestion
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2.XXV T188K-129M
Four women have been reported with prion disease due to the T188K
mutation, 3 from Germany and 1 from Austria96'95'324. None were known to be related
but the 3 German cases lived in relatively close proximity to each other. In addition
to the CSF being positive for 14-3-3, in 1 case the tau was elevated and in another
the NSE was significantly raised324. The mutation was also found in the healthy 51
year old brother and 79 year old father of 1 case. Flowever it was not found in
German controls. Overall the phenotype resembles that of sCJD-MMl.
Table 2.32 T188K-129M Clinical ohenotype, investigative and
neuropathological findings
Origin Onset (years) Duration (months) Codon 129
Austria & Germany 57 to 76 5 to > 12 MM
Onset Clinical features FHx
Variable; gait disturbance & incoordination
or cognitive decline & dizziness;
or personality change & visual loss
Dementia, myoclonus & other
involuntary movements, cerebellar










Spongiform change, astrocytosis & gliosis. Moderate atrophy. PrP c positive
(Details available for 1 case only355)
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2.XXVI T188R-129V
Only 2 individuals with the T188R mutation have been reported, both of
whom had an illness consistent with prion disease but only 1 ofwhom had
Tcr "2QO TO/I
neuropathological confirmation ' ' Both had valine encoded at codon 129 of
the mutated allele. In the family of the individual reported by Tartaglia et al. there
were several individuals with early onset dementia (none of whom underwent PRNP
genotyping), and 2 asymptomatic carriers of the mutation. One carrier was the
patient's father, who was in his 80s, suggesting that the mutation has low penetrance.
Table 2.33 T188R-129V Clinical phenotvpe and investigative findings of the
patient reported bv Roeber92 324
Origin Sex Onset (years) Duration (months) Codon 129
Germany Female 66 16 VV
Onset Clinical features FHx
Visual loss Dementia, mild ataxia Negative
EEG Neuroimaging 14-3-3
Periodic complexes 2 small white matter lesions Positive
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Table 2.34 T188R-129VClinical phenotvpe, investigative and
neuropathologies! findings of the patient reported bv
Tartaoii^
Origin Sex Onset (years) Duration (months) Codon 129
Mexican-American Male 55 14 MV*
Onset Clinical features FHx
Personality & behavioural change Dementia, myoclonus, seizures, mutism Positive
EEG Neuroimaging 14-3-3
Diffuse slowing; focal slowing in
temporal lobe
Mild cortical atrophy. Subtle basal ganglia
and cortical high signal
'inconclusive'
Neuropathological findings
Spongiform change in numerous brain regions. Status spongiosus in the inferior temporal gyrus.
Synaptic & plaque-like PrPSc deposition. Type 1 PrPRes
*Valine on the mutated allele
2.XXVII E196K
The E196K mutation is rare, and until recently there was doubt as to whether
• 338it was truly pathogenic . However 4 cases with the mutation and
neuropathologically confirmed prion disease have now been reported; in addition 1
of these cases had a first degree relative with probable gPD and the same mutation92.
Interestingly, the mutation has been seen in individuals with methionine encoded for
at codon 129 of the mutated allele, and in a valine homozygous patient. The mean
age at onset reported (72 years) is older than is usually seen with gPD, and the
duration (4 months) shorter. Coupled with the lack of a family history in most cases,
this makes coming to a correct diagnosis even harder than is usual in prion disease.
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Table 2.35 E196K-129M Clinical phenotvpe, investigative and
neuropatholoQical findings
Origin Sex Onset (years) Duration (months) Codon 129
Germany Male & female 69 to 77 2 to 8 MM & MV cases
Onset Clinical features FHx
Dementia; gait problems;
tremor
Ataxia, dysarthria, pyramidal signs, akinetic
mutism
Positive in 1 case
EEG Neuroimaging 14-3-3
Periodic complexes
(2 of 3 cases)
White matter lesions
(2 of 3 cases)
Positive
(2 of 3 cases)
Neuropathological findings
Similar findings in the 2 MM and 1 MV case described
Spongiform change, astrocytic gliosis, neuronal loss
Cerebral cortex, basal ganglia, thalamus, brainstem nuclei and cerebellum particularly affected
Hippocampus mildly affected
Synaptic PrP deposition in 2 cases; both had PrPRes type 1
Synaptic PrP & plaque-like deposits in the cortex and cerebellum in 1 case, in whom PrRRes type
and 2 were seen.
Under-representation of non-glycosylated form of PrPRes seen in all cases
Table 2.36 E196K-129V Clinical phenotvpe. investigative and
neuropatholociical findings
Origin Sex Onset (years) Duration (months) Codon 129
Germany Male 72 2.5 VV
Onset Clinical features
Dementia Ataxia, visual hallucinations, dysarthria, rigor, akinetic mutism
EEG Neuroimaging 14-3-3
Periodic complexes Mild cerebellar & parietal atrophy Positive
Neuropathological findings
Spongiform change, astrocytic gliosis, neuronal loss
Basal ganglia, thalamus, cerebellum & brainstem nuclei involved; hippocampus severely affected
Synaptic & peri-neuronal PrPSc deposition & plaque-like deposits in cerebellum
Type 2 PrPRes (under-representation of non-glycosylated form)
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2.XXVIII F198S-129V
Three N. American families with prion disease due to a phenylalanine to
serine substitution at codon 198 of the PRNP gene are known, although only 2 have
been published93'94'125'305'312. Both of the 2 published families had a strong FHx of
neurodegenerative disease. The vast majority of published cases belong to a large
kindred in Indiana. The mutation is coupled with valine at codon 129; both valine
homozygous and heterozygous affected individuals have been reported. Homozygous
patients have a younger mean age at onset (44.7 years) than heterozygous patients
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(60.3 years); however the numbers of individuals in this analysis was very small .
The investigative findings have not been reported. Transmission to hamsters, mice
and marmosets has been attempted, thus far unsuccessfully.
Table 2.37 F198S-129V Clinical phenotype, investigative and
neuroDathoioaicai findings
Origin Onset (years) Duration (months) Codon 129
N. American Caucasian 40 to 71 2 to 12 VV & MV
Onset Clinical features FHx




Uni- & multi-centric PrP c positive amyloid plaques in the gray matter of the cerebrum, cerebellum &
mid-brain
Astrocytosis, atrophy & neuronal los
Neurofibrillary tangles in the neocortex & subcortical gray matter
Abnormal neuritis (similar to those of Alzheimer's disease)
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2.XXIX E200K-129M
In the 1960s and 1970s clusters of CJD cases were identified in rural
Slovakia248"249,269 and in Libyan immigrants to Israel190'26. Initially various
environmental sources of infection were postulated, such as consuming sheep brain
and eyeball8'9'161'27,10. However it soon became apparent that these clusters had an
underlying genetic cause274'268"267. The E200K mutation was first identified in a
Polish family138,136, and shortly afterwards in Israeli patients1"16. An A to G transition
at codon 200 of the coding region ofPRNP results in a change from glycine (E) to
leucine (K)138. The majority of cases of inherited prion disease in the world are due
to this substitution, which has been found in populations from England, Austria,
Chile, France, Germany, Greece, Italy, Japan, Libya, North American, Slovakia, and
Tunisia136'135'206'68'175. E200K has been shown to be causally linked to the occurrence
of prion disease10" and transmission to primates has been performed successfully59.
Slovakia and Israel remain the epicentre of two major clusters, and have rates of gPD
greatly in excess of the rest of the world.
The incidence ofE200K-129M in Libyan Jews in Israel is 43 cases per
million inhabitants per year417. The origins of this population can be traced back to
Spain in the 15th century; in 1492 the monarchs of Spain, Ferdinand and Isabella,
issued a decree ordering the expulsion of every Spanish Jew who refused to convert
to Christianity. This resulted in the forced migration of two hundred thousand
Sephardic refugees (Sephardic: a Jewish person of Spanish of Portuguese descent) to
North Africa, Turkey, France, Greece, Yugoslavia, Syria, Palestine and Italy. North
African Sephardim later emigrated to France and Libya. For the next 5 centuries the
Jewish community in Libya lived in relative isolation, resulting in decreased genetic
diversity. Many Libyan Jews emigrated to Israel when it was founded in 1948; others
left Libya and Tunisia when these countries gained independence in the 1950s and
migrated to France and Italy. High rates ofE200K-129M are seen in North African
immigrants to France55, and also in Chile38'113. The Chilean focus also has a Spanish
origin, with the majority of affected families able to trace back their ancestry to the
Conquistadors135. The Conquistadors in question were probably originally Jewish;
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many Spanish Jews who converted to Christianity found their position in Spain to be
precarious, and therefore emigrated to South America.
In Slovakia the clusters of gPD were originally reported from two isolated
rural areas, with a stable indigenous population and little immigration for some
centuries. In one of the cluster areas records of births, marriages and deaths
extending back to 1634 are available. These have provided genealogical evidence
that seemingly unrelated patients in fact share a common ancestor in the 17th or 18th
century266. However the records have not shown evidence of ancestors dying of
neurological or psychiatric causes, as would have been expected. This may reflect
the vagaries of historical records and the short life expectancy of pre-20th century
rural populations, but is nevertheless of considerable interest.
Modern genetic techniques allow us to directly elucidate the ancestral origin
of the E200K mutation. Libyan, Tunisian, Italian, Chilean and Spanish families share
a major haplotype on chromosome 20, suggesting that they also share a common
9T0
founder , confirming the theories outlined above. However the E200K mutation
appears to have arisen independently on several occasions, as the eastern European
cases tested showed major differences to the Mediterranean and South American
cases. German, Sicilian and Austrian patients also had a unique haplotype, as did a
Japanese family.
Penetrance
The early identification of elderly pre-symptomatic mutation carriers initially
lead to a mistaken belief that the penetrance of disease was around 0.56 135-136-
subsequent work demonstrated that penetrance is in fact dependent upon both age
and nationality. Amongst Libyan Jews the penetrance is high, rising to 0.96 is those
over 80 years of age349 . In the Italian Calabrian cluster the penetrance was found to
81be lower, 50% at 60 years of age and 61% at 70 years , with Slovakian cases having
a similar penetrance to the Italians.
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Pre-symptomatic Mutation Carriers
Increased levels of anxiety have been found amongst apparently healthy
carriers of the E200K mutation, and in older subjects poorer performance on some
neuropsychological tasks such as object learning and recognition131 . Changes in the
thalamus may also be detectable on neuroimaging prior to symptom onset229.
The effect ofcodon 129
The influence of the codon 129 status of the wild-type allele is unclear;
conflicting reports have emerged from studies in the Libyan Jewish and Slovakian
populations. In the Libyan Jewish cases no effect on age of onset or disease duration
was found106, whilst in the Slovakian group a significantly shorter disease duration
was found in the methionine homozygous patients, who also had different PrPSc
deposition patterns to the heterozygous patients . In the methionine homozygous
group a synaptic pattern of staining was seen on immunohistochemical analysis,
whilst in the heterozygous group granules and plaque like structures were seen.
Homozygosity for E200K-129M
A small number of cases of homozygosity for the E200K mutation have
appeared; these patients have a slightly younger age at onset, but otherwise appear to
be indistinguishable from heterozygous cases344'58. The authors also found a non¬
significant increase in disease duration; this could well simply be due to the younger
age at onset.
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Table 2.38 E200K-129M Clinical phenotype, investigative and
neuropatholoaical findings








(33 to 84 years)
6 months'15,261,251
(2 to 41 months)
MM or MV
Clinical features FHx
Similar to sCJDMMl; cognitive, psychiatric, cerebellar or visual problems or myoclonus
at onset
Later dementia in all cases, cerebellar signs in 79%, myoclonus in 73%, seizures in 40%,












Similar to sCJDMMl 295,115
Immunohistochemistry
Synaptic pattern of PrPSc deposition
Type 1 PrPRes; unglycosylated form under-represented115
Stripe-like PrPSc deposition in the cerebellum185
Cases with associated tau deposition, neurofibrillary tangles and amyloid angiopathy reported212
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2.XXX E200K-129V
The coupling of the E200K mutation and valine at codon 129 has only been
observed in a handful of patients.
Hainfellner et al.'50 reported a 66 year old woman, with an extensive family
history of dementia and depression (in relatives in their 7th decade). She developed
rapidly progressive dementia and pyramidal signs, and died 3 and a half months later.
There was a prodrome of a 2 and a half year history of slight memory problems. An
EEG showed slowing, with right frontal triphasic spikes, whilst CT and MRI showed
evidence of ventricular enlargement. Neuropathological examination revealed
atrophy and neurofibrillary degeneration (which may account for her prodromal,
mild cognitive decline). Diffuse spongiform degeneration, astrogliosis and neuronal
loss occurred in the cerebral and cerebellar cortices and basal ganglia. PrPRes type 2
was present in a synaptic pattern in the cerebral cortex, basal ganglia, brainstem and
cerebellar cortex. In addition there were plaque-like deposits in the cerebellar
granular layer and subcortical white matter. Little unglycosylated PrPRes was found.
The patient was valine homozygous at codon 129.
317The female patient described by Puoti et al. developed ataxia at the age of
67 years, followed by dementia and myoclonus, dying 6 months after symptom
onset. The EEG showed slowing only. There was no known FEIx. Genotyping
demonstrated the E200K mutation with valine on the mutated allele and methionine
on the wild-type allele. PM analysis demonstrated type 2 PrPRes in most brain
regions, with the exception of the cerebellum, where a double band was found on
Western blot. The nationality of the patient was not given, but the case report
originated in Italy.
It would appear that the phenotype of E200K-129V does differ from that of
E200K-129M, but there is insufficient data to categorise it further. It is unclear to
what extent the codon 129 of the wild-type allele influences the presentation. The
difference in PrPRes type is striking.
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2.XXXI D202N-129V
One English individual and 1 (unpublished) Canadian family are known with
prion disease due to this mutation304'312. The salient features of the British case are
given below; very few details of the Canadian family are available. Investigative
findings for the British case have not been reported.
Table 2.39 D202N-129VClinical phenotvpe, investigative and
neuropatholoaical findings
Sex Origin Onset (years) Duration (years) Codon 129
F England 73 6 VV
Onset Clinical features FHx
Cognitive decline Dementia, cerebellar features Unknown
Neuropathological findings Immunohistochemistry
Abundant PrPSc amyloid deposition in the
cerebrum & cerebellum
Neurofibrillary tangles in the cerebral cortex
No spongiform degeneration
Absence of21-30kDa band
Similar pattern to F198S
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2.XXXII R208H-129M
Only 4 patients have been reported with neuropathologically confirmed prion
disease and the R208H-129M (arginine to histidine) mutation have been
described244'325'49'61. In all cases the family history was negative, although in the
Chinese family several unaffected mutation carriers were found. Overall the
phenotype closely resembles that of sCJD MM1, however the case reported by
Roeber et al.325 had unusual features, namely tau positivity and a 17kDa fragment on
Western blotting. This fragment was more abundant in the cerebellum.
Table 2.40 R208H-129M Clinical phenotype, investigative and
neuropatholoaical findings
Origin Age at onset (range) Duration (range) Codon 129 FHx
N.America, China,
Italy, Germany
58 to 69 4 to 12 MM Negative
Onset Clinical features
Cognitive decline; gait disturbance
involuntary movement
Dementia, cerebellar syndrome, involuntary movements,
psychiatric symptoms
EEG Neuroimaging 14-3-3
Positive in 3 of 4 tested Atrophy in one case; high signal in cortex or
basal ganglia not reported
Positive in 1 of 3 cases
tested
Neuropathological findings
Atrophy, severe spongiosis, neuronal loss & astrocytosis
Synaptic PrP deposition reported in 2 cases
Occasional neurofibrillary tangles & tau positive in 1 case
Immunohistochemistry
PrPKes type 1
17kDa fragment in 1 case
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2.XXXIII R208H-129V
One patient with definite prion disease and the R208H mutation coupled with
• 90
valine at codon 129 has been described . In contrast to those cases due to
R208H-129M, this case had a long duration, and neuropathological changes more in
keeping with GSSS.







France 58 36 VV
Onset Clinical features FHx
Cognitive & behavioural decline Cerebellar ataxia, primitive reflexes, pyramidal
signs, gaze paresis, nystagmus, demyelinating





Severe spongiform change & gliosis.
Kuru plaques in the cerebellum, especially in the molecular layer.




The V210I mutation has been described in patients ofEuropean, N.
American, Chinese and Japanese Origin307-320',03'341'53'272'392-172'242'32°'307. Within
Europe it is particularly seen in the Campania and Umbria regions of Italy223. Most
cases have negative family histories, and the mutation has been demonstrated in
elderly, asymptomatic family members. This suggests that the penetrance is low. A
summary of the reported clinical features is given below.
Table 2.42 V210I-129M Clinical phenotype, investigative and
neuropathoioaicai findings





6 (2 to 24) MM & MV
Onset Clinical features FHx
Memory or gait problems, dystonia,
dysarthria, sensory symptoms





Periodic complexes Atrophy or cortical & basal ganglia high signal Positive
Neuropathological findings Immunohistochemistry
Fine spongiform degeneration & gliosis of the grey matter PrPRes type 1A
Overall the clinico-pathological features strongly resemble those seen in
sCJD, and in several cases the patient was originally diagnosed with sCJD prior to
genotyping being performed. Transmission to transgenic mice and bank voles has
been successful242'3. Both studies found PrPSc type 1, and neuropathological changes
resembling those of animals inoculated with sCJD MM1 or MV1. The mutation has
not been found in control subjects.
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2.XXXV E2110-129M
Two apparently unrelated families with prion disease due to the E21 HQ
999 909
(glutamic acid to glutamine) mutation have been reported ' . The French family
consisted of a proband with neuropathologically confirmed disease, and 3 siblings
with similar illnesses but no neuropathological examination. The proband was found
to have both the E211Q mutation and the rare silent polymorphism G124G on the
mutated allele. The Italian family consisted of a proband with probable prion disease
and 3 siblings, 2 with probable and 1 with possible prion disease.
Table 2.43 E2110-129M Clinical phenotvpe. investigative and
neuropatholoaical findings of the family reported by Peoc'bM)2
Origin Mean Onset (years) Duration (months) Codon 129
France 64 6 MM
Onset Clinical features FHx
Behavioural change & cerebellar ataxia Dementia, myoclonus Positive
EEC Neuroimaging 14-3-3




Table 2.44 E2110-129M Clinical phenotvpe, investigative and
neuropathotoaicai findings of the family reported bv
Ladoaana222
Origin Mean Onset (years) Duration (months) Codon129
Italy 68 5 MM
Onset Clinical features FHx




Periodic complexes Atrophy Positive
2.XXXVI 0212P-129M
The rare Q212P mutation has only been described in 2 individuals, 1 of
whom was homozygous for the mutation. It is unclear if this is a pathogenic mutation
with a low penetrance, or possibly a non-pathogenic polymorphism. In the Irish
pedigree investigated by Beck et al, the proband was homozygous ofQ212P-129M,
9 S
and several elderly relatives were heterozygous for it and unaffected"". The only
positive family history comes from a maternal grandmother with dementia in old age.
However the mutation has not been found in control populations, and the affected
American individual had neuropathologically confirmed prion disease, increasing the
likelihood that it is a pathogenic finding.
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Table 2.45 0212P-129M Clinicalohenotvoe. investigative and
neuropatholoaicat findings of the individual reported bv
Young 407
Origin Onset (years) Duration Codon 129
USA 60 8 years MM
Onset Clinical features FHx
Incoordination, slurred speech, difficulty swallowing Ataxia, preserved cognition Negative
EEC Neuroimaging 14-3-3
Not done MR1 normal Not done
Neuropathoiogicai Findings
Mild amyloid deposition, particularly in the cerebellum. PrP positive on IHC
Axonal degeneration in the anterior and lateral corticospinal tracts
Table 2.46 Q212P-129M Clinicalphenotvpe, investigative and
neuropathoiogicai findings of the individual reported by
Beck 25
Origin Onset (years) Duration Codon 129
Ireland 36 Alive 4 years after onset MM
Onset Clinical features FHx
Balance problems, slurred speech Cerebellar & pyramidal signs; dementia Positive
EEG Neuroimaging 14-3-3
Diffuse slowing Moderate cerebral atrophy Not done
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2.XXXVII 0217R-129V
Two N. American families and 1 Swedish family have been described with
• • 122 123 170 396 * * * * *this mutation ' ' ' , which causes an arginine for glutamine substitution. Thus
far attempts to transmit the disease to experimental animals have failed170. One
patient from the Swedish family was reported to be heterozygous at codon 129; a
further individual from a different family was reported to be valine homozygous 396.
Further details are given in the tables below.
Table 2.47 0217R-129V Clinical phenotvpe, investigative and
neuropatholoaical findings122
Origin Onset (years) Duration (years) Codon 129
N. America, Sweden <63 to 65 >4 to 6 MV
Onset Clinical features FHx
Cognitive decline Dementia, gait ataxia, dysphagia, parkinsonism Positive
Neuropathological findings
PrP positive amyloid plaques
Numerous PrPSc deposits in the cerebral cortex, basal ganglia, thalamus, cerebellum & midbrain
Neurofibrillary tangles & neuropil threads in the cerebral cortex, basal ganglia, thalamus &
hippocampus
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Table 2.48 0217R-129WClinical phenotvpe, investigative and
neuropathoioaicai findings396
Origin Onset (years) Duration (years) Codon 129
Canada 45 13 VV
Onset Clinical features FHx





Abundant PrP positive large amyloid plaques
Smaller multi-centric plaques. Neurofibrillary tangles.
Minor focal spongiosis. Neuronal loss and astrocytic gliosis
Immunohistochemistry
Bands at 18 to 19 kDa and 27 to 29kDa following digestion with protease K
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2.XXXVIII M232R-129M
The M232R-129M mutation has been identified in unrelated Japanese,
Chinese and Korean individuals1 6,1 7'41 '64, none whom had positive family histories.
It is the fourth commonest mutation associated with gPD in Japanese patients • One
patient was identified with the mutation and pathological evidence of DLB203. It has
also been identified in conjunction with the VI801 mutation (on the other allele) in a
single case164. Brain homogenate from patients with M232R-129M has been
successfully used to transmit disease to animals166. Some authors divide cases into a
rapidly progressive group and a slowly progressive group ' , which may have
differences in PrPSc type and staining pattern. The numbers reported are small and it
is difficult to know how clear a divide there is between these groups. The mutation
has not been found in Japanese or Chinese controls166'416.
Table 2.49 M232R-129M Clinical phenotype, investigative and
neuropatholoaical findings
Origin Age at onset (range) Duration (range) Codon 129
Japan & China 44 to 70 years 18 months (4 to 24) MM*
Clinical features FHx




Periodic complexes or slow Atrophy or cortical & basal ganglia high signal Positive*
Neuropathological findings
Spongiform change, neuronal loss, severe astrocytosis
Diffuse PrPSc deposition in the grey matter. No plaques.
Type 1 PrPRes in a synaptic distribution in the 'slow' cases
Type 2 or type 1 and 2 PrPRes in a synaptic and perivacuolar distribution in the 'rapid' cases353
* In addition there is an unpublished case which was heterozygous at codon 129312.
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Table 2.50 M232R-129M & V180I-129M Clinical phenotvoe. investigative
and neuropatholoaical findings
Origin Mean age at onset (range) Mean Duration (range) Codon 129
Japan 84 12 MM
Clinical features FHx
Dementia, altered taste, myoclonus (mild), startle response, akinetic mutism. Negative
EEG Neuroimaging 14-3-3
Diffuse slowing Cerebral & basal ganglia atrophy; cortical high signal Not done
Neuropathological findings
Cortical spongiform change
PrPRes present with an unusual glycoform ratio
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2.XXXIX PRNPMutations Reported as Single Cases
A number of PRNP mutations have been reported as occurring in single
individuals only. The pathogenenicity of such mutations may therefore be uncertain,
as in most cases the family history is negative or unknown. Details are given in the
tables below.
Table 2.51 Single cases clinical phenotvpe (1)




S97-129M416 F China 74 Alive at 77 years MM
VI801 & M232R197 ? Japan 84 1 year MM
T188A-129M71 F Australia 82 4 months MM
T1931-129M208 F Greece 70 9 months MM
F198V-129M416 M China 56 Alive at 60 years MM
D202G-129V159 M Germany 55 16 years MV
V203I-129M302 M Italy 69 1 months MM
V2031-129V187 F Korea 66 2 months MV
R208C-129M416 M China 81 Unknown MM
Y218N11 ? Spain Unknown Unknown Unknown
M232T232'33 ? Poland 44 6 years MV
Y226X-129V182 F Holland 55 27 months MV
Q227X-129V182 F Holland 39 72 months MV
P238S392 ? Germany Unknown Unknown Unknown
24 nucleotide insertion163 M Canada 31 Unknown MV*
* The insertion was in cis with methionine at codon 129.
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Table 2.52 Single cases clinical phenotvoe (2)
Haplotype Clinical features FHx
S97-129M416 Dementia, hallucinations, delusions, visual loss, pyramidal signs.
Clinical diagnosis of Alzheimer's disease
Negative
V180I & M232R197 Dementia, myoclonus, akinetic mutism Negative
T188A-129M7' Dementia, myoclonus, hyper-reflexia, extensor plantars, frontal
release signs, visual hallucinations, cortical blindness
Negative
T1931-129M208 Dementia, behavioural change, visual hallucinations, hyper-reflexia,
gait problems, myoclonus & startle response
Negative
E196K-129M302 Behavioural change, dementia, chorea-athetosis & mutism Positive
F198V—129M416 Behavioural change, dementia, visual hallucinations, myoclonus,
extrapyramidal signs
Negative
D202G-129V159 Dementia & hypersomnolence, marked cerebellar syndrome,
pyramidal & extrapyramidal signs, akinetic mutism, mild autonomic
dysfunction
Positive
V203I-129M302 Diplopia & dizziness followed by dementia, visual hallucinations,
ataxia, nystagmus, myoclonus
Negative
V203I-129V187 Gait disturbance and dementia followed by involuntary movements
(including myoclonus) and extrapyramidal signs
Negative
R208C-129M416 Dementia Negative
Y218N" Dementia (consistent with Alzheimer's disease or frontotemporal
dementia)
Positive
M232T232-33 Cerebellar syndrome, dementia, spastic paraparesis Negative
Y226X-129V182 Cognitive impairment, pyramidal signs, myoclonus, akinetic mutism Positive
Q227X-129V182 Cognitive decline, extra-pyramidal signs, seizures, mutism Positive
P238S392 'Possible prion disease' (no further details reported) Unknown
24 nucleotide
insertion163
Cognitive decline, epilepsy, gait disturbance, slurred speech,
paratonia, axial rigidity, myoclonus
Negative
96
Table 2.53 Single cases investigative findings
Haplotype EEG Neuroiinaging 14-3-3
S97-129M416 Slow Atrophy Unknown
V180I & M232R197 No periodic complexes Unknown Unknown
T188A-129M71 Periodic complexes Atrophy (normal for age) Positive
T193I-129M208 Periodic complexes Atrophy (normal for age) Positive
E196K-129M302 No periodic complexes Unknown Unknown
F198V-129M4'6 Slow Atrophy Unknown
D202G-129V159 Slow Cerebellar atrophy Positive
(SI00b >30ng/ml)
V203I-129M302 Periodic complexes Unknown Unknown
V203I-129V187 Not done Cortical high signal Positive
R208C-129M416 NA Atrophy Unknown
Y218N11 Unknown Unknown Unknown
M232T232'33 Unremarkable Unremarkable Unknown
Y226X-129V182 Periodic complexes White matter high signal Positive
Q227X-129V182 Not done Moderate atrophy Not done









Table 2.54 Single cases neuropatholoaical findings
Haplotype Neuropathological findings
S97-129M416 Not done
VI801 & M232 R197 Typical spongiform change in the cerebral cortex, basal ganglia & thalamus.
Neuronal loss & gliosis in the cortex
Weak PrPSc staining. Highest molecular weight PrPRcs band absent
T188A-129M71 Spongiform change (most severe in occipital cortex);
PrP 1HC negative. Amyloid plaques ('normal for age')
T193I-129M208 Not done
E196K-129M302 CJD (sic) & protease resistant PrP
F198V-129M4'6 Not done
D202G-129V159 Unknown
V203I-129M3"2 CJD (sic) & protease resistant PrP
V203I-129V187 Moderate spongiform degeneration and vacuoles in the
frontal cortex with synaptic PrP. Type 1 PrPRes
Granular PrPSc deposition in the granular layer of the cerebellum
R208C-129M4'6 Not done
Y218N11 PrPKes deposition. Widespread tau pathology
Mutant ubiquitin in neurofibrillary tangles and dystrophic neurites.
Multiple PrPRes bands ranging from lOkd to 80kd.
M232T232'33 Severe atrophy
Multiple PrPSc positive, kuru-type & multi-centric plaques in the molecular
layer of the cerebellum, cerebral cortex and hippocampus
Y226X-129V182 Diffuse severe amyloid angiopathy, strongly PrPSc positive
Faint synaptic PrPSc deposition. Focal tau deposition
Q227X-129V182 Scattered status spongiosus
Numerous multicentric and unicentric plaques




Mild neuronal loss, microspongiosis, multi-centric plaques
(Right frontal gyrus brain biopsy specimen)
In addition an I138M mutation has been reported in a French patient
described as having 'frontal dementia, not CJD'. A G142S mutation has been reported
in a N. African male with multiple sclerosis and a Mali female with viral
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meningoencephalitis. However G142S has been found in healthy control populations,
and it may well be a normal polymorphism ' ' . A number of other
polymorphisms have been identified in both control populations and prion disease
25
patients, which are thought to most likely be non-pathogenic .
2.XL Insertional and Deletional Mutations
PRNP normally has a repeating oligopeptide coding sequence between
codons 51 and 91. These can distinguished by their nucleotide code and as classified
as : R1 - R2 - R2 - R3 - R4 24'51. Families with 1, 2, and 4 to 9 and 12 extra repeat
insertions have been described with prion disease. Pathogenicity due to 3 extra
repeats has not been seen. Possible and definite CJD linked to a 2 repeat deletion has
also been described219. The clinicopathological phenotype seen varies according to
the number of repeats present; broadly speaking those with 4 or less repeat insertions
resemble CJD, and those with higher number of repeats have a GSSS-like disease.
The codon 129 status may also influence the phenotype seen.
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2.XLI Two-Octapeotide Repeat Deletion
Two cases of prion disease due to a deletion of 2-octapeptide repeats have
been reported2 '
Table 2.55 2-octapeptide repeat deletion clinical ohenotype, investigative
& neuropathoioaicai findings of the family described by Beck24
Sex Origin Onset (years) Duration (months) Codon 129
F N. Europe 85 23 MM
Onset Clinical features FHx
Confusion Dementia, pyramidal, extrapyramidal & cerebellar signs Negative
EEG Neuroimaging 14-3-3
Non-specifically abnormal White matter high signal & cerebral atrophy Not done
Octapeptide repeat sequence
R1-2-4 (deletion of R2-3)
Table 2.56 2-octapeptide repeat deletion clinical phenotvpe, investigative
& neuropathoiogicai findings of the family described by
Capeiiari et ai.51
Sex Origin Onset (years) Duration (months) Codon 129
M Italy 62 18 MM
Onset Clinical features FHx
Personality & behavioural
change, dizziness
Dementia, myoclonus, balance problems Positive
EEG Neuroimaging 14-3-3
Periodic complexes Normal Positive
Octapeptide repeat sequence
R1-3-4 (deletion ofR2-2)
The deletions seen in the 2 cases were different; the first case had a diagnosis
of possible CJD, and the second had neuropathologically confirmed prion disease,
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with fine spongiosis and gliosis seen, accompanied by severe neuronal loss. The
thalamus and pulvinar were relatively spared. Type 1 PrPRes Was seen, with a
synaptic pattern of deposition. Capellari et al. concluded that their case resembled
sCJD MM1, although the duration was significantly longer than is typically seen in
sCJD. The only FHx was of the patient's mother having died at the age of 80 years
with a diagnosis of Alzheimer's disease. The significance of this is unclear. The 2-
repeat deletion has not been found in normal controls, and is therefore likely to have
been pathogenic in these 2 cases.
2.XLII One-Octapeptide Repeat Insertion
Three male cases of CJD due to 1 extra octapeptide repeat have been
OOA OA/
described (Case 1 Cases 2 and 3 ). A summary of the clinical features and
investigative findings is given in the tables.
Table 2.57 1-OPRI clinical phenotvpe (1)





x 216 M France 73 4 MM R1 - R2 - R2 - R2 - R3 - R4
2^06 M Italy 58 5 MM R1 - R2 - R2 - R3g - R3 - R4
2 306 M Italy 64 6 MV* R1 - R2 - R2 - R3g - R3 - R4
* The extra repeat was on the M allele.
Table 2.58 1-OPRI clinical ohenotvpe (2)
Case Onset Clinical features FHx
.226 Dizziness Visual agnosis & later cortical blindness, cerebellar ataxia,
dementia, myoclonus, akinetic mutism
Positive
2J06 Visual loss &
paranoia
Gait ataxia, myoclonus, drowsiness Negative
2 306 Paraesthesia Behavioural change, dementia, aphasia, gait difficulties,
hallucinations, myoclonus, Babinski positive, akinetic mutism
Negative
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Table 2.59 1-OPRI investigative findings
Case EEC Neuroimaging 14-3-3
j 226 Positive Normal NA
2306 Positive Normal Positive
3 306 Positive Atrophy Positive
Only case 1 had any significant family history, with the patient's father
having died of an unknown neurological illness at the age of seventy years.
Only case 3 underwent a PM. Gliosis and spongiosis of the cortex were
observed, with a diffuse, synaptic pattern of PrPSc staining in the cortex and sub¬
cortical grey matter. A granular and thread-like pattern of PrPSc deposition was found
in the thalamus, basal ganglia, hypothalamus and amygdala. The amygdala also had
florid plaque-like lesions. In the cerebellum an irregular pattern of PrPSc deposition
was observed. Both type 1 and type 2 PrPRes were present, with the former being in
the cortex and the latter in the thalamus, hypothalamus, striatum, pallidum and
cerebellum.
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2.XLIII Two-Octapeptide Repeat Insertion
Two families have been described with gPD due to a 2-OPRI mutation. The
family described by Goldfarb et al.133 had a history of dementia affecting the
proband, her mother and maternal grandmother. The proband and her mother both
had the same PRNP insertion; however the proband died at the age of 58 years after a
3 month long illness characterised by a rapidly progressive dementia, whereas her
mother had onset at the age of 75 years and was still alive with severe dementia at
the age of 88 years.
The Dutch family described by van Harten et al.366 comprised the proband,
who died of dementia at the age of 68 years, and did not have a PM. There was a
history of dementia in both parents and also her brother; however her brother did not
have any mutation of the PRNP gene. The proband had a different insertional
mutation (to the American family) and also had substitution of R2 for the normal R3.
It is therefore unconfirmed if the proband's illness was actually due to prion disease
or not; of significance are the marked white matter abnormalities seen on
neuroimaging, the cause of which is not known.
Table 2.60 2-OPRI clinical phenotvpe, investigative and neuropathological
findings of the family described bv Goldfarb133
Sex Origin Mean Onset (years) Duration (range) Codon 129
F N. America 71 (58 to 80) 3 months to 15 years Not reported
Clinical features FHx Octapeptide repeat sequence
Progressive dementia; mutism Positive Rl-R2-R2-R3-R2a-R2a-R4
EEG Neuroimaging 14-3-3
Periodic activity Incidental benign meningioma Not reported
Neuropathological Findings
Spongiform change, gliosis & neuronal loss
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Table 2.61 2-OPRI clinical phenotvoe. investigative and neuropathoioQicai
findings of the family described bv van Harten366
Sex Origin Onset (years) Duration (months) Codon 129
F Holland 61 7 years VV
Clinical features FHx Octapeptide repeat sequence
Dementia & gait ataxia Positive Rl-2-2a-2-2a-2a-4
EEG Neuroimaging 14-3-3
Not done Severe cortical atrophy; frontal leukoencephalopathy Not done
2.XLIV Three-Octapeptide Repeat Insertion
No cases of neurological illness due to a 3-OPRI have been identified. During
large-scale screening of the PRNP gene in Chinese individuals a 3-OPRI was been
identified in an 11 year old Chinese girl; she was healthy at the time and had no
family history of neurological illness408.
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2.XLV Four-Octapeptide Repeat Insertion
Four different extra octapeptide repeats have been associated with prion
disease in 5 cases47,226'174'400'329. In 1 further case the mutation was found in an
individual with no clinical or neuropathological evidence of prion disease134. The 59
year old sister of one of the affected cases also carried the mutation but was
unaffected329. The clinicopathological phenotype and investigative findings are
summarised in the tables. In 3 families the mutation was on an allele encoding
methionine at codon 129 and in 1 family valine; the codon 129 status in one further
family was unknown.
Table 2.62 4-OPRI clinical phenotvpe (1)





Campbell47 M Britain 56 8 weeks MM R1-2-2-2-2-2-2-3-4
Laplanche226 F France 82 4 months VV R1-2-2-3-2-2-2-3-4
Rossi329 M Italy 65 6 months MM Rl-2-2-3g-2-3g-2-3-4
Isozaki174 M Japan 62 7 years Unknown Unknown
Yangihara400 M Japan 56 5 months MM R1-2-2-2-3-2-2-3-4
Table 2.63 4-OPRI clinical phenotvpe (2)
Family Onset Clinical features FHx
Campbell4r Dementia, gait
problems, myoclonus
Dementia, cerebellar signs, myoclonus, primitive
reflexes, terminal akinetic mutism
Negative
Laplanche226 Dizziness Ataxia, visual agnosis, dementia, cortical blindness,
myoclonus, akinetic mutism
Positive
Rossi329 Speech & gait
problems
Dementia, gait ataxia, pyramidal signs, myoclonus,
terminal akinetic mutism
Negative
Isozaki174 Not reported Dementia & extrapyramidal signs Unknown
Yangihara400 Cerebellar ataxia &
myoclonus
Visual loss, gait problems, dysarthria, ataxia,
dementia, myoclonus, increased tone, hyper-reflexia
Negative
105
Table 2.64 4-OPRI investigative and neuropathoiogicai findings
Family EEG Neuroimaging Neuropatliological Findings
Campbell47 Positive Mild global atrophy Spongiform change, astrocytosis & neuronal
loss; PrPSc deposition in the molecular layer
of cerebellum
Laplanche226 Positive Normal Not done
Rossij29 Positive High signal in striatum
& thalamus
Spongiosis, neuronal loss, gliosis, diffuse
PrPSc deposition in a synaptic pattern
Isozaki174 Not done Not done Spongiform change
Yangihara400 Positive Cerebellar atrophy Not done
In addition CSF analysis in one case was positive for 14-3-3329. In one case
an unusual pattern of PrPSc deposition in the molecular layer of the cerebellum was
seen, with the PrPSc being perpendicular to the leptomeningeal surface47.
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2.XLVI Five-Octapeptide Repeat Insertion
Eleven different five-octapeptide insertions have been reported; the findings
are summarised below.





'Kel' family134 R 1 -2-2-3-2-3g-2-2-3 -4 Unknown N. American 2
Cervenakova57 Rl-2-2-2a-2-2a-2-2-3-4 M N. American 1
Cochran66 R1-2-2-3-2-2-2-2-3-4 M Ukrainian 10
Wiiidl3^ R1 -2-2-3-2-2-2a-2-2-4 V German 2
Skworc345 R1 -2-2-3g-3g-3g-2-2-3-4 M German 3
Cervenakova5' R1-2-2-3-2-2-2a-2-3-4 M American 1
Beck23 R1-2-2a-2-2-3g-2-2-3-4 M Japanese 1
Mead(l)256 R1 -2-3-2-3-2-3g-2-3-4 M S. African 5
Mead (2)256 Rl-2-2-3g-2-2-2-2-3-4 M English 3
Mead (3)256 R1 -2-2-3-2-3g-2-2-3 -4 M N. Irish 1
Jansen180 R1-2-2-2-2-2-2-3-4 M Holland 2
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Table 2.66 5-OPRI clinical phenotvpe (2)
Reference Onset
(years)
Duration Codon 129 FHx
'Kel' family134 36 10 years Unknown Positive
Cervenakova57 Not reported M* Positive
Cervenakova Not reported M* Positive
Cochran66 49 9 months to 16 years MM Positive
Windr2 Not reported MV** Unknown
Skworc345 54 9 months to 8 years MV Positive
Beck"3 45 > 4 years (alive) MM Positive
Mead (if6 46 18 months to 7 years MM Positive
Mead (2f6 45 9 years MV & MM Negative
Mead (3f6 63 10 months MM Positive
JansenIS0 35 92 months MM Positive
* The codon 129 status of the wild type allele was not reported; no clinical details
have been published for these families; both were documented as having pathological
evidence of prion disease but no further details are available.
** No further details are available regarding these cases.
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Table 2.67 5-OPRI clinical phenotvpe (3)
Reference Onset Clinical features








Gait ataxia, pyramidal signs, cerebellar signs, dementia,
increased tone, seizures, myoclonus
Beck'3 Cognitive decline Slowly progressive cognitive problems & cerebellar ataxia
Mead (1 )256 Personality change Dementia, ataxia, myoclonus, akinetic mutism
Mead (2)266 Cognitive & balance
problems
Dementia, rigidity, paratonia, primitive reflexes, ataxia
Mead (3)2i6 Visual disturbance Dementia, visual hallucinations, ataxia, myoclonus,
hypertonia, pyramidal signs, akinetic mutism
Jansen180 Memory loss,
dysgraphia
Dementia, parkinsonism, anxiety, vertical gaze palsy
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Table 2.68 5-OPRI investigative findings
Reference EEG Neuroimaging CSF 14-3-3
'Kef family134 Slow Not reported Not reported
Cochran55 Non-specitlcally abnormal Atrophy Not analysed
Skworc345 Slow (1 case)
Periodic complexes (1 case)
Atrophy Negative
Beck23 Slow Atrophy Not analysed
Mead (I)256 Spike & wave complexes but not periodic Atrophy Not analysed
Mead (2)256 Non-specifically abnormal Atrophy Not analysed
Mead (3)256 Periodic sharp waves Cerebral atrophy Positive
Jansenl8(r Not reported Atrophy Negative
Table 2.69 5-OPRI neuropathoiogicai findings
Reference Neuropathoiogicai Findings
'Kel' family134 Spongiosis, gliosis & neuronal loss
Cervenakova57 Prion disease (no further details given)
Cervenakova57 Prion disease (no further details given)
Cochran66 Atrophy, spongiosis, neuronal loss, gliosis
Skworc345 Spongiosis, gliosis, neuronal loss.
Most Purkinje cells in molecular layer; PrPSc plaques in the cerebellum
Beck23 No details available
Mead (l)256 Atrophy, severe spongiosis, neuronal loss & astrocytosis. Severe Purkinje cell
loss in granular layer of cerebellum. PrPSc deposition in a synaptic pattern &
plaques
Mead (2)256 Spongiosis, neuronal loss, astrocytosis. PrPSc deposition in the cerebellar
molecular layer, perpendicular to the glial surface
Mead (3)256 No PM performed
Jansen180 Mild spongiosis & astrocytic gliosis;
frontal, temporal & parietal lobes worst affected
Moderate gliosis of the cerebellar molecular layer;
unusual localisation of Purkinje cells
Faint synaptic PrPSc deposition; PrPRcs types 1 and 2
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In the family reported by Skworc et al.345 there was no evidence of
anticipation, but there was a history of other family members requiring treatment for
psychiatric problems, and 1 affected family member had a history of a long-standing
personality disorder. The cerebellar appearances found in the family reported by
Skrowc et al.345 varied between individuals, but all had unusual findings in the
cerebellum, with most Purkinje cells being localised to the molecular layer, and PrP
positive plaques being present in the molecular and / or granular layers.
The family reported by Cochran et al.66 had a strong history of psychiatric
problems, and 1 affected member had a long-standing personality disorder. Only
very limited details were available regarding the families described by Windl et al.392
and Cervenakova et al.57
14-3-3 analysis was performed in 2 cases and was negative in one66 and
positive in the other256.
Of note is the fact that the insertion differed between the families, except in
the case of the 'Kef family134 and the Northern Irish patient described by Mead et
al.256
The patient described by Jansen et al.180 had an unusual pattern of PrPRes
deposition, with both Type 1 and 2 being present in the frontal cortex and cingulate
gyrus; type 1 only in the parietal cortex; type 1 and a trace of type 2 in the occipital
cortex and type 2 only in the cerebellar cortex and caudate nucleus.
Overall most patients had symptom onset in middle age, with the main
features being cognitive decline, gait problems, cerebellar and pyramidal signs and
myoclonus. Usually the duration was around a decade, with only a few individuals
dying within a year of symptom onset. In most cases there was a positive FHx of
prion disease, and several families there were findings of background long-term
psychiatric or behavioural problems, even in individuals who tested negative for any
PRNP mutation. The pathological findings were similarly to sCJD-MMl, with
additional features in the cerebellum of unusual PrP deposition or abnormalities of
Purkinje cells. In summary the patients described resemble sCJDMMl, albeit with a
longer duration and some unusual pathological features.
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2.XLVII Six-Octapeptide Repeat Insertion
Seven families and one individual with a 6-OPRI in the PRNP gene are
known; 2 have not been published in detail. Each has a different insertion.
Table 2.70 6-OPRI genotype and clinical phenotype fl)




Poulter'09 R1 -2-2-2-3-2-3g-2-2-3-4 M Britain 86
Nicholf76 R1 -2-2-3-2-3g-2-3g-2-3-4 M Britain >2
Oda282 R1 -2-2-3g-2-2-3g-2-2-3-4 M Japan 6
Capellari52 R1-2-2-2-2-2-2-2-2-3-4 M Spain 3
Cervenakova57 R1-2-2-2-2-2-2-2-3g-3-4 M N. America ?
Cervenakova57 Rl-2-2-2c-2-2-2-2-2-3-4 M Britain ?
Gelpi120 R1-2-2-2-2-2-2-2-2-3-4 M Austria 1
Kovacs213 R1 -2-2-3-2-3g-3-2-2-3-4 M Hungary 2
Vital368 R1-2-2-3-2-3g-2-2-2-3-4 V France 1











(SD 5) MV Positive
Nicholl2'6 34 & 46 2 months & 4 years Unknown Positive
Oda282 26 to 34 5 to 10 years MM Positive
Capellari52 31 to 38 4 to 10 years MV Positive
Gelpi120 65 4 months MM Negative
Kovacs213 33 & 35 3 years MM Positive
Vital368 65 9 months MV Negative
* The disease duration was not significantly different in the MM and MV patients.
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Table 2.72 6-OPRI clinical phenotvpe (3)
Reference Onset Clinical features
Poulter309 Behavioural change; cognitive
decline
Cortical dementia, cerebellar & pyramidal signs;
myoclonus. Variable clinical phenotype
Nicholl276 Cognitive decline; unsteadiness &
cortical visual loss in 1 case
Dementia, cortical blindness, pyramidal signs, myoclonus,
paratonic rigidity, ataxia & akinetic mutism in 1 case.
Cerebellar signs, chorea & dementia in 1 case
Oda282 Behavioural change, dysarthria Dementia, cerebellar & extrapyramidal signs
Capellari52 Behavioural change, memory loss Dementia, myoclonus, cerebellar, extrapyramidal &
pyramidal signs; seizures in 2 cases
Gelpi120 Ataxia, dizziness, choreo-athetoid
movements, rest tremor, apraxia
Saccadic speech, language problems, dementia, myoclonus
Kovacs213 Memory problems Dementia, cerebellar signs, rigidity, behavioural change
Anosmia in 1 case
Vital368 Rapidly progressive dementia Dementia, cerebellar ataxia, extrapyramidal rigidity,
myoclonus
Table 2.73 6-OPRI investigative findings
Reference EEG Neuroimaging CSF 14-3-3
Poulter309 Non-specifically abnormal Normal or Atrophy Positive (1 case)
Nicholl2'6 Periodic complexes in 1 case Atrophy Not reported
Oda282 Slow Generalised atrophy Not reported
Capellari52 Slow in 2 cases
Periodic complexes in 1 case
Atrophy Not reported
Gelpi120 No periodic complexes Diffuse atrophy Positive
Kovacs213 Slow Atrophy Negative




Table 2.74 6-OPRI neuropatholoaical findings
Reference Neuropathologies! Findings
Poulter3™ Atrophy in some cases; variable spongiosis with cerebellum usually spared
Dense PrPSc staining in the cerebellar molecular layer;
perpendicular to pial surface
Plaque like deposits in parahippocampal gyrus in some cases. Type 2 PrPRes
Nicholl276 Widespread spongiform change with neuronal loss & gliosis in the cerebral
cortex & basal ganglia; patchy changes in the cerebellum (molecular & granular
layer)
Status spongiosis in the visual cortex in 1 case with cortical blindness
PrPSc deposition in the cerebral cortex & cerebellum
Oda282 Diffuse atrophy; patchy neuronal loss
Spongiosis of the cerebral cortex (frontal area worst affected)
Astrocytosis of the frontal cortex, amygdala, hippocampus
PrPSc positive plaques in the molecular layer of the cerebellum
Capellari52 Diffuse spongiform change, astrocytosis & neuronal loss in 1 case
No spongiform changes in 1 case
Elongated patches of PrP in the molecular layer of the cerebellum
Type 1 PrPRes present
Gelpi120 Moderate spongiform change in cerebral & cerebellar cortex; neuronal loss in
basal ganglia & occipital cortex
Numerous eosinophilic globules in the molecular layer & parahippocampal gyrus
Kovacs213 Mild frontal atrophy; neuronal loss in all cortical areas
Mild spongiform change & astrocytosis of the cerebellar molecular layer
& marked PrPSc deposition perpendicular to the leptomeningeal surface.
Strong PrPSc deposition in the olfactory tract & bulb (1 case examined)
Vital368 Marked spongiosis of the cortex, caudate & putamen
Kuru plaques, especially in the molecular layer of the cerebellum
PrPSc deposits perpendicular to the cerebellar parenchyma
In the original reports of the Poulter309 et al. family it was reported that
premorbid personality disorders were common; however in a recent re-analysis of the
family this finding was not upheld230. No premorbid personality disorders were
• • 989
reported in the Japanese family either
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One case reported by Kovacs et al.213 had PrPSc deposition in the olfactory
tract & bulb, associated with symptoms of anosmia. Interestingly the pathological
190 • •
appearances of eosinophilic globules found by Gelpi et al. in their patient were
also present in one individual from the Poulter et al.309 family. Overall the clinical
phenotype was variable, and to some degree influenced by the codon 129 status of
the wild type allele, with MV individuals having an older age at onset, although the
• 250 • j* •disease duration was unchanged . This finding is borne out by the Basque family
reported by Capellari et al/2, where 2 MV individuals had disease onset at 38 years,
with durations of 4 and 10 years. In the Poulter et al.309 family an older age at onset
seemed to be associated with a more aggressive disease course. This family is also of
interest as multiple generations are known to have been affected, and genetic analysis
has shown the mutation to be stable over time.
The only case to be reported with valine at codon 129 of the mutated allele is
that reported by Vital et al.368, which is notable for having neuropathological
appearances consistent with GSSS, although the clinical picture resembled that of
sCJDMMl. It is difficult to speculate further as to how codon 129 may have
influenced the clinicopathological features when only 1 case with valine on the
mutated allele has been described, but there does seem to be a trend for valine at the
mutated allele to be associated with GSSS neuropathology.
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2.XLVIII Seven-Octapeptide Repeat Insertion
Four families and 3 individuals have been reported to have prion disease due
to the 7-OPRI mutation with the majority being neuropathologically confirmed. The
clinical phenotype in those cases coupled to methionine on the mutated allele is one
of a young age at onset and prolonged duration; the clinical features resemble those
of sCJDMMl with dementia being a dominant feature, accompanied by a pyramidal,
cerebellar or extra-pyramidal signs and myoclonus. However the investigative
findings do not resemble those of sCJDMMl, with neuroimaging typically showing
atrophy, and EEG periodic complexes only being reported in 1 case. Pathologically
spongiform encephalopathy is seen, and in 1 family84 elongated PrPSc deposits in the
cerebellum. One member of this family also carried the E318G mutation of the PSEN
gene, but the authors concluded that this had no effect on the phenotype seen.
Different repeat expansions have been reported in the different families. One
case has been shown to have developed a de novo insertion, as genotyping of both
parents was normal (with paternity being confirmed by haplotype analysis). Despite
the different insertions seen, the clinical and pathological features are relatively
consistent between the different families246'146'373'48'84'41'134. No asymptomatic
mutation carriers have been reported, suggesting a high level of penetrance.
One Dutch family has been reported with a 7-OPRI coupled with valine at
184codon 129 of the mutated allele . The age at onset was significantly younger
compared to previously reported cases with 7-OPRI 129M, and the duration
significantly shorter. As with many mutations associated with valine on the mutated
allele, the neuropathology showed multicentric amyloid plaques. GSSS is a
neuropathological diagnosis classically associated with an ataxic illness with late
cognitive decline; however in many cases the clinical features and the pathology do
not both match these criteria.
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Goldfarb1'4 R1-2-2c-3-2-3-2-3-2-3g-3-4 Unknown N. America 3
Dermaut84 Not reported M Belgium 3
Lewis231 R1-2-2-3-2-3-2-2-2-2-3-4 M Australia 3
Wang373 Rl-2-2-2-2-2-3g-2-3g-2a-3-4 M China 3
Canella48 Rl-2-2-3-2-2-3g-2-2-2-3-4 M Italy 1
Guo146 R1 -2-2-2-2-2-3g-2-3g-2a-3 -4 M China 1
Jansen184 R1 -2-2-2-2-2-2-3g-2-2-3-4 V Holland 6























6 to 50 months MM Negative
Canella48 18 > 10 MM Negative
Guo146 44 4 MM Positive
Jansen184 52.2 2.4 MV & VV reported Positive
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Table 2.77 7-OPRI clinical ohenotvpe (3)
Reference Onset Clinical features
Goldfarb134 Behavarioural change, gait or
cognitive problems
Dementia, behavioural change, cerebellar signs,
myoclonus & rigidity
Dermaut84 Cognitive or cerebellar
problems




Dementia, involuntary movements, generalised tonic-
clonic seizures
Wang373 Forgetfulness Dementia, dysarthria, hypertonia, ataxia
Canella48 Behavioural change Depression, psychosis, bipolar disorder, dementia,
cerebellar ataxia
Guo146 Slowly progressive dementia Dementia, myoclonus, pyramidal and cerebellar signs
Jansen184 Slowly progressive dementia Dementia, depression, hypokinetic-rigid syndrome





Wang373 Periodic complexes Normal
Canella48 Unknown Atrophy
Guo14b Periodic complexes & slow waves Normal
Jan sen184 Periodic complexes in 1 case;
Non-specific slowing in 2 cases
Basal ganglia high signal in 1 case;
atrophy in 1 case
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Table 2.79 7-OPRI neuropatholoaical findings
Reference Neuropathologieal Findings
GoldfartT4 Spongiosis, gliosis & neuronal loss
Trace of PrPSc present
Dermaut84 Atrophy, spongiosis, gliosis & neuronal loss
Elongated deposits of PrPSc in the cerebellum, perpendicular to the leptomeningeal
surface
Lewis231 Atrophy, marked spongiosis, gliosis & neuronal loss in the
cerebral cortex & basal ganglia.
Atrophy & synaptic PrPSc deposition in the cerebellum. Type 2 PrPRes
Wang373 Diffuse spongiform change, astrocytosis & neuronal loss
Type 2 PrPRes
Canella48 Unknown
Guo146 Spongiform change, diffuse neuronal loss, mild astrocytic gliosis
Predominantly monoglycosylated PrPRes. Type 1 PrP es
Jansen184 Numerous multicentric & unicentric amyloid plaques throughout the cerebrum &
cerebellum & variable spongiform degeneration & astrocytosis
Type 1 PrPRes & a 8 kDa fragment
AO
The individual described by Cannella et al. was shown to have a de novo
mutation, as the insertion was absent from both parents (paternity was confirmed
genetically). This is the first confirmed de novo case reported.
2.XLIX Eiqht-Qctapeptide Repeat Insertion
Prion disease due an 8-OPRI has been identified in 3 families; all had an
autosomal dominant pattern of inheritance134'365'227. Two families had an insertion on
an allele carrying valine at codon 129, and 1 family on an allele with methionine. All
families had different repeat insertions. In 2 individuals an EEG showing periodic
triphasic waves was documented, and in 1 a MRI showing basal ganglia high signal.
In other individuals the EEG was normal or non-specifically abnormal and
neuroimaging was normal or showed atrophy. Overall the clinical and pathological
features were consistent with GSSS369.
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Table 2.80 8-OPRI genotype and clinical phenotvoe (1)
Reference Repeat Mutated allele Origin No. patients
reported
Goldfarb134 R1-2-2-3-2-2-2-2-2-2-2-2a-4 V France 4
van Gool365 R1 -2-2-3g-3-2-2-2-2-2-2-3-4 V Netherlands 6
Laplanche227 R1-2-2-3-2-2-2-2a-2-2-2-3-4 M France 11






Goldfarb134 45 2.3 Not reported Positive
van Goof65 43 3.3 VV&MV Positive
Laplanche227 28 3.8* MM Positive
* The mean duration for deceased patients is given; other members of the kindred
were alive at up to 12 years after onset.
Table 2.82 8-OPRI clinical phenotvpe (3)
Reference Onset Clinical features
Goldfarb134 Not documented Behavioural change, cerebellar & pyramidal signs,
myoclonus, mutism
van Gool365 Cognitive decline; personality
& gait disturbance
Dementia, cerebellar signs, myoclonus, primitive
reflexes, pyramidal signs, rigidity,
Laplanche227 Psychiatric or cerebellar
features
Psychiatric symptoms, cerebellar signs, later
dementia; terminal rigidity
120
Table 2.83 8-OPRI investigative and neuropathological findings
Reference EEG Neuroimaging Neuropathological Findings
Goldfarb134 Triphasic
complexes










NA Atrophy & gliosis of the molecular layer
of the cerebellar cortex; kuru plaques;
multicentric plaques; PrPSc positive;
minimal spongiosis
2.L Nine-Octapeptide Repeat Insertion
Two families with probable prion disease due a 9-OPRI have been described;
in both cases only 1 family member has undergone PRNP genotyping215'285. The case
descriptions are given in the tables.
Table 2.84 9-OPRI genotype and clinical phenotvpe of the family reported
bv Owen285
Origin Onset (years) Duration (years) Codon 129
England 53 2.5 M*
Onset Clinical features FHx
Behavioural change; gait problems Dementia, apraxia, gait ataxia, myoclonus Positive
Octapeptide repeat sequence
R1 -2-2-3-2-3g-2a-2-2-2-3g-2-3-4
* The insertion was combined with methionine at codon 129; the codon 129 status of
the wild type allele was not documented.
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Table 2.85 9-OPRI genotype and clinical phenotvpe of the patient reported
by Krasemanri15
Origin Onset (years) Duration (years) Codon129
Germany 32 >2 (still alive) MM
Onset Clinical features FHx
Behavioural change;
gait problems
Dementia, dysarthria, visual disturbance, gait
ataxia, cerebellar signs, postural tremor.
Positive
EEG Neuroimaging 14-3-3
Non-specific slowing Cortical atrophy Not done
Octapeptide repeat sequence
R1-2-2-3-2-3-3g-2-2a-2-3-2-3-4
The English case had a FHx of early onset dementia; the German case had a
family history of her mother, maternal grandmother and great-grandmother having
died in their early 40s with dementia and spastic paraparesis.
No pathological details are known for either case.
2.LI Twelve-Octapeptide Repeat Insertion
One North American family with a 12-OPRI has recently been reported by
Kumar et al.221 3 members with affected, all of whom had a clinical phenotype which
resembled behavioural variant frontotemporal dementia, with slowly progressive
personality and behavioural change, social disinhibition and increased appetite.
Additional features not typically associated with frontotemporal dementia were
present in the form of gait ataxia and seizures, leading to PRNP genotyping which
demonstrated a 288 base pair insertion (presenilin 1 and microtubule protein
associated tau were also analysed and no mutations found). In keeping with the
clinical features were the MRI and PM findings of severe bilateral frontal atrophy. In
the 2 individuals for whom neuropathology was performed a mixed picture ofmulti¬
centric PrPSc positive plaques and numerous neurofibrillary tangles and neuropil
threads was seen. This family further expands the possible phenotypes associated
122
with an OPRI ofPRNP, which may be responsible for a frontotemporal type
dementia.
Table 2.86 12-OPRI genotype and clinicopatholoaical phenotvpe
Origin Onset (years; mean) Duration (years; mean) Codon 129
USA 44 8 Unknown
Onset Clinical features FHx
Personality changes Dementia, frontal type affect, seizures, ataxia Positive
EEC* Neuroimaging* 14-3-3*







Multi-centric PrPSc positive plaques, particularly in the cerebellar cortex
Numerous neurofibrillary tangles and neuropil threads
* Investigation results were only known for the proband.
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2.LII Animal Transmission Studies and Transgenic Animal Models
Introduction
Animal transmission studies played a crucial role in elucidating the nature of
prion diseases, or as they were previously called, 'slow virus' infections. Early studies
used a variety of animals including non-human primates, cats and guinea pigs. More
recently transgenic humanised mice have been developed which are more susceptible
to human prion diseases, which facilitates research studies. Transgenic work has also
led to the creation of animal models of gPD, which are useful to investigate whether
or not PRNP mutations are truly pathogenic, and to study their clinico-pathological
properties. Experimental transmission studies have involved surprisingly few PRNP
mutations, most ofwhich have been successful, although not always in wild type
animals. Murine PRNP appears to exert an inhibitory effect on disease transmission,
and the use of humanised mice with a transgenic form of PRNP encompassing
360human elements tends to be more successful . In this section I will review those
PRNP mutations which have been the subject of animal transmission studies or
transgenic models.
P102L
GSSS was one of the earliest gPD to be studied, due to the distinct
clinicopathological features. The exact underlying mutation is not always identifiable
in early studies, but patients from a family subsequently found to carry the P102L
mutation were involved in the work ofMasters et al241. They transmitted disease to
various animals (primarily non-human primates) using brain tissue from a selection
ofGSSS patients. P102L was successfully transmitted from a male patient who had
died at the age of 42 years after an illness consistent with GSSS, with spongiform
change at post-mortem. Brain tissue was inoculated intracerebrally into spider and
squirrel monkeys and chimpanzees. Both types of monkey developed spongiform
encephalopathy after between 20 to 30 months incubation, but the chimpanzee was
unaffected 7 years post-inoculation. Transmission to spider monkey, chimpanzee and
guinea pig was attempted using brain tissue from another affected member of this
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family but the results were negative after 3 years incubation. Intriguingly, no
primates developed amyloid deposits.
P102L has also been transmitted via intracerebral inoculation to marmosets,
who after between 25 to 32 months incubation initially became quiet and dishevelled,
followed by balance problems which progressed to a broad based ataxic gait19. They
later developed social withdrawal, drooling, daytime somnolence and disturbed
nocturnal sleep. Neuropathologically the thalamus was the most severely affected
brain region, with additional vacuolation of the molecular and granular layers of the
cerebellar and fine vacuolation of the brain stem. Samples from the affected animals
were subsequently passaged into second line marmosets, with further successful
transmission and shorter incubation times.
17Asante et al. attempted to create a mouse model of PI 02L using animals
carrying humanised PRNP homozygous for P102L and the murine PRNP gene
knocked out. These animals did not develop spontaneous disease, living to a normal
life expectancy with no clinical or pathological, or immunohistochemical
abnormalities. However these animals were susceptible to P102L when inoculated
with human brain homogenate, with a high attack rate and relatively short (compared
to similar animals inoculated with sCJD) incubation time of 185 to 191 days.
Neuropathologically there was generalized synaptic PrP deposition in the cerebral
cortex, basal ganglia, hippocampus and thalamus, with the brain stem and cerebellum
being less severely affected. There was widespread spongiform change but no multi¬
centric plaques. The only difference between transgenic animals inoculated with
P102L and sCJD was somewhat less intense PrP staining seen in P102L. This model
is difficult to interpret, as it is not truly a mouse model ofP102L, given that none of
the animals developed spontaneous prion disease. An earlier, probably more useful
358model was reported by Telling et al " , who bred transgenic mice over-expressing
murine PRNP with the murine equivalent of the P102L mutation. These animals
developed spontaneous disease, but with a variable age at onset. This led the authors
to ablate the wild-type murine PRNP in mice over-expressing P102L, which led to a
very consistent pattern of disease onset at 145 days of age, with myopathy and
peripheral neuropathy. Spongiform change and plaques were seen, and disease could
be transmitted to healthy animals. These studies possibly provide more new
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questions than answers, with the identification of complex interactions between wild-
type and mutated PrP. The wild-type murine PRNP appears to be an inhibitory factor
to the development of disease due to P102L.
The codon 129 status of the patients used in the early studies ofMasters et
al.241 and Baker et al.19 is not known. It is likely that they would be P102L-129M,
this being the commonest haplotype. P120L-129V has been used to attempt to
transmit disease to humanised mice, but no clinical or pathological changes
resulted361. However when brain homogenate from the same individual was
inoculated into humanised mice with the P102L mutation (which develop
spontaneous prion disease), these animals developed disease significantly earlier than
uninoculated animals. As before, interpreting this result is somewhat difficult -
carriage of the P102L mutation appears to be permissive for disease transmission, but
it is unclear why.
A117V
Transmission studies of the Al 17V mutation have not been reported, but a
mouse model with the murine equivalent (Al 16V) and over-expression of PrP has
been published402, with animals developing spontaneous disease. Progressive ataxia
began at a mean age of 140 days, with death by 170 days. This ataxia was reported to
be more prominent and prolonged than that seen in mouse models of sCJD.
Neuropathologically there was mild scattered vacuolation, and prominent PrP
positive plaques, mostly affecting the cerebellum. A weakly protease resistant PrP
fragment was identified, similar to that seen in human Al 17V cases.
D178N
As with other mutations, it is difficult to sub-divide transmission studies of
the D178N mutation by the codon 129 status as this is often not known in early
studies, and as previously discussed, 129 M or V cases cannot be distinguished
definitively by their clinical phenotype. Brain homogenate from D178N cases of
39various nationalities was transmitted to non-human primates by Brown et al. , with
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an approximately 46% transmission rate. The authors also used inocula from cases of
7-OPRI and E200K, and all 3 mutations had similar disease durations.
The first successful transmission of FFI to wild-type mice found most
animals became symptomatic after a 400 to 600 day incubation period.
Neuropathologically there was spongiform change, astrocytic proliferation, neuronal
loss and abnormal PrP deposition, with the thalamus being most severely affected356.
Although the data is limited, there is some evidence that the codon 129 status
influences transmissibility ofD178N-129M359. Of the cases with D178N-129M, 3 of
4 methionine homozygous patient samples transmitted disease, whilst only 1 of 3
heterozygous patient samples did so. A single D178N-129V case failed to transmit.
In affected animals there was a distinctive PrPSc deposition pattern, with intense
staining of the thalamus (in particular the antero-ventral and medio-dorsal nuclei)
and rostral corpus callosum. After digestion with protease K a 19kDa fragment of
PrP was found, unlike that seen in the same line of animals following E200K
inoculation, where a 21kDa fragment was seen.
There is a trend for FFI to be harder to transmit than other forms of gPD, and
some authors feel that this relates to the levels of detectable PrPSt present, which are
low in FFI39. Whilst this is a plausible theory, the numbers of donor patients and
recipient animals are relatively small, making it is difficult to draw definite
conclusions regarding this.
Animal models have been created of both D178N-129M and D178N-129V.
Knock-in mice homozygous for D178N-129M developed age-related behavioural
changes, with sleep disturbance and temperature disregulation. MRI at 16 months of
age showed atrophy of the cerebellum and flattening of the motor cortex, with
enlarged ventricles and abnormalities of the thalamus. At neuropathology there were
changes similar to those seen in human cases, with deep cerebellar white matter
vacuolation, reactive gliosis and severe neuronal loss in the thalamus. Protease
resistant PrP was rarely detectable, with only one animal having positive findings .
The clinical and neuropathological findings resembled those seen in human FFI
cases.
Transgenic mice with a murine homolog of D178N-129V also develop
spontaneous disease, with motor dysfunction, memory impairment and severe
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abnormalities of the sleep-wake cycle on EEG. The phenotype was altered by
varying the level of PrP expression, with over-expressing animals having shorter
incubation times and those with a below normal level of endogenous PrP not
developing disease. Whilst sleep disorders are not considered a typical feature of
_ 89D178N-129V in humans, this has been infrequently reported .
E200K
As could be expected with the commonest cause of gPD world-wide, the
E200K mutation has been the subject of a number of transmission studies and
transgenic mouse models. Brain homogenate from patients of various nationalities
has been inoculated intracerebrally into non-human primates with resultant
spongiform encephalopathy after incubation periods varying from 13 months40 to 6
years59. The most detailed description of disease in non-human primates comes from
Chapman et al59, who reported a chimpanzee which developed disease 6 years after
intra-cerebral inoculation with a 10% suspension of brain homogenate from a Jewish
Libyan patient. The animal displayed frightened behaviour, trembling, gait and
truncal ataxia and terminal indifference, decreased spontaneous movement and
vocalisation. The illness lasted 3 weeks, and on neuropathological examination there
was extensive spongiform change.
Further information on the neuropathological and immunohistochemical
patterns seen in animal studies of E200K comes from humanised mice (with the
murine PRNP gene knocked out) inoculated with E200K brain homogenate. The
same strain of animal was inoculated with D178N-129M. Compare with the FFI
animals, E200K transmission resulted in more hypothalamic vacuolation but less
severe changes to the corpus callosum. The PrP deposition in E200K was widespread
throughout the brain, unlike FFI where the thalamus and corpus callosum were most
severely affected, and the brainstem spared. Following protease K digestion, a 21kDa
fragment of PrP was found in the E200K animals, which is similar to that seen in
359human patients . Another study using similar transgenic humanised animals found
diffuse PrPSt deposition in the cerebral cortex, with intense staining of the
242
hypothalamus and locus coeruleus of the brainstem .
128
The E200K mutation has also been the subject of transgenic animal models.
Friedman-Levi et al.100 used a chimeric mouse/human PRNP construct with an
E199K substitution, equivalent to the E200K mutation in humans. This was
generated on a background of either null/null murine PRNP, or wild-type PRNP.
Both lines of mice were affected, with an illness characterised by asymmetrical hind
limb weakness progressing to paraplegia, leg clasping and lower body atrophy and
occasional tremor. The manifestations were similar in knock-out and wild-type mice.
Around 10% developed myoclonus. The mean age at onset was 5.4 months in wild-
type animals with a mean duration 14.9 months. The onset was slightly later (mean
6.7 months) and duration shorter (mean 11.6 months) in murine PRNP knock-out
animals. PrP immunohistochemistry demonstrated intraneuronal dot-like and
granular immunostaining in a widespread distribution, with neurons of the spinal
cord, basal ganglia, thalamus, frontal cortex and brainstem being particularly
affected. Focal spongiform change was seen at the end-stage of disease, mostly of the
frontal cortex and basal ganglia.
After establishing that this line of mice spontaneously develop disease,
animals were assessed for abnormal PrP deposition at different stages. Protease K
resistant PrP was absent at 1 month of age, and then progressively accumulated over
time, in a fashion which correlated with age and clinical disease manifestations.
Passaging into further transgenic mice from the same lines was performed,
with successful transmission to asymptomatic animals. These passaged animals
displayed a greater degree of spongiform change and astrogliosis, and diffuse
synaptic type PrP immunoreactivity.
V210I
The V210I mutation has been successfully transmitted to transgenic mice
with humanised PRNP, and to wild type bank voles and mice242'3. Tissue from 3
different patients was used to inoculate transgenic mice, all ofwhich transmitted
disease with incubation times varying from 182 to 233 days. Affected animals
developed ataxia, a hunched back and behavioural change. Pathologically there was
spongiosis, astrocytic gliosis localized to the entorhinal cortex and cingulate gyrus.
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No variation was seen between animals inoculated with samples from different
patients, despite there being significant phenotypic variation between the patients.
Neuropathological findings were compared to animals inoculated with sCJD, E200K
or D178N-129M samples. V210I most resembled sCJD neuropathologically.
Similar neuropathological conclusions were drawn from the transmission of
V2101 to bank voles, which survived for 157 days. The disease was highly
transmissible, with PrPSc type 1 being present in both the human and animal subjects.
The vacuolar degeneration and lesion pattern seen was very similar to animals
inoculated with VI201, sCJD MM1, sCJD MV1 or E200K.
Q217R-129V
One study used brain homogenate from 2 unrelated patients with Q217R-
129V (1 from Sweden, 1 belonging to the Indiana kindred) to attempt to transmit
disease to rodents; this was unsuccessful170.
M232R
The rare M232R mutation has been successfully transmitted via intracerebral
inoculation of brain homogenate to New Zealand white mice, which developed
disease after around 700 days incubation. Neuropathologically the animals displayed
spongiform change of variable severity, astroglial proliferation and neuronal loss,
with a neuropil distribution of abnormal PrP. Overall the neuropathological findings
were similar to those seen when sCJD was transmitted to this line ofmice. The
authors166 also attempted transmission using lymph nodes and spleen from the same
patients, but this was unsuccessful.
Animal Transmission Studies and Transgenic AnimalModels: Conclusions
Animal studies have obvious limitations. The use of humanised transgenic
animals partly compensates for genetic differences between humans and animals.
However studying clinical features in animals is difficult, and subtle changes in areas
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such as behaviour and cognition will be hard to detect. The main features recorded in
such studies are the attack rate and incubation period, which are fairly crude disease
characteristics. Useful neuropathological data can be obtained (albeit limited by
anatomical differences between the different hosts), in particular the serial
examination of animals at different stages of disease incubation or progression. The
most striking feature of the literature regarding animal transmission studies and
models of gPD is how few of the many PRNP mutations have been studied. There is
scope for a great deal of interesting further work in this area, in particular
establishing ifPRNP mutations reported in a single case only are definitely
pathogenic and transmissible. The use of the same animal strains in different studies
should be encouraged to allow direct comparisons to be made of different results.
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2.LIII Literature Review: Conclusions
In this chapter I have summarised the disease characteristics of all pathogenic
PRNP mutations reported to date. This is not always straightforward, due to the
marked variability between individuals carrying the same mutation, and limitations
of the available data. Often only a very small number of cases are reported, with a
wide range in the level of clinical, genetic and pathological detail provided. If the
codon 129 status (and in particular the status of the wild type and mutated alleles) is
not available, then classifying and analysing cases according to haplotype becomes
very difficult. Frequently only a handful of cases of a known PRNP haplotype were
found in the literature. There are likely to be significant number of undiagnosed
cases, the clinicopathological features of which could be very different to the
currently published cases. Making comparisons between small numbers of cases is
difficult and may lead to invalid conclusions being drawn; however some general
trends do emerge.
The majority of point mutations and octapeptide repeat insertions are in cis
with methionine at codon 129. Heterozygosity at codon 129 is frequently reported,
but methionine homozygotes are in the majority, and valine homozygosity is
relatively unusual. Methionine appears to somehow be permissive for either
mutational events or the development of disease (or both). gPD thus shows
similarities with other forms of prion disease such as vCJD, the development of
which is strongly linked to methionine at codon 129.
It is difficult to be clear as to how the codon 129 status of the wild-type and
mutated allele influences the clinico-pathological phenotype. The most widely
studied phenomenon is with the D178N-129M, where dramatic differences in
clinico-pathological phenotype are determined by the wild-type allele codon 129.
Even here though, there are reported exceptions to the rule that D178N-129MM
causes FFI and D178N-MV causes a sCJD like phenotype. Another trend is for
GSSS type cases to be associated with valine on the mutated allele, but again this is
not a hard and fast rule. This link and the higher prevalence ofmethionine at codon
129 may explain why GSSS features are less common than sCJD-like cases. Where
comparisons can be made between the same mutation in cis with either methionine or
valine, this often (but not always) affects age at onset and disease duration, with a
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tendency for valine to give rise to an older age at onset or longer disease duration.
Heterozygosity at codon 129 also seems to have the same effect with a number of
different mutations. Interestingly, this is seen with E200K in Slovakian cases but not
in cases from other regions of the world, which implies that other, as yet unidentified
genetic factors are at work. It seems highly likely that genetic factors other than the
PRNP mutation and codon 129 influence disease development and phenotype; these
may well involve genes other than PRNP.
The dominance of a small number of mutations world-wide is very
interesting; the majority of individuals affected by gPD will have either E200K,
D178N, or P102L. This is probably due to a combination of factors, including the
likelihood ofmutational events occurring at a particular PRNP locus, disease
penetrance, age at onset and socio-economic factors (e.g. family size and emigration
patterns).
Interpreting the data must be done with caution due to the small numbers of
cases involved. In order to systematically examine these tendencies, it is crucial that
gPD cases (and unaffected carriers) undergo complete sequencing of the PRNP gene,






Potential cases of gPD were identified from the records of the NCJDRSU
(1990 to 2009), and from two earlier surveillance projects which are described below
(1970 to 1990)388'75'389'385.
The NCJDRSU & earlier studies
The NCJDRSU (previously known as the National CJD Surveillance Unit)
was established in 1990 as a result of Southwood Committee report 346. The
NCJDRSU aims to identify all individuals with prion disease in the UK. Referrals of
potential cases are made by clinicians via a national reporting system or by informal
discussion of doubtful cases, by neuropathologists encountering cases at PM, and by
a twice yearly review of death certificates encoding any form of prion disease as a
cause of death. In addition cases may be reported by allied heath professionals such
as public health officers, organisations such as The UK CJD Support Network and
members of the public.
Surveillance data was also available for the period 1970 to 1990 from the
following studies:
'A retrospective study ofCJD in England and Wales'412.
In the 1970 to 1979 period, cases were ascertained primarily by a review of death
certification.
'A retrospective epidemiological study of CJD in the UK' 386>4'2
From 1980 to April 1990, cases were obtained retrospectively from death
certification and referrals of suspected cases of prion disease by UK clinicians.
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3.II Visiting Patients
After a suspected case is referred to the NCJDRSU permission is sought from
the patient (if possible), their family and local consultant for a research clinician to
visit the patient. During the visit, the patient is interviewed (if possible), and
examined, and an epidemiological questionnaire completed by an interview with a
close relative. This includes questions regarding residential and occupational history,
a detailed family tree, and a dietary history. A history of the illness is obtained,
including past medical and drug history and investigative findings. Copies of medical
records, the EEG and neuroimaging are taken with written consent from the patient
or their next of kin. If a patient is referred after their death then the family is
contacted (with the permission of the local consultant or general practitioner) and
visited to complete the questionnaire, to obtain a clinical history and consent for
review of the medical records. The family may decline the offer of a visit in which
case the case notes are reviewed if possible. The quantity and quality of data
collected therefore varies, and the investigations performed reflect the technology
available at the time of the patient's illness and their specific clinical features.
3.Ill Clinical Symptoms and Signs
Data about the timing of disease onset, the presenting symptoms and the
symptoms and signs present over the entire disease course were extracted from the
available information in the questionnaire, history and medical notes. The point of
onset was taken to be the earliest date at which novel symptoms attributable to prion
disease were noted by the patient, their family or doctor. Where the symptoms could
not be exactly dated an approximation was made using the available data (for
example the date of referral; if a month of onset was given the 15th of the month was
used; if a year was given then the 15th of June was used). In the large majority the
onset was defined within 1 to 2 months. A certain amount of error will therefore be
present, especially with regard to the precise date of onset of insidious symptoms.
The disease duration was calculated using the date of onset and date of death
(inclusive), or if the patient was still alive at the end of data collection then
136
30/10/2009 was used as the latest possible date of death for the purposes of this
study. The presenting symptoms were taken from the questionnaire.
The presence or absence of each individual symptom or sign was recorded (a
list of those recorded is given in Table 3.2). Difficulties sometimes arose when
interpreting the examination findings documented by different clinicians and the
symptoms described by the patient and their family. Clinical judgement was used to
decide if what was described fitted with a symptom or sign; for example if the family
described 'jerking movements' and clearly imitated myoclonus then this was
interpreted as being myoclonus. However if the patient was described in the medical
notes as having 'involuntary movements' without further details being given then this
was classified as 'involuntary movement'.
3.IV Investigations
Investigations were carried out as clinically indicated by the referring
physicians, who would at times request advice regarding this from the NCJDRSU.
Not all patients underwent EEG, neuroimaging and lumbar puncture, either due to
limitations in the services available in the referring hospital, or if tests were not felt
to be clinically justified. A significant number of individuals presented prior to the
widespread availability ofMRI (the early 1990s) and CSF 14-3-3 analysis (which
began at the NCJDRSU in November 1996).
CSFanalysis
The results ofCSF analysis for total protein, glucose and the number of red
and white cells present were obtained from the medical notes. Where possible the
paired serum glucose level was also recorded. Analysis of CSF 14-3-3 and SI 00b
were carried out by Dr A. Green in the NCJDRSU, according to previously published
methodology142. In some early cases (during 1996) CSF analysis was carried out in
the USA by Dr P.Brown.
137
EEG analysis
Representative pages from EEG recordings were reviewed independently in
the NCJDRSU by Prof R. Knight and Prof R. Will. These were classified into those
showing periodic triphasic complexes, or those which were non-specifically
abnormal or were normal. In some cases only an EEG report from the referring
hospital was available; details ofwhich EEGs were not reviewed in the NCJDRSU
are given in the results section.
Neuroimaging
Computed tomography (CT) and / or MR images were obtained either as hard
copies or recordings on CD. These were reviewed by a consultant neuroradiologist
with an interest in prion diseases (Dr D.Summers or Dr D.Collie). Details of any
abnormal findings were noted, with particular reference to the presence or absence of
changes associated with prion disease (basal ganglia high signal and / or cortical high
signal in three or more brain regions on Fluid Attenuated Inverse Recovery; FLAIR
or Diffusion Weighted sequences). Note was made of any cases with changes
suggestive of vCJD (high signal in the pulvinar region of the thalamus).
Genotyping
PRNP sequencing and codon 129 analysis were carried out according to
previously published methodology31. Either blood or frozen brain tissue was used,
depending upon which was available. Full gene sequencing (genotyping) in order to
search for any PRNP mutations was only performed with informed consent from the
patient or their next of kin. Data were also obtained from genetic testing performed
by the National Prion Clinic, London. Genotyping became available in the early
1990s and therefore cases prior to this only had genotyping performed if appropriate
stored samples and consent were available.
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Individuals in the 4-OPRI group were studied in collaboration with the
National Prion Clinic. PRNP microsatellite haplotype analysis and relatedness testing
was performed by Dr S.Mead192.
Neuropathology
Where possible neuropathological tissue was examined in the NCJDRSU; in
some cases tissue was not available but a PM report issued by another centre was
available. As case ascertainment spanned 1970 to 2009, a range of neuropathological
methods were used, and modern immunohisochemistry (IHC) and Western blotting
was not always performed. Details of which cases were reviewed at the NCJDRSU
and which underwent IHC and Western blotting are given in the results section.
Ideally both tissues fixed in formalin and frozen samples were obtained.
Extensive neuroanatomical regions were sampled to provide representative tissue
from frontal, temporal, parietal and occipital cortex, the basal ganglia, thalamus,
hippocampus, hypothalamus and brain stem.
Histopathological examination made note of spongiform change, plaques,
gliosis, neuronal loss and any other changes such as Alzheimer-type pathology or
amyloid deposits.
IHC staining was performed using two anti-PrP antibodies410. The pattern of
PrPSc deposition was recorded, including features such as plaques or unusual PrPSc
patterns. The main patterns seen can be defined as follows:
Patchy/ perivacuolar : immunolabelling mostly around vacuoles
Diffuse synaptic : multiple tiny immunolabelled dots in the neuropil
generally, with occasional coarser, larger deposits
Neuronal : pericellular punctuate or granular immunolabelling around
neuronal perikarya.
Plaque : usually small to medium sized 'kuru' amyloid plaques with a fringed
outline. These are typically reactive to periodic acid-Schiff, Congo
red and alcian blue stains; the Congo red staining disappears after
formic acid treatment.
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Plaque-like : areas of dense PrP-positivity only visible following IHC
staining.
Prion protein typing was carried out using Western blot analysis to determine
the size and relative abundance of the different PrPRes glycoforms. These are
classified according to their molecular weight into Type 1 (nonglycosylated form
with a molecular weight of 21kDa) or Type 2 (nonglycosylated form with a
molecular weight of 19kDa). If the diglycosylated band predominates in Type 2 then
it is termed Type 2B. If the diglycosylated band does not predominate then it is
termed Type 2A409.
Neuropathological examinations at the NCJDRSU were carried out by Prof J.
Ironside and Prof J. Bell. Immunohistochemical analysis and PrP isotyping was
carried out by the team ofDr M.Head.
3.V Data Extraction
As a research registrar at the NCJDRSU between July 2007 and January 2010
I visited suspected cases of prion disease (of any type). This included 5 cases of gPD.
1 reviewed the case notes for all cases of gPD known to the NCJDRSU (N= 147).
Additional records were reviewed for a number of cases which were not included in
the final data set: in 3 cases a diagnosis of gPD was suspected on neuropathological
grounds but there was insufficient clinical data to substantiate this; records of a
number of non-UK cases were reviewed but it was later decided that non-UK cases
should not be included. Data extraction was performed by reviewing the existing
NCJDRSU databases, copies of medical records (both hospital and GP notes), the
NCJDRSU questionnaires, the death certificates and the neuropathological records.
In cases where the records held were incomplete I requested copies from the local
hospital or GP. Some data was also provided by the National Prion Clinic, London.
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I created an SPSS database and recorded the following data:
Table 3.1 Data collection (1)
ID number Classification Visited by NCJDRSU? Date of onset
Age at onset Date of referral Date of death Disease duration
EEG done? Date of EEG EEG result Time from symptom onset
to EEG
CT done? Date ofCT CT result Time from symptom
onset to CT
MRI done? Date of MRI MRI result Time from symptom onset
to MRI
PRNP mutation Codon 129 status gPD suspected during
life?
Family history
Lumbar puncture done? Date of lumbar
puncture
CSF 14-3-3 result CSF SI00b result
Sex Birthplace (city) Country of origin Ethnicity






I also recorded the presence or absence of the following symptoms and signs:
Table 3.2 Data collection (2)
Aggression Akinetic mutism Anxiety Apathy
Cerebellar signs Delusions Depression Extrapyramidal signs
Gait disturbance Gegenhalten Hallucinations Headache
Involuntary
movements
Myoclonus Muscle wasting Oculomotor signs







Social withdrawal Speech disturbance Vertigo Visual disturbance
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The following definitions were used :
Table 3.3 Clinical definitions
Clinical symptom or sign Definition
Cerebellar signs Cerebellar ataxia, pronator drift, dysdiadochokinesia, nystagmus,
intention tremor, staccato speech.
Extrapyramidal signs Cogwheel rigidity, pill-rolling tremor, bradykinesia, festinant gait.
Gait disturbance Description by family of change to walking such as shuffling,
decreased balance, unsteadiness or falls.
Ataxia, festinant gait, or non-specific gait disturbance.
Gegenhalten Increased tone where the patient apparently resists examination
Involuntary movements Tremor, myoclonus, dystonia, chorea, twitching.
Oculomotor signs Abnormality of saccadic or pursuit movements or palsy of the
third, fourth or sixth cranial nerves.
Primitive reflexes Grasp, pout, snout or palmo-mental reflex.
Pseudobulbar problems Upper motor neurone lesions of the 10th, IIth and 12,h cranial
nerves.
Psychiatric disturbance Anxiety, depression, psychosis, mania.
Pyramidal signs Pathologically brisk reflexes, Babinski sign, weakness in a
pyramidal distribution, spastic hypertonicity.
Speech disturbance Description by family of slurring, word finding difficulties or
change in speech quality.
Dysarthria, dysphonia, dysphasia or staccato speech.
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3.VI Case Classification
Cases were classified according to internationally accepted diagnostic
one
criteria (Boxes 3.1 and 3.2). In order to capture as many cases as possible, those
meeting criteria for probable or definite prion disease in whom PRNP genotyping
was not performed but where a second degree relative was affected by gPD were also
included. PRNP genotyping was not always performed, either due to cases being
referred prior to this being available, or due to family wishes, or due to the lack of
availability of suitable tissue or blood samples. Details of the classification of
individual cases are given in the results section, as is the exact justification for
including those who did not meet the diagnostic criteria for gPD. The diagnostic
criteria have changed over time; the criteria given below (which were current at the
time of data collection and analysis) were applied to all cases.
Box 3.1. Classification ofdefinite and probable genetic prion disease
Definite genetic prion disease
Definite (neuropathologically confirmed) prion disease
AND definite or probable prion disease in a first degree relative.
OR
Definite prion disease and a pathogenic PRNP mutation.
Probable genetic prion disease
Progressive neuropsychiatric disorder AND
definite or probable prion disease in a first degree relative.
OR
Progressive neuropsychiatric disorder and a pathogenic PRNP mutation.
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Box 3.2. Neurooatholoaical definitions ofOP, GSSS and FFI
Genetic CJD
A person with an affected first degree relative
or a disease associated PRNP mutation AND
Spongiform encephalopathy in cerebral and/or cerebellar cortex,
and/or sub-cortical grey matter and/or
Encephalopathy with PrPSc immunoreactivity
(plaque and/or diffuse synaptic and/or patchy/peri-vacuolar types).
GSSS
A member of a family with dominantly inherited progressive ataxia
and/or dementia and one of a variety of PRNP gene mutations
and encephalomyelopathy with multi-centric PrPSc plaques.
FFI
A member of a family with a D178N-129M PRNP mutation,
and thalamic degeneration, and variable spongiform changes in the cerebrum.
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Box 3.3. Clinical criteria for probable and possible sporadic prion disease
Probable (in the absence of an alternative diagnosis):
Progressive dementia AND at least two of the following:
*Myoclonus *Visual or Cerebellar disturbance
* Pyramidal or Extra-pyramidal dysfunction Akinetic mutism
AND
An EEG showing triphasic complexes with a periodicity of one Hertz
AND/OR positive CSf 14-3-3 AND disease duration of less than two years
AND/OR high signal in the basal ganglia on MRI
Possible:
Progressive dementia AND EEG atypical or not known AND
disease duration less than two years AND at least two of the following:
*Myoclonus * Visual or Cerebellar disturbance





4.1 Prion Disease in the UK, 1970 to 2009
The number of cases of prion disease on the database of the NCJDRSU for
the time period 1970 to 01/10/2009 are given below, subdivided according to the
type of prion disease found or suspected. Details of case classification and the source
of cases for each time period are given in the methodology section.
Table 4.1 Prion disease cases in the UK, 1970 to 2009
Time period 1970- 1979 1980- 1985 1986- 1990 1991-2009 1970-2009
Probable gPD 1 2 2 110 115
Definite gPD 1 2 4 25 32
gPD (all) 2 4 6 147* 159*
Possible sCJD N/A N/A 23 106 129
Probable sCJD 29 26 60 303 418
Definite sCJD 1 18 97 76 805 1096
sCJD (all) 147 123 159 1214 1643
Possible iCJD N/A 0 0 0 0
Probable iCJD 1 0 1 14 16
Definite iCJD 0 0 5 47 52
iCJD (all) 1 0 6 61 68
Possible vCJD 0 0 0 4 4
Probable vCJD 0 0 0 54 54
Definite vCJD 0 0 0 116 116
vCJD (all) 0 0 0 174 174
Total no. cases 150 127 171 1596 2044
* Not all cases of gPD identified could be classified according to the current
diagnostic criteria; details are given in section 4.III. A further 12 unclassifiable cases
are included in the totals marked *.
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Table 4.2 Proportion ofprion disease cases with full PRNP genotvping
Time period 1970-1979 1980-1985 1986- 1990 1991 -2009
sCJD (all) 147 123 159 1214
sCJD & full PRNP genotyping 0 0 0 561 (46.2%)
iCJD (all) 1 0 6 61
iCJD & full PRNP genotyping 0 0 1 (16.7%) 15 (24.6%)
vCJD (all) 0 0 0 174
vCJD & full PRNP genotyping 0 0 0 143 (82.2%)
Total no. cases of prion disease
(sporadic, variant or iatrogenic)
148 123 165 1449
Total no. cases of prion disease
(sporadic, variant or iatrogenic)
& full PRNP genotyping
0 0 1 (0.6%) 765 (52.8%)
In total there were 2044 cases of possible, probable or definite prion disease
identified in the UK from the NCJDRSU database between 1970 and October 2009,
of which 159 (7.8%) were gPD.
In addition to the gPD disease cases listed above, a number of cases were
identified with a potential diagnosis of gPD, but where this diagnosis could not be
substantiated. Three cases had definite prion disease, with neuropathological findings
ofwidespread microvacuolar spongiform change and linear deposition of PrPSc in the
cerebellar cortex. In 1 case both type 1 and type 2 PrPRes were present. The findings
were felt to be strongly suggestive of gPD due to an insertional mutation ofPRNP.
However PRNP genotyping was not performed in any of these cases, and the FHx
was either unknown or negative for prion disease. These cases are therefore not
included in the following results.
Of those classified as having sCJD, iCJD or vCJD, just over half underwent
complete sequencing of PRNP. The majority of those with vCJD had PRNP
genotyping, which reflects the difficulty diagnosing vCJD, and the emphasis placed
on excluding all possible alternative diagnoses. Only 46.2% of those with sCJD had
full PRNP genotyping, which raises the possibility that there are undiagnosed
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patients with gPD in this group. As described above, several individuals with
neuropathological findings suspicious for gPD were seen, but without PRNP
sequencing this cannot be confirmed.
4.II Pathogenic PRNP Mutations Identified in the UK, 1970 to 2009
The different pathogenic PRNP mutations found in the UK between 1970 and
2009 are given below. Where known the codon 129 status of the mutated allele is
shown.
Table 4.3 PRNP mutations found in the UK
PRNP Mutation Number of Cases
P102L- 129 M 32
P105L- 129 V 1
A117V- 129 V 14
S132I - 129 M 1
Y163X 2
D167G- 129 M 1
D178N- 129 M 5
D178N- 129 V 2
E200K- 129 M 34
D202N- 129 V 1
V2101- 129 M 2
Q212P- 129 M 1
2-OPRI - 129 M 1
4-OPRI — 129 M 10
5-OPRI - 129 M 10
6-OPRI -129 M 36
7-OPRI 1
Details of the exact octapeptide repeat insertion were available for some of
the 4-OPRI and 6-OPRI cases, but not any of the 2-OPRI or 5-OPRI cases.
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4-OPRI Insertion Sequence
The complete PRNP open reading frame was sequenced in 9 patients. DNA
was unavailable for patient 9. All patients tested were shown to have an additional 4
R2 repeats, and to be homozygous for methionine at codon 129. No other sequence
variations were detected. The OPRI sequence in all cases was thus:
R1-2-2-2-2-2-2-3-4
6-OPRI Insertion Sequence
The exact insertion was known for 24 of the 6-OPRI patients, who either
underwent full sequencing or were related to an individual who had undergone
sequencing.
Table 4.4 Octapeptide repeat sequences seen in 6-OPRI cases
OPR sequence
(insertion in bold)
Number of Cases Affected Codon 129 of mutated allele
R1 -2-2-3-2-3g-2-3g-2-3-4 2* Unknown
R1-2-2-2-3-2-3g-2-2-3-4 21** Methionine
R1-2-2-2c-2-2-2-2-2-3-4 ] *** Methionine
* Cases 1 and 12
** Cases 2 to 9, 14, 17, 20,21,24, 25,27, 29 to 31, 33, 34 and 36
*** Case 13
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4.Ill Case Classification (1)
Each case was classified according to internationally agreed diagnostic
criteria (as detailed in the methodology) as being either 'definite' or 'probable' gPD.
Relatives were considered to be affected if they had definite or probable prion
disease, or were described by relatives or in the medical notes as having prion
disease. Relatives with neurological or psychiatric problems of uncertain aetiology
were not included. Certain cases were identified which were not classifiable using
the diagnostic criteria; details ofwhich are given below:
5-OPRI Group
It was not known if Case 10 was symptomatic from gPD.
P102I Group
It was not known if Case 30 was symptomatic from gPD.
A117VGroup
Case 3 in the A117V group had neuropathologically confirmed prion disease
and is a second degree relative of 2 other A117V cases. He did not undergo PRNP
genotyping and did not have any first degree relatives with probable or definite prion
disease.
Case 7 of the A117V group was described as having GSSS on the death
certificate. No further details are known; she is included in the A117V group because
she has the same surname as other A117V cases and is from the same geographical
area.
Y163XGroup
It was not known if Case 2 of the Y163X group was symptomatic from gPD.
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E200KGroup
Case 18 had neuropathologically confirmed prion disease, but did not
undergo PRNP genotyping. There were no known first degree relatives with prion
disease, but 2 first cousins (Cases 26 and 32) were found to have the E200K
mutation. Case 18 is therefore currently classed as having sCJD within the
NCJDRSU surveillance system.
Case 19 had probable prion disease, and not undergo a PM or PRNP
genotyping. There are no known first degree relatives with prion disease; she is a
first cousin of Case 14.
Case 28 had probable prion disease, but did not undergo a PM or PRNP
genotyping. There are no known first degree relatives with prion disease, but she is
the niece of Case 27. Case 28 is currently classified by the NCJDRSU as having
sCJD.
GSSS (PRNPmutation unknown)
All 4 cases in this group had neuropathological evidence ofGSSS with multi¬
centric amyloid plaques. None of the cases underwent PRNP genotyping and none
had a FHx of GSSS. They therefore cannot be classified as having gPD according the
NCJDRSU diagnostic criteria.
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Graph 4.2 The codon 129 status ofeach mutation group
The results are expressed as a percentage of those for whom this
information is available (the number ofcases in each group for whom this












Not all patients underwent full PRNP sequencing. Some were classified as
having a particular mutation based on the results of a relative(s)'s PRNP genotyping.
A small number of cases were classified as having GSSS on neuropathological
grounds without any genotyping data, and 1 individual was classed as having gCJD
on the grounds of herself and her sister both having CJD.
Table 4.5 The percentage ofeach group for whom full PRNP aenotvpina
data was available
PRNP Mutation Total No. cases













D178N - Codon 129 M 5 100.0





Genetic CJD (PRNP mutation unknown) 1 0.0
GSSS (PRNP mutation unknown) 4 0.0
All Cases 159 86.2
* The case with gPD due to the Q212P mutation was homozygous for this mutation.
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Graph 4.3 The PRNP codon 129 status of the wild-tvpe allele
(this data was only available for a small number ofcases; the total number is
shown in brackets and the results expressed as a percentage of those for
whom this information was known)
The Codon 129 Status of the Wild Type Allele
Mutation
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Graph 4.4 The PRNP codon 129 status of the mutated allele
(this data was only available for a small number of cases; the total number is
shown in brackets and the results expressed as a percentage of those for
whom this information was known)




4.V Other PRNP Polymorphisms
(Other than Codon 129 & the Pathogenic Mutation)
A small number of individuals had other polymorphisms of the PRNP gene
besides the pathogenic PRNP mutation and the polymorphic residue at codon 129. In
all 12 such cases (8.8%) were found, details of whom are given below.
4-OPRI Haplotype Analysis
In the 4-OPRI group additional analyses were performed in collaboration
with D.Kaski and S.Mead of the National Prion Clinic, London.
The insertion sequence in all patients was the same; this is shown in Figure
4.1. Relatedness testing at unlinked microsatellites confirmed a mother-son
relationship between patients 3 and 4 (p =6 x 10~6, maximum likelihood of parent
offspring 0.57). Other relatedness in this patient series, closer than second degree,
were excluded by this analysis. For linked microsatellites, patients 2, 7, and 10
shared a haplotype of 2.5Mb, differing from the mother/son, and each other, at a
single 3' marker (D20S194). Two further patients, 1 and 6 shared with the above 5
patients a central core haplotype spanning approximately 1.2Mb (D20S889 to
D20S895). Finally, patients 5 and 8 demonstrated a shared 1Mb haplotype with those
described above between D20S97 and D20S895 only, although these 2 patients
shared an extended haplotype of 2Mb (D20S181 to D20S849). Overall the data was
consistent with multiple (at least 2) ancestral occurrences of 4-OPRI in the UK.
rsl029273C (upstream ofPRNP) and PRNP codon 129 (rsl799990) have
been identified as risk factors for SCJD253,370'288'254. Genotyping revealed
homozygosity for codon 129MM (rsl799990AA) and rsl029273CC in all 4-OPRI
patients. At least 1 rsl029273C-129M haplotype would be expected in each patient if
the 4-OPRI mutations had all occurred on this haplotype background. This
assumption is conservative as the microsatellite genotyping suggests multiple
separate events, however, the haplotype of the wild-type chromosome is independent
of the presence of the mutation, and the haplotypes seen on the unaffected
chromosome were not expected to be different from the control population. The
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rsl029273C-129M haplotype occurs at a frequency of 0.339 in the control UK
population (384/1132 UK control haplotypes). The probability that all wild-type
haplotypes would be rsl 029273C-129M is P=5.9 x 10"5 (binomial probability).
rsl029273C is usually (92%) found on a 129M chromosome, but the significance of
the association of rsl029273C and 4-OPRI could not be accounted for by an
association driven by 129M alone (P=0.003, binomial probability, of finding that all
9 wild-type alleles were rsl 029293C, with the assumption that all patients were
genotype 129MM).
The clinical phenotype of 4-OPRI was compared with slightly larger
insertional mutations. OPR1 length had a profound effect on mean age of onset with
5- and 6-OPRI having earlier ages of onset. Mean age at onset in UK 5-OPRI
patients was 42.3 in those with codon 129MM (range 26-63, SD = 12.4, n = 6256). In
UK 6-OPRI patients with 129MM mean age of onset was 31.4 years (range 20-49
9 SO
years, SD = 5.7 years, n= 30 ~ ); P=0.04 for comparison between 4-OPRI and 5-
OPRI, and P<0.001 for 4-OPRI compared to 6-OPRI. Duration of disease was also
highly significant (PO.OOl) compared to 6-OPRI patients. However, there no
significant differences were found between 4- and 6-OPRI for a number of clinical
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P105L
The single case with P105L mutation was also heterozygous for the V209M
polymorphism.
A117V
Cases 10 and 14 of the A117V group had the A117A silent polymorphism
(GCA-GCG) on the wild-type allele and were G/A heterozygotes at -21nt from start
of 5TJTR.
E200K
Case 21 had a deletion ofR34, a polymorphism found in healthy Caucasian





The proportion of each group which was male or female is given below.




Male (%) Female (%)
2-OPRI 1 1 (100.0) 0 (0.0)
4-OPRI 10 5 (50.0) 5 (50.0)
5-OPRI 10 5 (50.0) 5 (50.0)
6-OPRI 36 21 (58.3) 15 (41.7)
7-OPRI 1 0 (0.0) 1 (100.0)
P102L 32 9(28.1) 23 (71.9)
P105L & V209M 1 0 (0.0) 1 (100.0)
A117V 14 5 (35.7) 9 (64.3)
S132I 1 0 (0.0) 1 (100.0)
Y163X 2 0 (0.0) 2 (100.0)
D167G 1 0 (0.0) 1 (100.0)
D178N — Codon 129 M 5 2 (40.0) 3 (60.0)
D178N - Codon 129 V 2 2 (100.0) 0 (0.0)
E200K 34 16(47.1) 18 (52.9)
D202N 1 0 (0.0) 1 (100.0)
V210I 2 0 (0.0) 2 (100.0)
Q212P 1 0 (0.0) 1 (100.0)
Genetic CJD
(PRNP mutation unknown)
1 0 (0.0) 1 (100.0)
GSSS
(PRNP mutation unknown)
4 2 (50.0) 2 (50.0)
All Cases 159 68 (42.77) 91 (57.23)
Where possible the place of birth was identified from the death certificate.
The distribution of cases according to geographical and ethnic origin is given below.
Cases were classified as being ofUK origin if they were born in the UK, or if their
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origin was unknown and they were UK resident and not otherwise documented as
being of non-UK origin.
Nine cases ofwere identified of non-UK origin based on their FHx and
birthplace. Details are given below. In all this represented 5.7% of all cases.
Details of the non-UK origin cases are given on the next page. Details of the
parental origin are given if they were known to be of non-UK origin; in most cases
the parental origin was not known.
P102L Group
Case 21 was bom in Sicily and was of Italian ancestry.
E200K Group
Case 4 was bom in the UK but her mother was Syrian and her father a Libyan
Sephardic Jew. Case 12 was a Caucasian individual born in the Republic of Ireland.
Cases 21 and 30 were an Italian brother and sister. Case 23 was born in Spain and
was of Spanish ancestry. Case 29 was a Caucasian individual born in Trinidad and
Tobago.
V2101 Group
Case 1 was from the Campania region of Italian, and was of Italian ancestry.
Case 2 was born in Libya (and was of Libyan ancestry).
165
4.VII Age at Onset
The age at onset of symptoms attributable to prion disease is given below.
The median and inter-quartile range is given for groups of 5 or more individuals.
Where the exact age at onset was not known an approximate value was calculated
using the available information (details of how this was performed are given in the
methodology section). If it was unknown if individuals were symptomatic or not they
were not included. The E200K group was analysed as an entire group, and also
subdivided into cases with methionine homozygosity or heterozygosity at codon 129.
Therefore some E200K cases appear twice in the table. The age at onset was known
or calculated for 148 cases.
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Table 4.7 The age at onset












2-OPRI 1 1 57.0 -
4-OPRI 10 10 58.0 (52.0 ; 66.0) 37.0 to 85.0
5-OPRI 10 9 49.0 (45.0; 61.0) 41.0 to 68.0
6-OPRI 36 35 35.0 (31.0; 40.0) 24.0 to 63.0
7-OPRI 1 1 30.0 -
P102L 32 32 50.0 (40.5; 57.8) 27.0 to 65.0
P105L& V209M 1 1 34.0 -
A117V 14 10 41.0 (35.5; 42.0) 24.0 to 45.0
S132I 1 1 61.0 -
Y163X 2 1 53.0 -
D167G 1 1 68.0 -
D178N
Codon 129 M
5 5 59.0 (38.5; 62.0) 38.0 to 62.0
D178N
Codon 129 V
2 2 56.0 & 58.0 56.0 to 58.0
E200K
(All cases)
34 34 58.5 (52.5; 65.5) 37.0 to 77.0
E200K
Codon 129 MM
21 21 56.0 (51.0; 60.0) 42.0 to 70.0
E200K
Codon 129 MV
4 4 63.0 (56.3; 66.0) 55.0 to 66.0
D202N 1 1 72.0 -
V210I 2 2 64.0 & 61.0 61.0 to 64.0
Q212P 1 1 36.0 -
Genetic CJD
(PRNP mutation unknown)







All Cases 159 152 49.0 (38.0 to 59.0) 24.0 to 85.0
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Graph 4.5 The aae at onset in the OPRI cases














Number ofOctapeptide Repeat Insertions
The number of cases with known age at onset was as follows:
2-OPRI N = 1, 4-OPRI N = 10, 5-OPRI N = 9, 6-OPRI N = 35, 7-OPRI N
4.VIII Disease Duration
The disease duration (time from date of onset to date of death in days) is
given below. The median and inter-quartile range is given for groups of 5 or more
individuals. Where the disease duration was not known an approximate value was
calculated using the available information (details of how this was performed are
given in the methodology section). If it was unknown if individuals were
symptomatic or not then they were not included. The E200K group was analysed as
an entire group, and also subdivided into cases with methionine homozygosity or
heterozygosity at codon 129. Therefore some E200K cases appear twice in the table.
When cases were still alive, 01/10/2009 was used as the earliest possible date
of death in order to calculate the minimum disease duration. The disease duration
was known or calculated for 158 cases.
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S1321 1 1 1382.0 -
Y163X 2 1 1359.0 -




























D202N 1 1 2555.0 -
V210I 2 2 28.0 & 111.0 28.0 to 111.0
Q212P 1 1 2208.0 -
Genetic CJD
(PRNP mutation unknown)









Graph 4.6 The disease duration in the OPRI cases



















Number of Octapeptide Repeat Insertions
The number of cases with known disease duration was as follows:
2-OPRIN = 1, 4-OPRI N = 10, 5-OPRI N = 9, 6-OPRI N = 35, 7-OPRI N
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4.IX The Earliest Noted Symptoms and Signs
P102L
Table 4.9 The earliest noted symptoms and signs in P102L cases
PRNP mutation Symptom or Sign






Personality / behavioural change 1 (3.2)
P102L






Visual loss 2 (6.3)
Three of the cases with unsteadiness were described as being ataxic. 2 cases
had both sensory symptoms and unsteadiness. In 1 case sensory symptoms were due
to peripheral neuropathy. At onset, 22 (68.8%) of the P102L group had either
cognitive decline, unsteadiness or sensory symptoms. Combinations of these features
were not common.
P105L
The single P105L case had unsteadiness at onset.
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A117V
Table 4.10 The earliest noted symptoms and signs in All7V cases
PRNP mutation Symptom or Sign
Number of cases affected
(% of group)
Cognitive decline 3 (21.4)
Extrapyramidal features 1 (7.1)
Dizziness 1 (7.1)
A117V
Personality/ behavioural change 3(21.4)




Of the cases with speech problems, 1 had slow speech (probably of an extra¬
pyramidal type) and 1 had dysarthria. The features at onset in the A117V were quite
variable; cognitive decline and / or personality/ behavioural change were the
commonest onset (5 cases, 35.7% of the group).
S132I
The single SI321 case had cognitive decline at onset.
Y163X
In the Y163X group, the onset was unknown in 1 case and was with cognitive
decline plus balance problems due to peripheral sensory neuropathy and autonomic
neuropathy in the other case.
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D167G
The singe D167G case had cognitive decline at onset.
D178N-Codon 129 M
Table 4.11 The earliest noted symptoms and signs in D178N-129M cases
PRNP mutation Symptom or Sign




Cognitive decline 2 (40.0)
Dizziness 1 (20.0)
Excessive sweating 2 (40.0)
Headache 1 (20.0)
Insomnia 4 (80.0)
Personality/ behavioural change 1 (20.0)
Tiredness 3 (60.0)
Visual hallucinations 1 (20.0)
Weight loss 1 (20.0)
All D178N-129M cases had either insomnia or excessive sweating at onset.
All cases had more than 1 clinical feature at onset (e.g. insomnia plus tiredness plus
weight loss; or excessive sweating plus tiredness plus visual hallucinations).
D178N-Codon 129 V
Both of the cases with the D178N mutation and valine at codon 129 of the
mutated allele had cognitive decline and low mood at onset.
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E200K





Codon 129 MM (%)
E200K
Codon 129 MV (%)
Cognitive decline 10(29.4) 6(28.6) 2(50.0)
Diplopia 1 (2.9) 1 (4.8) 0
Dizziness 4 (11.8) 4(19.1) 0
Gaze paresis 1 (2.9) 1 (4.8) 0
Head ache 1 (2.9) 1 (4.8) 0
Insomnia 4 (11.8) 2 (9.5) 1 (25.0)
Involuntary movements
(other than myoclonus) *
3 (8.8) 3 (14.3) 0
Limb weakness 1 (2.9) 0 0
Low mood/ anxiety 6(17.7) 2(9.5) 1 (25.0)
Myoclonus 2 (5.9) 1 (4.8) 0
Personality/behavioural
change
9 (26.5) 4(11.8) 1 (25.0)
Sensory symptoms 3 (8.8) 0 0
Speech problems 4(11.8) 2(9.5) 1 (25.0)
Tiredness 2 (5.9) 1 (4.8) 1 (25.0)
Visual disturbance / loss 2 (5.9) 2 (9.5) 0
Visual hallucinations 1 (2.9) 0 1 (25.0)
Weight loss 2(5.9) 1 (4.8) 1 (25.0)
Unknown 1 (2.9) 1 (4.8) 0
Unsteadiness 9 (26.5) 6 (28.6) 1 (25.0)
* One case each had tremor, restless legs and chorea at onset.
The commonest features at onset were 1 or more of cognitive decline,
personality or behavioural change or unsteadiness (present in 23 cases, 67.6% of the




The single D202N case had cognitive decline at onset.
V210I
Of the 2 cases ofV210I, 1 had cognitive decline at onset, and 1 had tiredness
and dizziness.
Q212P
The single case ofQ212P had unsteadiness due to gait ataxia at onset.
gCJD (PRNPmutation unknown)
The single of gCJD (PRNP mutation unknown) had non-formed visual
hallucinations at onset.
GSSS (PRNPmutation unknown)
Table 4.13 The earliest noted symptoms and signs in GSSS
(PRNP mutation unknown) cases
Group Symptom or Sign





Cognitive decline 2 (50.0)
Gait & balance problems 2 (50.0)
Cerebellar problems 1 (25.0)
Low mood 1 (25.0)
Insomnia 1 (25.0)
Weight loss 1 (25.0)
176
2-OPRI
The single 2-OPRI case had sensory symptoms at onset.
4-OPRI
Table 4.14 The earliest noted symptoms and signs in 4-OPRI cases
PRNP mutation Symptom or Sign








Personality / behavioural change 1 (10.0)
Unsteadiness 1 (10.0)
The commonest onset in the 4-OPRI group was isolated cognitive decline.
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5-OPRI
Table 4.15 The earliest noted symptoms and signs in 5-OPRI cases
PRNP mutation Symptom or Sign
Number of cases affected
(% of group)
5-OPRI




Visual disturbance 1 (10.0)
Two 5-OPRI cases (20.0% of the group) had both cognitive decline and




Table 4.16 The earliest noted symptoms and signs in 6-OPRI cases
PRNP mutation Symptom or Sign
Number of cases affected
(% of group)
Cognitive decline 26 (72.2)
Cortical visual loss 1 (2.8)
Headache 1 (2.8)
Myoclonus 1 (2.8)
Paranoid delusions 1 (2.8)
Personality / behavioural change 8 (22.2)
6-OPRI Sensory symptoms 1 (2.8)
Seizures 1 (2.8)





Two of the cases with unsteadiness were documented as being ataxic. Two
cases had both cognitive decline and unsteadiness; 5.6% of the group. One case with
speech problems was documented as having dysarthria. Six cases (16.7%) had
cognitive decline and personality/behavioural change. The commonest features at
onset in the 6-OPRI group were 1 or more of cognitive decline, personality /
behavioural change or unsteadiness.
7-OPRI
The clinical features at onset were unknown for the single 7-OPRI case.
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All Cases
Table 4.17 Summary of the earliest noted symptoms and signs in all cases
Symptom or Sign Number of cases % of all cases
(N=159)
Ataxia 6 3.8
Cerebellar syndrome 5 3.1
Cognitive decline 69 43.4
Diplopia 2 1.3
Dizziness/vertigo 10 6.3
Excessive sweating 2 1.3
Extrapyramidal features 1 0.6







Limb weakness 1 0.6
Low mood or anxiety 10 6.3
Myoclonus 4 2.5
Neuropathy 1 0.6
Paranoid delusions 1 0.6
Personality/behavioural change 23 14.5
Seizures 2 1.3
Sensory symptoms 10 6.3





Visual hallucinations 3 1.9
Visual disturbance/loss* 6 3.8
Weight loss 4 2.5
* 1 was documented as having cortical visual loss
**4 had tremor, 1 chorea and 1 restless legs syndrome.
Considering all cases with gPD, the findings at disease onset were variable.
The commonest finding was cognitive decline, followed by unsteadiness, then by
personality or behavioural change. In 20 cases (12.6%) the symptoms and signs at
onset were not known.
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4.X Symptoms and Signs Present over the Entire Illness
The following tables give details of the symptoms and signs present over the
course of the illness, from onset to death. The percentages for each group were
calculated using the group as a whole (i.e. including cases where the symptoms and
signs present were unknown). In these tables the category 'involuntary movements'
refers to involuntary movements other than myoclonus (i.e. chorea, dystonia, alien
limb phenomenon etc.).
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Table4.19Symptomsndsignov rthe tireillnes(2) PRNPMutationHyper¬ tonia N(%)Involuntary movements** N(%)
























































































































































































































































































































































































































































































































4.XI Investigations: EEG analysis
All available EEG results are given below. The results are shown the number
of EEGs of each type and as a percentage of the number of EEGs in each group.
61.2% (N=52) of the EEGs were reviewed in NCJDRSU. Three of the EEGs
classified as showing periodic complexes were not reviewed in the NCJDRSU.







abnormal or slow (%)
Normal
(%)
2-OPRI 1 1 (100.0) 0 0
4-OPRI 9 2 (22.2) 6 (66.7) 1 (11.1)
5-OPRI 4 0 4(100.0) 0
6-OPRI 15 2(13.3) 1 1 (73.3) 2 (13.3)
7-OPRI 0 - - -
P102L 8 0 7 (87.5) 1 (12.5)
P105L 1 0 1 (100.0) 0
A117V 4 0 4(100.0) 0
S1321 0 - - -
Y163X 0 - - -
D167G 1 0 1 (100.0) 0
D178N - Codon 129 M 4 0 4(100.0) 0
D178N — Codon 129 V 2 0 1 (50.0) 1 (50.0)
E200K- All cases 28 8 (28.6) 20 (71.4) 0
E200K- Codon 129 MM 17 7 (41.2) 10(58.8) 0
E200K — Codon 129 MV 3 0 3 (100.0) 0
D202N 1 0 1 (100.0) 0
V210I 2 1 (50.0) 1 (50.0) 0
Q212P 1 0 1 (100.0) 0
Genetic CJD
(PRNP mutation unknown)
1 1 (100.0) 0 0
GSSS
(PR1WP mutation unknown)
1 0 1 (100.0) 0
All Cases 83 15(18.1) 63 (75.9) 5 (6.0)
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4.XII Investigations: CSF analysis
The percentage of each group with an abnormal CSF result is given in table
4.22 (the number in each group tested is given in brackets). Not all cases underwent
analysis of all CSF components, thus the numbers tested for each CSF component
varied within each group. 14-3-3 was negative in 17 cases; of these 76.5% had an
elevated SI00b. The white cell count was known for 45 cases; it was less than 5 cells
per mm3 in all cases tested.
The normal values are as follows: CSF protein 0.15 to 0.45 g/1
Tau, pTau, NSE, and SI 00b were considered to be abnormal if they exceeded the
following cut-offs: tau protein >1200pg/ml pTau-181 >120pg/ml S100b>0.41
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4.XIII Investigations: Neuroimaqinq Findings











1 (20.0%) with chronic subdural
4-OPR1 5 0 1 (20.0) 2 (40.0)
haematoma;
1 (20.0%) 'suspicious' of basal
ganglia/cortical high signal
5-OPRI 4 0 0 4 (100.0)
1 (25.0%) also had spinal cord
atrophy
& on later imaging a chronic subdural
haematoma
6-OPRI 8 0 0 7 (87.5)
1 (12.5%) foci ofhigh signal
(uncertain significance)
PI02L 8 0 3 (37.5) 1 (12.5)
3 (37.5%) 'suspicious' of basal ganglia
/cortical high signal
1 (12.5%) non-specifically abnormal
PI05L 1 0 0 1 (100.0) -
1 (16.7%) atrophy & a cystic lesion in
the right frontal lobe;
A117V 6 0 1 (16.7) 4 (66.7) 1 (16.7%) atrophy & foci ofhigh
signal in the
basal ganglia & caudate nucleus
D167G 1 0 0 0




3 0 2 (66.70) 1 (33.30) -
D178N —
Codon 129 V
2 2 (100.0) 0 0 -
E200K -
All cases
25 12 (48.0) 3 (12.00) 4 (16.0)




16 8 (50.0) 2(12.50) 2 (12.5) 2 (12.50%) non-diagnostic
E200K -
Codon 129 MV
4 1 (25.0) 0.00 2 (50.0) 1 (25.0%) non-diagnostic
V210I 1 1 (100.0) 0.00 0 -
Q212P 1 0 0 1 (100.0) -
All Cases 65 15(23.1) 10(15.4) 25 (38.5) -
23 (35.4) of all the MRIs were reviewed in the NCJDRSU. No MRI results
were available for the following groups: 2-OPRI, 7-OPRI, SI321, Y163X and
D202N. Definitions of'positive' MRI findings are given in the methodology section.
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CT Findings
Of the 58 cases with CT brain results available, 23 (39.7 %) were normal and
23 (39.7 %) showed atrophy.
4.XIV Neuropathology
P102L Neuropathologies! Findings
Neuropathological tissue was available for review in the NCJDRSU for 11
cases and the local PM report was available for a further 6 cases.
All cases were described as having either amyloid plaques, multi-centric
plaques or both. Kuru-type plaques were seen in 6 cases (35.3%), neuritic plaques in
4 (23.5%), multi-centric plaques in 11 (64.7%) and amyloid plaques in 12 (70.6%).
In 1 case (Case 9) there were an unusually low number of plaques seen (for a case of
GSSS).
Spongiform change was seen in 16 cases (94.1%); in 7 cases (41.2%) the
changes were severe, whilst in 9 cases (52.9%) it was mild to moderate, or varied
between different brain regions. Neuronal loss was seen in 12 cases (70.6%); gliosis
in 15 (88.2%) and atrophy in 7 (41.2%).
IHC was performed in 14 cases, all of which were positive for PrPSc. In all
cases tested the plaques were positive for PrPSc. In 7 cases (50.0% of those which
underwent IHC) there was additional PrPSc staining seen outwith the plaques; in 3
cases this was synaptic in nature.
Additional findings were: cerebral sinus thrombosis in 1 case; occasional
neurofibrillary tangles in 2 cases.
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A117VNeuropathologies! Findings
Of the A117V group, a full PM report was available for 3 cases (Cases 1, 4
and 6), and in 1 additional case (Case 4) tissue was available for review at the
NCJDRSU. Brief PM summaries were available for Cases 2 and 3, which stated that
the PM findings were consistent with GSSS, and similar to those of Case 1. All were
concluded to have findings consistent with GSSS.
Of the 3 cases with detailed PM data available, 2 (66.7%) had spongiform
change, 1 (33.3%) had neuronal loss, and 2 (66.7%) had gliosis. Atrophy was seen in
1 case (33.3%).
PrPSc positive plaques were seen in all cases; in 2 cases (66.7%) these were
described as being amyloid plaques, whilst in the remaining 1 case they were
multicentric in nature. The distribution of the plaques was variable; in 1 case the
cerebral cortex was primarily affected, whereas in the other 2 cases they were widely
distributed in the cerebrum, basal ganglia, thalamus and cerebellum. In 2 cases the
frontal and temporal lobes were particular affected by plaque deposition. In 1 case
plaques were present in the cerebellar molecular layer. In all 3 cases the plaques
were described as being confluent masses in some areas. The cerebellum was
relatively spared in all cases. PrPSc deposition was not seen outwith plaques.
SI321Neuropathologies! Findings
Neuropathological tissue was reviewed at the NCJDRSU for the single SI 321
case.
There were multi-centric amyloid plaques, accompanied by neuronal loss and
gliosis. There was severe cerebellar involvement and atrophy. There was mild
spongiosis of the frontal lobes. PrPSL IHC was positive. There was moderate tau
positivity. The plaques were larger and more rounded than those typically seen in
GSSS due to the P102L mutation. The findings were consistent with GSSS.
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D167G Neuropathological Findings
Neuropathological tissue was reviewed at the NCJDRSU for the single
D167G case.
Widespread spongiform change, neuronal loss and gliosis were present.
These changes were marked in the caudate nucleus and putamen and cerebellum
(with the molecular layer of the cerebellum being the most severely affected area).
No plaques were seen. PrPSt deposition was present, mostly in a synaptic fashion. In
the molecular layer of the cerebellum a coarse aggregated pattern of PrPSt was seen.
Type 1 PrPRes was seen. The findings were consistent with CJD.
D178N-129M Neuropathological Findings
PM tissue from 3 cases was reviewed at the NCJDRSU, and a local report
was available for 1 further case. The changes seen were variable. In Case 1 there was
atrophy, neuronal loss and gliosis of the cerebral cortex, neuronal loss and
astrocytosis in the basal ganglia, gliosis of the thalamus and hypothalamus, and in the
cerebellum severe atrophy and neuronal loss, with Purkinje cell deposition in the
granular layer of the cerebellum. There was neuronal loss in the dentate nucleus.
In Case 2 there was marked gliosis on the thalamus, mamillary bodies, medial
subiculum, caudate nucleus, putamen and inferior olives, with the thalami and
mamillary bodies being worst affected. There was also mild cerebellar atrophy, and
spongiform change in the anterior corpus striatum.
In Case 3 there was neuronal loss and gliosis in the cerebral cortex and basal
ganglia, and a few areas of vacuolation in the temporal cortex. In Case 5 there was
moderate patchy gliosis in the frontal and occipital cortex, with moderate gliosis in
the cerebellum and severe gliosis in the white matter.
Overall, in 2 cases (50.0%) very mild spongiform change was seen, neuronal
loss was present in 3 cases (75.0%), gliosis was present in all cases, and atrophy in 2
cases (50.0%). In only 2 cases (50.0%) was the thalamus particularly affected, and in
1 (25.0%) the olivary nuclei. The 2 cases with spongiform change were those with
the longest disease duration (317 and 348 days vs. 241 and 300 days).
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IHC was performed in 3 cases. In 1 case there was faint and patchy positive
reaction in the thalamus; in another there were multiple, fluffy and diffuse plaques in
the frontal and occipital cortex, heavy PrPSc staining of numerous neurones in the
cortex, and foci of synaptic and dendritic PrPSc deposition in the cerebellum. In the
remaining case there was no evidence of PrPSc deposition.
Additionally, in 1 case there were multiple small infarctions in the occipital
cortex and subcortical white matter. In 2 cases a diagnosis of prion disease was
made, and in 2 cases (Cases 1 and 3) no definitive diagnosis was made.
D178N-129VNeuropathological Findings
A local PM report was available for both D178N-129V cases.
Both of the D178N-129 V cases had severe spongiform change of the cerebral
cortex, with neuronal loss and astrocytosis. The most severely affected areas were in
Case 1 the frontal and occipital lobes, and in Case 2 the temporal lobes. In both cases
the cerebellum was spared. Both had a synaptic pattern of PrPSc deposition, and also
PrPSc plaques. In Case 1 there was a ribbon-like appearance to the PrPSc deposition in
the deeper cortical layers, and PrPSc plaques in the cerebellum. In Case 2 there were
numerous cortical amyloid plaques, heavy tau deposition and neurofibrillary tangles.
Overall both cases had findings consistent with CJD, and in Case 2 co-existent
Alzheimer's pathology (Braak & Braak stage VI).
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E200KNeuropathologies! Findings
Neuropathological tissue was reviewed in the NCJDRSU for 14 E200K
cases; in another 6 cases a PM report was available. In 1 further case (Case 2) only a
limited macroscopic report was available, with no overall diagnosis being made, and
this case was therefore not included in the analysis. In all cases (except Case 2) the
final neuropathological diagnosis was one ofCJD.
Considering the group as a whole, all cases showed spongiform change;
gliosis was seen in 15 (75.0%) and neuronal loss in 13 (65.0%). Plaques were not
seen in any cases. In 16 cases 1 or more areas were described as being most severely
affected. The most severely affected areas were: occipital cortex 11 cases (64.7%);
frontal cortex 6 cases (35.3%); basal ganglia 5 cases (29.4%); temporal cortex 3
cases (17.7%); cerebellum 3 cases (17.6%); parietal cortex 2 cases (11.8%);
hippocampus 1 case (5.9%).
IHC was performed in 15 cases; various different patterns of PrPSc deposition
were seen, with synaptic PrPSc in 9 cases (60.0% of those tested); perivacuolar PrPSc
in 6 (40.0%); granular PrPSc in 5 (55.6%); perineuronal PrPSc in 4 (26.7%); and
punctate PrPSc in 1 case (6.7%). Plaque-like PrPSc deposition was seen in 6 cases
(40.0%). In addition 2 cases had linear PrPSc deposition in the cerebral cortex; 1 of
these cases also had an unusual PrPSl" linear staining pattern in cerebellum suggesting
periaxonal accumulation of PrPSc. PrPSc was predominantly found in the cerebral
cortex (12 cases; 80.0%) or cerebellum in (10 cases; 66.7%).
Various cases had some unusual findings; Braak & Braak stage I or II tau
deposition was seen in 1 case, and a few Lewy bodies were seen in the substantia
nigra of 1 case. Mild cerebral arteriosclerosis was present in 1 case, and 6 had
occasional plaque-like structures.
The group was then sub-divided according to the codon 129 status. PM data
was available for 13 E200K Codon 129 MM cases; spongiform change tended to be
widespread and to primarily affect the cerebral cortex. Some cases had severe
involvement of the basal ganglia whereas in others there was none. Changes to the
molecular layer of the cerebellum were seen in 7 (53.8%) cases.
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Nine E200K Codon 129 MM cases underwent IHC; in all cases this was
positive for PrPSc. There were plaque-like deposits in 3 (33.3%) of cases. Synaptic
PrPSc deposition was seen in 5 cases. Overall the pattern of PrPSt deposition and the
anatomical areas affected were variable. Linear PrPSc deposition was seen in the
cerebral cortex in 1 case. Molecular typing of the abnormal prion protein was
performed in 3 MM cases, 2 ofwhich were shown to have Type IB PrPRes. The
remaining case also had type 1 PrPRes, but with a glycoform ratio intermediate
between A and B (i.e. under-representation of the non-glycosylated band).
PM data was available for 3 E200K Codon 129 MV cases. All had
widespread spongiform change; in 2 cases this was predominantly micro-vacuolar. In
all 3 cases the basal ganglia and granular layer of the cerebellum were severely
affected by spongiform change. Two cases had a granular and synaptic pattern of
PrPSt deposition; 1 also had a liner pattern of PrPSc deposition in the temporal,
parietal, frontal and occipital cortex and granular layer of the cerebellum. Type 1
protease-resistance PrPRes was present in this case, with a glycoform ratio
intermediate between A and B (i.e. under-representation of the non-glycosylated
band).
D202N Neuropathological Findings
PM tissue from the sole D202N case was reviewed at the NCJDRSU.
There were numerous amyloid plaques throughout the cerebral cortex, basal
ganglia, thalamus and particularly in the cerebellum. These were associated with
neurofibrillary tangles. There were vast accumulations of PrPSt positive amyloid
plaques in an almost linear distribution throughout the cerebral cortex and the
cerebellum. There was little associated spongiform change and occasional A(3
plaques. The findings were consistent with a GSSS variant.
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V210INeuropathological Findings
Neuropathological tissue from the sole V210I case was reviewed in the
NCJDRSU.
There was spongiform change, in particular of the cerebral cortex and the
molecular layer of the cerebellum. This was accompanied by neuronal loss and
astrocytosis. IHC was positive for PrPSc in a synaptic pattern in the cerebral cortex,
and also in the granular layer of the cerebellum. There were no plaques.
The overall conclusion was that the changes were consistent with CJD.
Genetic OD (PRNPmutation unknown) Neuropathological Findings
A limited local PM report was available for Case 1, which stated that there
was evidence ofCJD and frontal atrophy.
GSSS (PRNPmutation unknown) Neuropathological Findings
Neuropathological tissue from all 4 cases in this group was reviewed at the
NCJDRSU; all met diagnostic criteria for GSSS, with multi-centric PrPSL positive
plaques being present.
Cortical spongiform change was present in 2 cases (50.0%), with gliosis and
neuronal loss being present in 3 (75.0%) and 2 (50.0%) cases respectively. Multi¬
centric plaques were present in the cerebellum in all cases, with the molecular layer
being particularly severely affected in 2 of them (50.0%); plaques were seen in the
cerebral cortex in 3 cases, and in 1 case the deep grey matter was also affected. In
addition to the PrPSc deposition in the plaques, synaptic PrPSt deposition was found
in Case 6. More unusual findings were the presence of neurofibrillary tangles in
Cases 6 and 7; these were in an unusual linear pattern in Case 5, and accompanied by
A|3 amyloid angiopathy. In Case 7 the number of neurofibrillary tangles was small,
and they were confined to the medial temporal lobe.
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2-OPRINeuropathological Findings
Neuropathological tissue from the single 2-OPRI case was reviewed at the
NCJDRSU.
There was severe neuronal loss, spongiform change and astrocytosis in the
cerebral hemispheres. Astrocytosis was most marked in the occipital lobe, whilst
spongiosis was most marked in the frontal lobe. The caudate nucleus showed severe
gliosis. The cerebellum was severely affected with almost complete loss of granular
cells. Type 1A PrPRes was present.
4-OPRI Neuropathological Findings
Neuropathological results were available for 7 of the 4-OPRI cases. Tissue
from Cases 1, 2, 3, 6 and 7 was reviewed at the NCJDRSU.
The overall conclusion in all cases was that the neuropathological
appearances were consistent with sCJD. All cases had spongiform change and
gliosis; neuronal loss was seen in 6 cases (85.7%). In 6 cases (85.7%) the cerebral
cortex, cerebellum and basal ganglia were all affected. The brain stem and spinal
cord were either unaffected or showed only minor involvement. In 5 cases a
comment was made as to which region was most severely affected; this was variable,
being the temporal lobes in 1 case, occipital and parietal lobes in 1 case, the frontal
lobes in 1 case and the cerebral cortex generally in 2 cases. Three cases (42.9%) had
atrophy. Additional findings were of: rarefaction of the outer portion of the dentate
gyrus in Case 1; a recent focal haemorrhage in the left posterior putamen in Case 2;
occasional neurofibrillary tangles in Case 3; and a chronic subdural haemorrhage in
Case 8.
IHC demonstrated PrPSc in all cases; the cerebellum was involved in all cases,
and the cerebral cortex in 6 (85.7%); the midbrain was affected in 1 case (14.3%).
The molecular layer of the cerebellum was affected in 6 cases (85.7%); in 4 cases
(57.1%) this was in the form of linear PrPSt deposition. The granular layer of the
cerebellum was affected in 1 case (14.3%). The pattern of PrP'St deposition was
granular in 2 cases (28.6%), synaptic in 1 case (14.3%), plaque-like in 1 case
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(14.3%), perineuronal in 2 cases (28.6%) and diffuse in 2 cases (28.6%). The PrPRes
type was only known for 1 case; this was type 1.
5-OPRINeuropathoiogicai Findings
Tissue from case 3 was available for review in the NCJDRSU. The local PM
reports for cases 1 and 5 were also available. All reports concluded that the
neuropathological appearances were consistent with CJD.
All cases had spongiform change, neuronal loss, gliosis and atrophy; this
involved the cerebral cortex in all cases, and the cerebellum in 2 cases (66.7%).
There was patchy spongiform change and gliosis in the basal ganglia of Case 3, and
minor gliosis of the thalamus of Case 1. Overall the spongiform change was mild in
1 case (33.3%) and severe in 2 cases (66.7%). The most severely affected areas were
the occipital lobes in 2 cases (66.7%), and the left parietal lobe in 1 case (33.3%).
IHC was performed in Cases 3 and 5; both had PrPSt deposition in the
molecular layer of the cerebellum. In Case 5 the only other PrPSc deposition was in
the form of limited deposits in the parahippocampal gyrus; IHC for A[3 showed mild
to moderate deposits, mainly in the form of plaques and linear subpial deposits.
Silver impregnation showed little Alzheimer-type pathology but many axonal
swellings (torpedoes) of the Purkinje cells in the cerebellum. In Case 3 there was also
strong PrPSc deposition around areas of confluent vacuolation in the cerebral cortex,
and smaller areas of PrPSc in the hippocampus, thalamus and basal ganglia.
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6-OPRI Group Neuropathological Findings
Tissue was available for review in the NCJDRSU for 6 cases, and local PM
reports were available for an additional 10 cases; 1 ofwhich simply stated 'definite
CJD' with no further details being available. This case was therefore excluded from
the analysis, giving an overall total of 15 cases with available PM data. Spongiform
change was seen in 10 cases (66.7%), neuronal loss in 7 (46.7%), and gliosis in 11
(73.3%). Atrophy was seen in 3 cases (20.0%). The area which was worst affected
was variable; in 4 cases (26.7%) this was the cerebellum, and in 5 (33.3%) the
cerebral cortex; in the remaining cases this was not commented on. It is of note that
not all cases had spongiform change of any type.
IHC was performed in 13 cases; all were positive for PrPs\ and all had PrPSc
deposition in the molecular layer of the cerebellum. Nine (69.2% of those who had
IHC) had dense PrPSc deposition in the molecular layer in a linear arrangement at a
right angle to the pial surface. Where IHC was not performed (Cases 2 and 4) there
were comments that the appearances of the cerebellum were unusual. PrPSc
deposition in other areas and in other patterns was seen, but this was variable.
Plaque-like PrPSc deposits were present in 2 cases (15.4% of those which underwent
IHC).
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4.XV The Family History
The percentage of each mutation group with a FHx of prion disease, dementia
or neurodegenerative disease, or psychiatric illness is given below.
Information regarding the FHx was obtained from family members (as documented
in the medical notes of the index case). In most cases it was not possible to
independently verify the accuracy of this information. For the purposes of analysis,
only first and second degree relatives were included. Relatives who were affected
after the index case are included.
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Table 4.24 Family history ofprion disease, dementia, neurodegenerative or




















2-OPRI 1 0 0 1 (100.0) 0
4-OPRI 10 4 (40.0) 3 (30.0) 3 (30.0) 0
5-OPRI 10 8 (80.0) 0 2 (20.0) 0
6-OPRI 36 31 (86.1) 3 (8.3) 1 (2.78) 1 (2.8)
7-OPRI 1 0 0 0 1 (100.0)
P102L 32 18 (48.4) 9(28.1) 2 (6.25) 3 (9.38)
P105L 1 0 0 1 (100.0) 0
A117V 14 11 (78.6) 2 (14.3) 0 1 (7.14)
S132I 1 0 1 (100.0) 0 0
Y163X 2 0 0 0 1 (100.0)
D167G 1 0 1 (100.0) 0 0
D178N- 129 M 5 0 4 (80.0) 1 (20.0) 0
D178N —129 V 2 0 2 (100.0) 0 0
E200K 34 19(55.9) 8 (23.5) 7 (20.59) 0
D202N 1 0 0 0 1 (100.0)
V210I 2 0 0 2(100.0) 0








4 0 1 (100.0) 2 1
All cases 159 92 (57.9) 34 (21.4) 23 (14.5) 9 (5.7)
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4.XVI Death Certification
127 cases were known to have died. The death certificates were available for
115 of these. The commonest causes of death are given below, followed by causes of
death given in only 1 or 2 individual cases.
Table 4.25 Causes ofdeath documented at death certification (1)
Cause of death No. Cases
(% of those with available data)
Genetic prion disease 41 (34.8)
Prion disease (not specified as being genetic) 55 (46.6)
Prion disease NOT listed as a cause of death 21 (17.8)
Dementia 10(8.5)
Respiratory sepsis or failure 44 (37.3)
Table 4.26 Causes ofdeath documented at death certifcation (2)




Causes of death listed for 1 case only
Asperger's syndrome
Cardiac arrest due to vagal inhibition















In addition in several cases had multiple types of prion disease listed as a cause of
death, for example both CJD and GSSS, or both inherited prion disease and vCJD.
4.XVII PRNPPolymorphisms in vCJD
One hundred and forty seven cases of vCJD underwent PRNP genotyping, all
of whom were methionine homozygous at codon 129. One hundred and eighteen had
full PRNP sequencing; 5 of these had polymorphic loci other than codon 129. A
synonymous (silent) polymorphism at codon 202 (GAC-aspartic acid to GAT-
aspartic acid) was found in 2 cases, whilst a further 2 had a non-synonymous change
at codon 219 (GAG-glutamic acid to AAG-lysine; E219K), and 1 had a 24 base pair
deletion (DelR34). The cases with D202D and the individual with DelR34 had
definite vCJD, whilst the E219K cases were classified as probable vCJD. The E219K
polymorphism has previously been described in Asian and Pacific populations, but
not in white Caucasians. The 2 patients with this genotype in this study were not of
white Caucasian origin (further details about their ancestry are not known). The
D202D and E219K polymorphisms were not seen in the control group.
Table 4.27 PRNP sequence variation in vCJD cases
Codon Number Tested Genotype Data
129 (Methionine/Valine) 147 All cases MM
202 (Aspartic acid/Aspartic acid) 118 DD (N = 2)
219 (Glutamine/Lysine) 118 EK (N = 2)
24 base pair deletion 118 DelR34 (N = 1)
Of the 307 sCJD cases screened, 59.5% were MM, 21.4% MV and 19.1%
VV. Full PRNP sequencing found 13 cases with the silent A117A polymorphism
(GCA-alanine to GCG-alanine), with 1 of these having another silent polymorphism
at codon 68 (P68P). Four cases with a 24 base pair deletion in the octapeptide repeat
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region were also identified. Of these 17 patients, 13 were classified as having definite
and 4 probable sCJD.
In addition 1 case with a non-synonymous polymorphism at codon 167
(GAT-aspartic acid to GGT-glycine; D167G) was detected; details of this case have
been given earlier in this chapter.
The frequencies ofA117A and 24 base pair deletion were not statistically
different from control data.
Table 4.28 PRNP sequence variation in sCJD cases and control populations

















N = 13; 4.2% N=9; 4.7% N=47; 6.0%


















5.1 Structure of Discussion
Human gPDs are a heterogeneous group of conditions attributable to PRNP
mutations, of which over 50 have been described. The incidence of individual
mutations varies between different countries and ethnicities. To further complicate
matters the clinicopathological phenotype associated with each mutation is
potentially highly variable, with cases from within the same family sometimes
displaying very divergent features. Furthermore, several apparently non-pathogenic
polymorphisms ofPRNP have been located, the significance ofwhich is unclear.
The aim of this thesis was to review all cases of gPD referred to the
NCJDRSU between 1990 and 2009, plus those identified in earlier epidemiological
studies from 1970 to 1989. The PRNP mutations and polymorphisms found, the
resultant clinico-pathological phenotype, investigative findings and FHx have been
presented. In the discussion the incidence of gPD in the UK will be considered and
compared to that seen elsewhere in the world, as will the clinicopathological
phenotype seen within each different haplotype. The effect of codon 129 on gPD and
the influence of other polymorphisms ofPRNP on cases of sCJD and vCJD will also
be discussed.
Finally, comments will be made on the ethical implications ofPRNP
genotyping and the challenges researchers in this field face, with a review of the
current diagnostic criteria for gPD.
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5.II The Incidence of Genetic Prion Diseases in the UK
Over the time period 1970 to 01/10/2009, a total of 2044 cases of possible,
probable or definite prion disease were reported to the NCJDRSU, of which 159
could be attributed to gPD. Ifwe consider the period 1990 to 2009 only (on the
grounds that ascertainment is likely to have been incomplete in the earlier years, and
the initial studies did not cover the entirety of the UK), the figures are 1596 cases of
prion disease with 147 being genetic. Thus gPD was responsible for 9.2% of the
cases of prion disease in the UK, with an average incidence of 7.35 cases per year, or
0.13 cases per million population per year. This is comparable to reports from
countries such as Germany, France and Australia, but considerably lower than
Slovakia, Flungary, Libya and Chile, where the E200K mutation is particularly
common. Italy and Austria also have a higher rate of gPD; E200K-129M was
responsible for most Austrian cases, whilst in Italy V210I-129M was found in the
majority, with most of the remainder being due to E200K-129M210. The British
figures reported here are therefore consistent with the general European trend in
those countries not affected by clusters of the E200K mutation.
Table 1.7 in Chapter One summarised the incidence of gPD in different
countries, and the proportion of prion disease cases which are reported to be genetic.
These figures are taken from the available literature, and will be influenced by the
degree of prion disease surveillance in different countries, and the rate at full PRNP
sequencing of patients with suspected prion disease or undiagnosed unusual
neurological conditions. Table 5.1 shows a comparison of the international data with
the British figures from the current study. Tables 1.5 and 1.6 in Chapter One listed
all the currently reported PRNP mutations (point mutations, insertions and deletions).
Tables 5.2 and 5.3 highlight mutations identified in the current study.
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Table 5.1 The incidence ofgenetic prion disease worldwide
Adapted from Kovacs et al. 2005210 with additional information from other
sources. UK figures from the current study are shown in bold.
Country Genetic prion disease cases
(% of all prion disease cases)
Incidence
(per million population per year)
Australia 210 10.2 0.14
Austria 210 14.4 0.28
Canada 210 8.5 0.12
China118 7.8 -
France 210 9.0 0.18
Germany 210 7.6 0.13
Italy 210 17.4 0.30
Netherlands 210 2.1 0.02
Slovakia 210 69.5 1.07
Spain 210 10.3 0.23






Japan 270 15.90 -
Chile 113 45.00 -
Belgium 281 4.00 -
Sweden 235 0.92 -
Finland 214 27.27 -
Total210 10.2 0.17
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Table 5.2 PRNP point mutations identified in Britain and elsewhere
Those in bold were found during the current study.
Haplotype Epidemiology
S97-129M China; single case
P102L-129M Extensive range worldwide
P102L-129M, 219K Japan; single family
P102L-129V USA/Italian; 2 cases
P105L-129V Britain, Japan; rare
P105S-129V N. America; single family
P105T-129M E. India; 2 families
P105T-129V 1 family
G114V-129M Uruguay, China, S. India
A117V-129V Europe & N. America
G131V-129M America, Holland; 2 cases
S132I-129M Britain; single case
Y145X-129M Japan; single case
R148H-129M Germany, N. America; 2 cases
Q160X-129M Austria, N. America; 2 families
Y163X
(codon 129 status unknown)
Britain; 2 cases
D167N-129M Turkey; single case
N171S—129V Brazil; single family
D178N—129M Europe, N. America, Australia
D178N-129V Europe, N. America, Israel
D178N-129V &N171S-129V Single African-American family
VI80I-129M Japan, S. Korea, France, N. America
V1801-129 & M232R-129M Japan; single case
T183A-129M Germany, Brazil; 2 families
HI87R-129V N. America; single family
T188A-129M Australia; single case
T188K-129M Austria, Germany; 4 cases
T188R-129V Germany, N. America; 2 cases
T193I-129M Greece; single case
E196K-129M Germany; 3 cases
E196K-129V Germany; 1 case
F198S-129V N. America; large kindred
F198V-129M China; single case





PRNP point mutations identified in Britain and elsewhere
Haplotype Epidemiology
D202G-129V Germany; single case
D202N-129V Canada, 1 family; England, 1 case
V203I-129M Italian; single case*
V203I-129V Korea; single case
R208H-129M China, Europe, N.America; 4 cases
R208H-129V France; single case
R208C-129M China; single case
V210I—129M China, Europe, Japan, N.America
E211Q-129M France, Italy
Q212P-129M Britain, Ireland, N. America; rare
Q217R-129V N. America
Y218N Spain; single case
M232R-129M China, Japan, Korea
M232T Poland; single case
Y226X-129V Holland; single case
Q227X-129V Holland; single case
P238S Germany; single case
• 302* The patient was resident in France but described as being Italian
Table 5.3 PRNP octapeotide repeat insertion mutations identified in
Britain and elsewhere
Those in bold were found during the current study.
Mutation Epidemiology
del 24 base pair 129M Europe; 2 cases
24 nucleotide insertion Canada; 1 case
1-OPRI 129M France, Italy; 3 cases
2-OPRI
(codon 129 status unknown)
Britain
2-OPRI 129V N. America, Holland; 2 families
4-OPRI 129M Britain, Italy, Japan
4-OPRI 129V France; single case
5-OPRI 129M Britain, N. America, Ukraine, Germany
5-OPRI 129V N. America, Germany
6-OPRI 129M Europe, Japan, N. America
6-OPRI 129V France; single case
7-OPRI
(codon 129 status unknown)
Britain
7-OPRI 129M N. America (single family) & Japan (single case)
7-OPRI 129V Holland
8-OPRI 129M France; single family
8-OPRI 129V France, Holland
9-OPR1 129M England, Germany, 2 families
12-OPRI N. America; single family
In all, 15 different PRNP mutations with 16 different haplotypes were found
in the UK, with 3 mutations (6-OPRI, E200K and P102L) being responsible for
64.2% of all cases. It is noteworthy that while E200K is the commonest cause of gPD
in most of the world, in the UK 6-OPRI has caused the highest number of cases. The
majority of 6-OPRI cases belonged to a single family in the South of England, which
has been extensively studied250. Given the presence of this large family, it is
somewhat surprising that the overall rate of gPD in the UK is not higher, particularly
in comparison with countries such as Finland, where 27.3% of all cases of prion
disease have been reported to be genetic in nature, due to one large family with the
D178N mutation. This could be explained by under-ascertainment of gPD in the UK,
by excellent ascertainment of other, non-genetic forms of prion disease, by a
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combination of the two factors, or by natural variation in the de novo PRNP mutation
rate and penetrance of different mutations. Another possibility is that the background
level ofmutations other than 6-OPRI is lower in the UK than elsewhere.
Of all the cases classified as prion disease over the study period, 41.7% were
subject to genotyping to seek PRNP mutations. It is therefore entirely possible that
some cases of gPD were misclassified as sCJD. Information on the rate of
genotyping performed in other countries is sparse; the 2005 EuroCJD study cited the
Netherlands as having the lowest rate ofPRNP genotyping at 31.7%210. It is likely
that the UK is at least on a par with other European countries, with genotyping
targeted at those felt to be at high risk (either based on FHx, ethnicity or
clinicopathological phenotype) rather than applied in a blanket fashion.
All the commoner PRNP mutations (E200K, P102L, D178N, V210I) were
represented in the UK, although the relative scarcity of D178N and V210I compared
to elsewhere in Europe is notable, as is the fact that both cases of V210I were in fact
of non-UK origin, with one being Italian and one Libyan. In the E200K group there
were no cases in persons from Slovakia or nearby countries, but there was one
affected individual of Libyan Sephardic Jewish descent, two affected (and related)
Italians and one Spanish case. In the Italian and Spanish cases there was a strong
FHx of gPD, unlike the majority of the E200K cases of British ancestry. Whether or
not this reflects differences in the penetrance of the E200K mutation between
different families, or merely the combined effects of larger family size and chance, is
uncertain.
5.II.a Cases ofgCJD and GSSS Where the PRNPMutation was Unknown:
gOD
The second case identified during retrospective case ascertainment of prion
disease during the period from 1970 to 1979 was labelled as having gPD; the patient
had a 6 month long illness characterised by dementia, cortical visual disturbance and
myoclonus, triphasic periodic complexes on EEG and evidence of CJD on
neuropathological examination. There was a history of her sister having died
following a 'similar illness', but no further information was recorded. Genotyping had
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not been developed at the time of this patient's death, and no frozen tissue was
stored. The final diagnosis is therefore unclear; the clinicians involved at the time
diagnosed a hereditary problem. It was felt that this case should be included in the
current study for completeness, and to highlight the difficulties surrounding the
analysis of older cases.
5.1I.b Cases ofgOD and GSSS Where the PRNPmutation was unknown:
GSSS
Four cases were found with neuropathological features of GSSS, namely
multi-centric amyloid plaques, but for whom PRNP genotyping was not performed.
Three also had neurofibrillary tangles, which in 1 formed an unusual linear pattern.
They all also displayed a clinical picture which would be consistent with this
diagnosis. Flowever as the FHx was negative or unknown, these individuals cannot
be definitively diagnosed with GSSS. In addition to a simple lack of information,
there are a number of reasons why the FFIx may have been uninformative: de novo
mutations in the proband; the deliberate concealment of previously affected relatives;
or non-paternity. Clinicians are therefore left with a quandary; the neuropathological
features strongly point towards a dominantly inherited, fatal neurodegenerative
disease, but this diagnosis cannot be confirmed. What should the family, in particular
blood relatives, be told and should they be offered pre-symptomatic testing? In such
circumstances specialist genetic counselling will be particularly invaluable, but the
risk analysis of the public health risk posed by relatives in such cases will remain
very difficult, and a precautionary approach would be advisable. Restricting the
provision of full information to the family because of the diagnostic uncertainties is
probably not an acceptable approach.
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5.II.C Death Certification
A review of the death certificates of deceased individuals highlighted the
variable terminology used by the medical profession generally, and the frequent lack
of accurate documentation. Descriptions such 'Jakob-Creutzfeldt disease' were found,
and 1 patient was labelled as having both CJD and GSSS. Only 34.8% of patients
were certified as having gPD, and in 17.8% no form of prion disease was mentioned.
A wide variety of diagnostic labels from Asperger's syndrome to vCJD were listed.
This partly reflects the difficulties in making the diagnosis of prion disease during
life, but also demonstrates the inaccuracy of death certification generally, and
possibly a reluctance on the part of the physician to document the diagnosis for fear
of social stigmatisation of the family. This may cause public health problems if the
family are not fully informed of their own at-risk status and precautions needed
regarding surgical procedures and blood donation.
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5.Ill Codon 129 & other PRNP polymorphisms
5.III.a The Effect ofCodon 129 on Genetic Prion Disease
The polymorphic residue at codon 129 of PRNP gene is potentially an
important determinant of disease susceptibility and phenotype in sporadic and
iatrogenic human prion diseases. Methionine homozygotes are more susceptible to
sCJD, vCJD and iCJD, and of the gPD cases tested here 72.2% possessed this
genotype. Around a quarter were heterozygotes, with valine homozygosity being
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very rare (4.1% of those tested). This is in line with previous European reports . In
the vast majority of cases tested, the mutated allele carried methionine at codon 129
(although this data was only available for a small number of individuals). When
considering all the pathogenic mutations reported worldwide, the majority occur in
conjunction with methionine on the mutated allele (including the top 4 commonest
mutations). It would seem logical to postulate that many more individuals with
PRNP mutations and heterozygosity at codon 129 exist, but either do not manifest
disease or do so at such an advanced age as to not present to the attention of prion
disease surveillance teams. Testing this hypothesis is more difficult, as large scale
screening of asymptomatic individuals for an autosomal dominant, untreatable, fatal
condition is clearly an ethical minefield. It may well be that the presence of valine
csomehow stabilises the structure of PrP and reduces or nullifies the spontaneous
conformational change to PrPSc which presumably occurs in cases of gPD. Valine at
codon 129 is less likely to be associated with pathogenic PRNP mutations (although
it is entirely possible that those with valine at codon 129 and PRNP mutations simply
do not develop any prion disease and are therefore not captured by surveillance
mechanisms).
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5.1II.b PRNP Polymorphisms other than
Codon 129 in Sporadic and Variant CJD
Analysis ofPRNP in sCJD, vCJD and controls has demonstrated genetic
variation in vCJD that is not seen in sCJD. Full PRNP sequencing of 118 confirmed
UK vCJD patients found 5 with polymorphisms: 2 with E219K, 2 with D202D, and 1
with a 24 base pair deletion (del R34).
D202D is a synonymous polymorphism, with no impact on the amino acid
sequence of the prion protein, and no effect on protein folding kinetics. It has been
seen in isolated cases of sCJD and iCJD, but its frequency in healthy populations is
unknown. It may be that it has an as yet unknown effect on vCJD susceptibility, but
further investigation will be required to test this hypothesis.
E219K is a non-synonymous, miss-sense polymorphism causing a change
from glutamic acid (E) to lysine (K). This has not seen in Western European
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populations, but is relatively common in Japan and Korea ' , where it has been
reported to be protective against sCJD, and a modifying factor when associated with
the P102L mutation104. E219K did not cause any detectable alteration to the
clinicopathological phenotype of the 2 vCJD cases in whom it was found. Both
patients were of non-Caucasian origin, and may therefore come from populations
where this polymorphism is common. However a transgenic mouse model does
suggest that lysine at codon 219 renders PrP more susceptible to conversion to
PrPSc.
The 24 base pair deletion influences the metal binding domain of the PrPc N-
terminus, but it is not thought to affect prion disease susceptibility or phenotype. This




The 159 patients with gPD could be segregated into 90 separate families.
Twenty four families contained more than 1 individual with gPD; 35 families had
only 1 affected individual with a diagnosis of gPD but a positive history for
neurodegenerative, dementing or psychiatric illness; and 3 leases had a negative or
unknown FHx. Interestingly, whilst in the E200K group 25 separate families existed,
in the 6-OPRI group there were only 5. This supports previous research
demonstrating a common founder for the British 6-OPRI cases in the South-East of
England in (at the latest) the 18lh century, whilst the E200K mutation is likely to have
arisen on multiple different occasions. The presence ofmultiple unrelated families in
the UK with the E200K mutation supports the theory that this is probably a
mutational hotspot.
Considering the cases as a whole, only 19.5% had no known FHx of any form
of gPD, dementia, neurodegenerative or psychiatric illness. In over half there was a
history of some form of prion disease, in most instances gPD. It was often difficult to
obtain any level of detail regarding a relative's illness, and untangling ancestors with
common forms of age-related dementia from those with occult prion disease was
frequently not possible. It has previously been reported that a FHx of dementia is
significantly commoner in those with sCJD than in healthy, age-matched controls216.
Krasnianski et al. also found those with sCJD and a positive FHx to have a higher
incidence of the Apo E4 allele than those with sCJD and a negative FHx216. As the
presence of the Apo E4 allele is a significant risk factor for Alzheimer's disease, this
could explain the increased rate of relatives with dementia seen. In the present study,
it is likely that there is an element of ascertainment bias, as all the family trees were
subjected to extensive scrutiny, resulting in an increased rate of positive histories. If
a history of prion disease is removed from consideration, we are left with 23.3% of
individuals having a FHx of some other form of dementia or neurodegenerative
disease; still a doubling on that found by Krasnianski et al. in sCJD patients, but this
could be explained by the more detailed history taken here, or by the inclusion of
second degree relatives.
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5.V Investigative Findings in Genetic Prion Disease
5. V.a Electroencephalogram Findings
Only a very low incidence of EEG periodic triphasic complexes was seen,
with 18.1% (15 out of 83) of those tested having this feature. Interestingly, all bar 2
of the positive findings were in those with E200K or an OPRI. None of the mutations
associated with neuropathological appearances of GSSS were shown to have periodic
complexes. This trend follows the results of previous studies210'214, although the
incidence of periodic complexes tended to be much lower in the current group. This
may reflect more stringent EEG classification criteria, or possibly when the
investigation was performed. EEGs were reported as being normal in only 5
individuals, 4 with an OPRI and 1 with D178N-129V. In 4 cases it was possible to
calculate when the EEG was performed relative to the disease duration; 2 were
performed less than halfway through the illness and 2 were carried out late in the
illness (91.7% and 83.4% of the total illness duration). Of these EEGs only 1 was
reviewed as the NCJDRSU.
5. V.b Cerebrospinal FluidAnalysis
Analysing the diagnostic utility of CSF proteins in gPD is difficult owing to
the large number of different haplotypes, and the small amount of data available. In
the present study 14-3-3 results were known for 30.0% of cases, SI 00b for 27.2%,
pTau for 13.7% and Tau for 18.4%. The CSF total protein level was available for
33.3% of cases; whilst it was modestly elevated in 22.5% of those tested, only 2
cases had a level greater than 1 .Og/1. The marker most sensitive for gPD was SI00b,
which was elevated in 90.0% of those tested, whilst 14-3-3 was positive in 61.4%.
Just over half of those analysed had a raised Tau, but pTau was not positive in any
case tested (N = 20). Of those who had a negative 14-3-3 the majority (76.5%) had
an elevated SI 00b, whilst all of those with a normal SI 00b were also negative for
14-3-3.
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Further analysis of these results according to mutation group is problematic
owing to the small groups sizes; it is notable that positive 14-3-3 and elevated SI00b
were seen in most of the different haplotypes tested. Previous authors have attempted
to compare the results seen in FFI, GSSS, OPRI and gCJD210224. There are problems
with this approach: firstly the classification of cases partly according to mutation (i.e.
FFI or OPRI), partly according to neuropathological appearance (GSSS) and partly
by default (gCJD encompassing all other haplotypes) which will lead to considerable
group heterogeneity. One recent study224 found CSF biomarkers to be elevated in
gCJD but not in GSSS or FFI. I did not find positive 14-3-3 in the FFI cases tested,
but 2 of the 3 tested did have a elevated SI 00b. Looking at the P102L and A117V
groups together, only 37.5% had a positive 14-3-3 but 87.5% had an elevated SI00b.
The only gPD groups for whom reasonably sized data sets are available are
E200K, V210I and FFI224'262. A high level of 14-3-3 and SI00b sensitivity is reported
for E200K and V210I, but not for FFI (although the largest group tested for SI00b
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only comprised 10 patients ). Very little data is available on how the codon 129
status of the wild type allele influences CSF biomarkers. There is also the possibility
that the pathogenic PRNP mutation may interact with other polymorphic residues
and thus give rise to different CSF results in different families or ethnic groups.
Overall, 14-3-3 and SI00b are useful tests when investigating possible cases
of gPD, but further large scale collaborative studies will be needed to unpick how
their utility varies between different mutation haplotypes. Compared with sCJD,
SI 00b is more sensitive in cases of gPD and 14-3-3 less sensitive. In particular the
pattern of a negative 14-3-3 with an elevated SI 00b should raise the possibility of
gPD.
5. V.c Neuroimaging Findings
The typical MRI features of basal ganglia and cortical high signal were not
frequently seen in gPD. In fact, only a handful of E200K, D178N-129V and V210I
cases showed these changes, representing 23.1% of the 65 MRIs reviewed. A much
higher rate of typical MRI features has previously been reported in E200K101, and
they have also been observed in a smaller percentage ofOPRI, FFI, P102L and
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A117V cases210. All neuroimaging was performed in the patient's local centre for
diagnostic purposes, with a variety ofMRI scanner types and sequences used. The
quality and type of images was not always ideal, with a number being non-diagnostic
due to movement artefact. It is likely that if the same group of patients were imaged
in a research setting the 'hit rate' of typical MRI changes would be higher, but the
data shown here will more accurately reflect the results available to clinicians in the
real world. Atrophy was seen in just over a third of patients, whilst 15.4% had
normal neuroimaging. These findings should not dissuade a physician from a
diagnosis of gPD, whilst a typical MRI can be supportive. It is notable that the
pulvinar high signal associated with vCJD was not seen in any case.
5. V.d Summary of Investigative Findings in Genetic Prion Disease
Overall the pattern of investigative findings appears to vary somewhat
according to the underlying mutation. EEG and MRI are less sensitive than in sCJD,
although it was unusual to see a normal EEG. CSF biomarkers are helpful, with
SI 00b being more sensitive than 14-3-3, the reverse of the pattern seen in sCJD. It
would be difficult to clearly distinguish gPD from sCJD based on investigative
finding. In cases of unusual neurodegenerative illness with non-specific investigative
findings, PRNP genotyping is required to exclude a diagnosis of gPD.
5.VI Comparison of Each Mutation Group Seen in the UK
with Findings from Elsewhere in the World
Octapeptide Repeat Insertions:
5. Via Two-Octapeptide Repeat Insertion
Two-OPRI is a rare PRNP mutation, the only previous reports of which are in
1 North American family and 1 Dutch family. In the present study 2-OPRI was found
in a British male who developed symptoms in early middle age. Of note is the
unusual mode of symptom onset, which was with progressive paraesthesia of the
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right hand and arm. In other respects the clinico-pathological phenotype resembled
that of sCJDMMl, with PrPRes type 1A apparent at PM. The British patient was
methionine homozygous; the codon 129 status of the North American family was not
reported, whilst the single affected Dutch patient was valine homozygous. It seems
likely that this was a de novo mutation, given its overall rarity and the lack of a
suspicious FHx in the British case. Whether or not the codon 129 status affects the
phenotype seen is difficult to say given the paucity of genetic and clinical data
available.
5. VI.b Four-Octapeptide Repeat Insertion
All of the 4-OPRI patients were homozygous for methionine at codon 129
and for the previously described sCJD risk allele, rsl029273C253. This significant
finding suggests that the presence of the 4-OPRI mutation alone may be insufficient
for disease manifestation within a natural lifespan. Rather, this clinical disorder is
more likely to manifest in the presence of a mutation and additional genetic risk
factors. These additional factors being absent from relatives could account for the
reduced penetrance of the mutation indicated by a relatively low frequency of
familial concurrence of disease in these pedigrees. Whilst this possibility might have
been confirmed by genetic testing of healthy elderly relatives of 4-OPRI probands,
there would be major implications for the families and this was not possible.
The potential effect of PRNP codon 129 heterozygosity on susceptibility to
and/or incubation time is well documented in sporadic, acquired264'42 and some forms
of inherited prion disease377. In 5-OPRI, 6-OPRI, P102L and A117V, PRNP-129
heterozygosity is associated with an older clinical onset compared with
homozygosity377. One theory of prion disease susceptibility is that it is conferred at a
molecular level by homotypic protein-protein interactions with an important role for
the degree to which the wild-type and mutant prion proteins can adopt the same
pathogenic conformations67. Given that 4-OPRI-129MM has an older clinical onset
than many other gPD it is reasonable to predict that the age of onset of 4-OPRI-
129MV might lie beyond the average human lifespan. This would explain the
absence of 129MV patients in the present cohort. Whilst this explanation is plausible,
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the kinetics of prion replication are not well understood, and it is also possible that
the presence of the 129V on the wild-type allele prevents the stable generation of
prions in 4-OPRI.
The analyses support the concept of variable penetrance of the 4-OPRI
mutation that is dependent upon more than just homology between mutant and wild-
type PrP at codon 129. Additional factors upstream of PRNP presumably act by
altered expression ofwild-type PrP. Increased PrP expression has been known for
many years to be a potent susceptibility factor in transgenic mice44. It was assumed
that the rsl029273C-129M haplotype on the mutant chromosome was shared
between all patients because of common ancestry. This conservative assumption was
only partially supported by the haplotype analysis, which was in fact most consistent
with several different mutational events. In this latter scenario, the observation that
all mutant alleles were also associated with the rsl029273C-129M haplotype lends
further support to the increased susceptibility conferred by this haplotype.
4- through 5- to 6-OPRI shows a dramatically earlier clinical onset.
Insertional mutations larger than 5-OPRI show similar ages of clinical onset2r>l. Thus
a correlation between insertion size and clinical phenotype is clear over this short
range, and not for shorter or longer insertions. These clinical observations may form
the basis for an informed correlation between molecular properties ofmutant prion
proteins and the consequences for the onset and clinical phenotype of the human
disease.
Epistasis is a term used to describe an interaction between different loci, and
has recently received a great deal of interest in complex disease genetics. There are
no reported examples of neurological diseases caused by a mutation associated with
a common genotype at additional susceptibility polymorphisms. Despite a huge
effort in exploring genome-wide associations, common susceptibility polymorphisms
have been hard to identify in neurodegeneration, leading to speculation that rare high
risk alleles may be generally more significant. This 4-OPRI case series may thus
provide a useful precedent for understanding how a rare high-risk mutation might
typically manifest as a sporadic neurodegenerative disease.
The IHC in one case showed a distinct pattern from sCJD, with a very
delicate staining of axons and dendrites, rather than synaptic or plaque-forming
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deposits seen in sCJD. The cerebellum also showed prion protein deposits which
seem to follow the dendrites of the Purkinje cells, in that they extend perpendicularly
to the surface, giving the cerebellum a "tigroid" appearance. Remarkably, there was
frequent deposition of hyperphosphorylated tau in several cortical areas, even with a
very subtle involvement of the cerebellum. Although this tau pathology may have
arisen independently from the prion disease, the role of the prion disease in
triggering hyperphosphorylation and a secondary tauopathy remains likely, in
particular, as no deposition of amyloid beta was seen in any of the brain regions
examined.
In summary, this is the first demonstration of the requirement of inheritance
of a susceptibility allele in association with an OPRI mutation for manifestation of a
human prion disease. Whilst the molecular basis of the susceptibility allele is
unknown, one possibility remains that it is linked to homology at codon 129 and
higher levels of expression of PRNP, although this is yet to be demonstrated. This
example of epistasis may provide a valuable model for the understanding of sporadic
neurodegenerative disease in man.
5. VI. c Five-Octapeptide Repeat Insertion
The majority of those affected by the 5-OPRI mutation belonged to a single
family based in Wales, which contained at least 7 affected individuals (and a further
11 relatives with diagnoses such as death at 32 years from 'creeping paralysis'). In all
5 generations were involved, with multiple cases in each generation bar the first.
Assuming the first generation to contain the founding mutation, this instance of the
5-OPRI mutation arose in the mid-19th century, and appears to have a high
penetrance. Unfortunately the exact insertion sequence present is not known for this
family. In addition 3 other apparently unrelated individuals were found, two of
whom had a negative FHx. The remaining case256 had a parent described as having
died of Pick's disease.
Overall the phenotype was typified by cognitive decline and/or gait
disturbance at onset, with these features appearing in the majority as the disease
progressed, accompanied by myoclonus, pyramidal signs and dysphasia. These
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features are consistent with previous reports, a surprising finding given that the
actual repeat structure shows considerable heterogeneity between different families.
It has previously been hypothesised that the codon 129 status influences disease
susceptibility and age at onset, with MV cases having a later age at onset. There was
only one such case found in the current series, the age at onset for whom (49 years)
was rather lower than that of the MM cases (who had a median age at onset of 55
years). However it is not possible to draw firm conclusions based on such a small
sample size, and the paucity ofMV affected individuals is certainly supportive of the
idea that valine at codon 129 of wild type allele prevents or delays disease onset.
The investigative findings reported here add significantly to the world
literature on 5-OPRI; no individuals with periodic complexes on EEG were seen, nor
were basal ganglia high signal or cortical ribboning seen on MRI in any case.
However on CSF analysis positive findings were made, with the majority having
positive 14-3-3, elevated SI 00b, tau and total protein. All of the cases which came to
autopsy had clear spongiform change, gliosis and atrophy of the cerebral cortex, with
the cerebellum also being involved in the majority. Of the 2 which underwent IHC,
both showed abnormal PrP in the molecular layer of the cerebellum, with one having
plaques and linear subpial deposits. Overall a consistent picture emerges of the effect
of a 5-OPRI, which does not appear to be significantly modified by the exact repeat
composition. However the small number of cases known does limit the strength of
this conclusion; nevertheless it is in keeping with the findings of previous authors.
5. VI.d Six-Octapeptide Repeat Insertion
The main source of the 6-OPRI is postulated to be a person living in the 18th
century in the South-East of England, amongst whose descendents at least eighty six
cases of 6-OPRI have been described in detail (the 'Brain kindred' " ). It is not
surprising therefore, that most of the cases reported to the NCJDRSU belonged to
this family. Only 3 individuals could be said to definitely not be related to this
kindred; namely 2 brothers with a different insertion (R3-R2-R3g-R2-R3g-R2 as
opposed to the Brain kindred's R2-R3-R2-R3g-R2-R2) and one female with an R2c-
R2-R2-R2-R2-R2 insertion. On comparing the 'Brain' and 'non-Brain' cases, no
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marked differences in clinical phenotype stand out; the typical pattern of dementia,
cerebellar, pyramidal and/or extra-pyramidal signs and myoclonus remain the
cardinal features. Of note however is the fact that 2 of the 3 'non-Brain' individuals
were heterozygous at codon 129 and both had EEGs with periodic complexes. They
were in fact the only 6-OPRI cases who had periodic complexes; none of the 'Brain'
cases described here or elsewhere had this finding. Whilst this observation only
applies to a very small number of individuals, it does raise interesting questions
about the effects of the specific insertional sequence; could the sequence itself (rather
than just its size) have an affect on the disease manifestations?
Whilst Mead et al. found the codon 129 polymorphism to materially affect
age at onset, they did not see any affect on disease duration256. However in the
present series there was a significant affect of codon 129 status on both age at onset
and duration, with MM cases clearly having an earlier age at onset (a median of 34
years vs. 43 years in the MV cases) and a much longer disease duration (3,396 vs.
627 days). This finding could possibly be explained by our use of days to measure
duration, whereas earlier authors have used months or years; the use of a broader
measure of time may have masked differences in disease duration.
The degree of spongiosis, gliosis and neuronal loss seen varied considerably
between individuals and indeed within the brain regions of single cases. Typically
abnormal PrP was found deposited in the molecular layer of the cerebellum, often in
a linear fashion (a finding which is now considered a pointer towards gPD). It is
noteworthy that in the two related 'non-Brain' cases these linear deposits were not
seen, again raising the possibility of the exact insertional sequence may be
influencing the clinicopathological phenotype.
5. VI. e Seven-Octapeptide Repeat Insertion
Of the 1 case of the 7-OPRI mutation found in the UK very little is known.
The patient was symptomatic at the age of 30 years, and died at the age of 31; the
maximal age at onset was therefore 30 years and the minimal disease duration 305
days. The age at onset is comparable to that reported internationally (where most
cases are in their late twenties to early thirties) although the disease duration is
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probably shorter, with the majority of previously published cases surviving for a
decade or more; however as the age at onset cannot be said with precision in the
British case no conclusions can be drawn from this. Further clinico-pathological
information was not known.
5. VI f Octapeptide Repeat Insertion Mutations Considered as a Whole
A wide range of insertional mutations have occurred in the UK, with a
correspondingly varied roster of clinical and pathological manifestations. The
differences between individuals with the same number of insertions can only be
partly explained by the polymorphic residue at codon 129, leading to speculation
about the effects of the exact insertional sequence itself, or indeed the presence of
other modifying genetic factors outwith PRNP. Within the 4-OPRI group a new
susceptibility allele without which the disease does not seem to manifest itselfwas
identified, a remarkable finding which raises the possibility of the existence of
unaffected mutation carriers. Many unanswered questions remain: why do insertions
of 2 or 4 repeats cause disease when 3 do not? What factors influence the stability of
a mutation across generations? How often do de-novo mutations occur? Are there a
significant number of unaffected, unidentified mutation carriers in the general





The third commonest PRNP mutation in this study was P102L, with 32 cases
found. These belonged to multiple different kindreds, with most having a FHx of
either prion disease (48.4%) or dementia or neurodegeneration (28.1%). In only 2
cases was the FHx negative (in the remaining 3 it was unknown). This led to a
genetic condition often being suspected during the patient's lifetime, although the
clinical phenotype was very variable. Some cases developed rapidly progressive
dementia and bore a close resemblance to sCJD-MMl, whilst others manifested a
cerebellar syndrome in isolation for some time before other neurological features
appeared. A review of the clinical phenotype by codon 129 status was made, but as
full genetic data was only available for 18 cases, only limited conclusions can be
drawn. Eleven patients were MM, whilst 7 were MV and none VV. Most of the MM
cases presented with gait and balance problems, with cognitive disturbance being a
late feature. Of the MV cases, 4 had an early onset of rapidly progressive dementia,
whilst 3 displayed gait and balance problems followed by cognitive decline. Whether
or not codon 129 significantly affected the clinical picture is difficult to say when the
numbers of cases are so small. A recent large-scale international analysis ofP102L
cases investigated this point and did not find a correlation between codon 129 type
and clinical features, although again numbers were small . They did however, note
the age at onset to be significantly younger in methionine homozygotes. This
tendency was seen in the current study (median age at onset in methionine
homozygotes 42 years vs. 56 years in heterozygotes) and the disease duration was
also longer in MM cases (median of 1825 days vs. 867 days in heterozygotes).
However the case numbers are too small for definite conclusions to be drawn from
this data.
A number of cases met the clinical criteria for a diagnosis of sCJD, but of
those tested none had EEG periodic complexes or MRI changes to support this.
However 60% (3 of 5) were positive for CSF 14-3-3, all of whom also had an
elevated SI00b. On reviewing the clinical details for these cases, only one fulfilled
the diagnostic criteria for sCJD (the other 2 having a duration greater than 2 years).
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Therefore overall although the symptoms and signs are heterogeneous, the
combination of a careful FHx and a lack of typical EEG and characteristic MRI
changes should a pointer towards a diagnosis of gPD. Although the P102L mutation
is described as being a cause of GSSS, it does not necessarily cause a classical GSSS
clinical picture.
The neuropathological findings were more consistent than the clinical ones,
with all of those who underwent PM examination having amyloid plaques. However
the number of plaques present and the degree of spongiform change seen were very
variable. Whilst spongiform change was present in 94.1%, this was severe in only 7
of the 17 cases with available data (41.2%). All of those who underwent IHC showed
positivity in the plaques themselves, with half having additional abnormal PrP
deposition outwith the plaques.
The finding ofmultiple, apparently unrelated cases is consistent with
previously published haplotype analysis376, and suggests that the P102L mutation has
arisen independently on a number of occasions. The codon 129 status possibly
influences the age at onset and clinical features seen, but the small numbers of cases
in each group limit the conclusions that can be drawn from this data. The P102L
mutation should be considered as a possible diagnosis not only in patients with
unusual progressive cerebellar syndromes, but also in those with a rapidly
progressive dementia resembling sCJD but negative EEG and MRI results, and a
significant FHx.
5. VI.h P105L
The single British case with the P105L mutation carried this in conjunction
with the V209M polymorphism, a previously unknown combination. Indeed all of
the previously published cases of P105L were of Japanese origin. A comparison of
the Japanese and British phenotypes is thus of particular interest; the age at onset in
the British case was outwith the age range observed in Japan (albeit by a mere 4
years) whilst the duration is so far comparable (the British case being still alive 10
years after onset, whilst the disease duration observed in Japan ranged from 5 to 12
years). The clinical features were very similar, with gait apraxia, cerebellar and
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pyramidal signs and dementia, atrophy on neuroimaging and non-specific EEG
abnormalities. CSF findings were not reported for any Japanese cases, whilst in the
British case the 14-3-3 was negative with a modestly elevated SI00b. However
unlike the Japanese cases (which had a strong FHx) there was no suspicious FHx in
the British case, which may therefore have been a de novo instance of this rare
mutation.
5. VI. i A117V
Four separate kindreds carrying the A117V mutation were identified; the
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largest of these has already been published elsewhere . Several different patterns of
clinical onset and progression were seen, with the majority having a rapidly
progressive dementia with later cerebellar problems, pyramidal signs and myoclonus.
In some cases there was a near simultaneous onset of gait and cognitive problems,
whilst in a small number there were prominent extra-pyramidal features early on.
The age at onset ranged from the third to the sixth decade, with a disease duration
from less than 1 year to over 3. These results are consistent with previous reports,
which have also commented on the tendency for valine homozygotes to have a
younger age at onset. Codon 129 data was only available for 4 individuals in the
present study; the 2 heterozygotes had older ages at onset and shorter disease
duration than the 2 VV cases but given the small numbers of cases it is not possible
to analyse this further. Data on investigations were also limited: 6 underwent MRI,
none ofwhom had basal ganglia or cortical high signal; and 4 had EEGs, none of
whom displayed periodic complexes. CSF 14-3-3 was negative in the 3 cases
analysed, 2 ofwhom had an elevated SI 00b. The neuropathological findings were
similarly variable; although all were felt to represent GSSS, there was variability in
the distribution of amyloid plaques, which in some cases were widespread whilst in
another primarily restricted to the cerebral cortex. All of those for whom detailed
neuropathological data was available showed relative sparing of the cerebellum. The
clinicopathological phenotype of A117V remains variable, and although all of those
who underwent neuropathological examination were diagnosed with GSSS, this was
often not a diagnosis made during their lifetime on clinical grounds. Indeed, on
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reviewing the family trees, there was in all cases a strong history of
neurodegenerative disease, but in most cases relatives died with a diagnosis other
than prion disease. It is likely that the phenotypic heterogeneity and the frequent
absence of classical features of GSSS such as early, prominent ataxia have often
muddied the diagnostic waters, further emphasising the role that PRNP genotyping
should play in investigating hard to diagnosis hereditary neurodegenerative diseases.
5. VI.j SI321
The single instance of the SI 321 mutation described here is the only known
case worldwide; there was a strong FHx with the patient's brother having died of
ataxia and dementia, and ancestors in the previous 3 generations dying with dementia
in middle-age. It is reasonable to assume that these individuals were affected by the
same mutation which was transmitted in an autosomal dominant fashion. Although
dementia was the dominant feature of the illness, it is noteworthy that the proband's
brother was described as being ataxic, whilst the proband herself had no cerebellar
signs. The neuropathological findings in the proband were of multicentric amyloid
plaques similar to but larger than those seen with the P102L mutation. This novel
mutation highlights the difficulties of using the terms 'gCJD' and 'GSSS'; here the
clinical features of the proband most closely resemble CJD, but the neuropathology
fits with GSSS criteria.
5. Vl.k Y163X
Y163X is a rare mutation resulting in the truncation of PrP with loss of the
glycophospholipid anchor. Only 2 individuals with this mutation have been referred
to the NCJDRSU, regarding 1 of whom very little information is available, to the
extent that it is unknown whether or not the she is actually symptomatic. Therefore
only 1 case of gPD due to Y163X can be said to have been identified in the current
study. This codon 129 heterozygous individual is thought to be still alive, at least 4
years after the onset of cognitive problems, followed by cerebellar signs. Of note is
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the pre-existing autonomic and sensory neuropathy, which may well in fact be part of
the disease phenotype in light of the recent publication of a family carrying this
mutation, characterised by autonomic failure, sensory neuropathy and chronic
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diarrhoea, followed some years later by cognitive decline and seizures . Although
temporally disparate, the 2 constellations of symptoms seem to be linked, as
evidenced by the presence of abnormal PrP not only in the CNS but also in the
duodenum. Further neuropathological data of the effects of this mutation (possibly
from the same family although this is not specified by the authors) describe vascular
and parenchymal PrP deposition with extensive neurofibrillary tangles319. These
intriguing reports further demonstrate the heterogeneity of prion disease, and the
need for vigilance when planning surgical procedures (even non-neurosurgical ones)
in those with or at risk of gPD; transmission studies of gastrointestinal tissue from
those with the Y163X mutation and abnormal PrP in the duodenum would be
invaluable in furthering our knowledge of the iatrogenic potential of this condition.
5. VI. I D167G
The single case of the D167G mutation described here remains the only
known instance of this mutation; although there was a FHx of cognitive impairment
this had been attributed to dementia puglisitica and may therefore not be relevant.
The clinical phenotype seen closely resembled that of sCJDMMl, with the onset of
cognitive impairment in old age, followed by pyramidal signs, visuo-spatial deficits,
visual hallucinations, myoclonus and death after less than 2 years. It is
understandable therefore, that the patient was originally classified as having probable
sCJD (based on the clinical features and a positive CSF 14-3-3). Neuropathologically
there was little to go against this diagnosis, with widespread spongiform change,
neuronal loss and astrocytosis. The only slightly unusual finding was that the most
severely affected region was the molecular layer of the cerebellum, where a coarse
aggregated pattern of type 1 PrPRes was found. Evidence for this novel mutation
being causative of gPD disease (rather than being a silent polymorphism in a case of
sCJD) comes from the likelihood that the substitution of a large hydrophilic amino
acid for a small hydrophobic one may disrupt the physical properties of PrPc, and
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from animal models suggesting that codon 167 is involved in the binding of
chaperone molecules207. However in the absence of further affected family members
D167G cannot be definitively said to be a pathogenic mutation.
5. VI.m D178N-129M
Only 5 cases of FFI were seen in the UK, none of whom were related or had a
FHx of gPD (although 3 did have first degree relatives with neurodegenerative
disease). The onset typically involved sleep disturbance and non-specific complaints
such as tiredness and headache. This was true of both the 4 MM cases and the single
MV case (although having valine on the wild-type allele has previously been
• i • • • 312associated with an ataxic onset and later sleep disturbance, this was not seen here) .
The overall clinical phenotype was one of frequent sleep disturbance, dementia,
visual hallucinations, cerebellar and pyramidal signs, with non-specific EEG and
MRI findings. Three subjects were tested for 14-3-3 and SI00b; 14-3-3 was negative
in all but S100b elevated in 2 cases.
The neuropathological findings in the 4 MM subjects examined were
variable, and were not entirely in accord with findings reported in the literature on
the subject. Methionine homozygosity is typically associated with severe
degeneration of the thalamus, but this was only seen in 2 of the 4 MM cases
examined here. The degree of abnormal PrP deposition was very variable, with none
in 1 case, faint patchy thalamic deposits in another, whilst in the remaining case there
was heavy PrPSc staining of neurones in the cortex, foci of synaptic and dendritic
deposition in the cerebellum, and multiple, fluffy diffuse plaques in the frontal and
occipital cortex. These unusual neuropathological findings were not associated with
any strikingly different clinical features. Several very large FFI families have been
described in the international literature323'214, and it is of interest that the British cases
were all apparently unrelated and none had relatives affected by gPD. This again
raises the issue of de novo mutational events, or indeed interactions between the
pathogenic PRNP mutations and other genetic or environmental factors, with a net
effect on disease susceptibility and manifestation.
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5. VI.n D178N-129V
The D178N mutation with valine on the mutated allele was even less
common than FFI, with only 2 cases found in the UK. Both carried methionine on
the wild-type allele, and displayed a clinical phenotype resembling sCJDMMl,
presenting with rapidly progressive dementia followed by cerebellar problems and
myoclonus. One of the cases did have sleep disturbance, but this was not a prominent
or early feature. Both had extensive cortical ribboning on MR imaging and positive
CSF 14-3-3, with non-specific changes on EEG. They had similar neuropathological
findings with severe spongiform change of the cerebral cortex, neuronal loss,
astrocytosis, and abnormal PrP deposited in a synaptic pattern plaques. In Case 1
there was a ribbon-like appearance to the PrPs< deposition in the deeper cortical
layers, and PrPSt plaques in the cerebellum. In Case 2 there were numerous cortical
amyloid plaques, heavy tau deposition and neurofibrillary tangles, felt to represent
co-existent Alzheimer's pathology (Braack and Braack stage VI). Whilst the severe
spongiform change is not unusual, the PrPSc plaques are, especially as the cerebellum
was involved (it typically being spared in D178N-129V).
5.VI.0 E200K
A large proportion of the cases of gPD identified in this study were due to the
E200K mutation, although in contradistinction to other countries it was not the
commonest mutation seen. The difficulties in distinguishing gPD due to E200K and
sCJD are highlighted by the fact that 44.1% of the cases in this series were initially
diagnosed with sCJD, and therefore it is possible that case ascertainment was not
complete.
The presenting complaint was typically one of cognitive decline, personality
or behavioural change, gait disturbance or a combination of these features. This was
very similar to that of sCJD, although sleep disturbance was a much commoner
presenting feature with CJD-E200K, especially in the MV sub-group.
A comparison of clinical features seen over the entire illness revealed a
similar rate of cognitive problems, cerebellar and pyramidal signs and myoclonus in
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sCJD and CJD-E200K. However extra-pyramidal signs such as bradykinesia and
cog-wheel rigidity were less common in CJD-E200K whilst involuntary movements
other than myoclonus (e.g. chorea, dystonia and tremor) were much more frequently
observed in CJD-E200K.
The incidence of seizures in the present series (23.5%) was lower than has
been previously reported191'40. There was also a lower incidence of extra-pyramidal
signs, and a higher rate of visual disturbance or loss, and of involuntary movements
other than myoclonus. The median age at onset seen here agreed with that reported
by Mead (58 years), although the disease duration in the present series was
noticeably briefer (130 vs. 213 days)251.
In the current series there was a lower incidence (28.6%) of periodic
complexes than previously reported in CJD-E200K40 and in sCJDMMl293. However
these figures are comparable to those previously reported in sCJD by the NCJDRSU
(34%)74. The present findings are unlikely to be attributable to EEG timing, as on
average the EEG was performed later in those cases which did not have typical
periodic complexes.
The CSF 14-3-3 was positive in 82.4% of those tested (comparable to the
86% sensitivity reported in sCJD63), whilst SI00b showed a tendency to be higher
than is usually seen in sCJD, with over half of those tested having a result over
1.00ng/ml, and 12.5% have a results greater then 2.00ng/ml.
Around half of the cases which underwent MRI of the brain showed basal
ganglia or extensive cortical high signal, and the true figure may in fact be higher,
given that 16% of the available scans were non-diagnostic due to poor image quality.
A previous study of 15 individuals from 1 family with CJD-E200K found 87% to
have basal ganglia signal abnormalities on FLAIR, a much higher hit rate than is
usually reported in sCJD cases101.
The neuropathological findings in the current series were similar to those of
sCJDMM 1, with the exception of the PrPRes type seen. Of the 4 cases in which the
PrPRes type was determined, Type IB (21kDa nonglycosylated band and
diglycosylated band predominating) was found in 2 MM E200K cases, and a type
intermediate between 1A and 1B (i.e. under-representation of the non-glycosylated
band) in 1 further MM cases and in a single MV case. These PrPRes types are unusual
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and typically associated with gPD, and provide an important feature distinguishing
sCJD from E200K.
Only 11.8% of the cases in the present series were heterozygous at codon
129; the codon 129 status of the wild type allele was only known for 1 of these cases,
which was methionine. These findings agree with the picture seen worldwide, where
the majority are MM, and only a very small number with valine on the mutated allele
2iohave been described .
Overall our MM and MV E200K cases had a similar age at onset, symptoms
and signs and CSF findings. The disease duration was longer in the MV cases, and
there was a tendency towards a lower incidence of periodic complexes and MRI
positivity in the MV group. They may also have more severe basal ganglia and
cerebellar involvement on neuropathology. However the small size of the MV group
makes it difficult to draw firm conclusions.
Of the 34 cases identified, only 2 could be linked to known clusters of the
E200K mutation; 1 case was of Sephardic Jewish ancestry (with no known FHx of
prion disease) and 1 case was of Spanish ancestry and had an extensive FHx of gPD.
In total 25 separate families were identified, 3 of which were not ofUK Caucasian
origin. Detailed genealogical research was not done, therefore it is possible that there
were hidden links between these families. Only 44% of families had more than 1
affected individual. This data supports the view that the E200K mutation has arisen
on multiple occasions. Over a fifth of cases had no FHx of prion disease,
neurodegeneration, or psychiatric illness, raising the possibility that these cases
represent de novo mutational events. It is of interest that the majority of cases appear
to occur in isolation, in contrast to the findings in the Slovakian and Sephardic
Jewish clusters. This raises the possibility that the penetrance of the mutation may be
variable, possibly depending on other polymorphisms of the PRNP gene. In
conclusion it remains a difficult task to separate out cases ofCJD-E200K from those
of sCJD, and clinicians should be particularly alive to the possibility of gPD when
unusual features such as a young age at onset, early sleep disturbance, chorea,
dystonia or tremor or a very high S100b are present.
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5. VI.p D202N
D202N is a rare mutation, with only 2 cases reported worldwide, 1 of them
British. This lady had an unusual illness, with a slowly progressive dementia lasting
for 7 years; additional gait problems were only noted a mere 5 months prior to her
death. Whilst prion disease was suspected by her physician, the initial
neuropathological analysis did not in fact support this, with a diagnosis of
Alzheimer's disease being made in the early 1980s. It was only upon a review some
years later that numerous amyloid plaques with associated neurofibrillary tangles
were identified throughout the cerebral cortex, basal ganglia, thalamus and
particularly in the cerebellum. These were positive for abnormal PrP, and in places
aligned in almost linear fashion. These appearances were felt to be consistent with a
GSSS variant, which lead to analysis of the PRNP gene. It is noteworthy that in
common with mutations such as P105L and A117V which give rise to
neuropathological appearances classifiable as GSSS, the individual with D202N was
valine homozygous at codon 129. This is at variance with the mutation which
classically causes a GSSS-type picture, P102L, in which group the majority are MM
at codon 129. As has previously been discussed, this raises interesting points about
the interactions between these point mutations and codon 129. Is valine at codon 129
a permissive factor in the occurrence of these mutations? Or is D202N in conjunction
with methionine a non-pathogenic polymorphism? As such it has certainly not been
detected in population studies to date. Transgenic animal studies would be of great
interest in order to further explore the interactions between these mutations and
codon 129.
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5. VI. q V210I
Scattered instances of the V210I mutation have appeared across Europe, N.
Africa, S. America and Asia. Both the cases seen in the UK were immigrants, with
one being born in Italy to a family resident for several generations in the Campania
region, and the other Libyan. Both manifested a similar clinical phenotype, with
onset of a rapidly progressive illness resembling sCJDMMl in the seventh decade,
and methionine homozygosity at codon 129. The first case had periodic complexes
on their EEG, whilst the second had asymmetrical basal ganglia high signal on MRI
and positive CSF 14-3-3 with an elevated SI00b. This led to both being classified in
their lifetimes as having sCJD, neither having a positive FHx. This mutation has
already been observed in a Moroccan person of Berber ancestry; the exact racial
extraction of the present North African case was not known, but there was no FHx of
neurodegenerative disease.
No link could be made between the Italian case and any reported V210I
family in Italy, but this individual was from the Campania region, an area in which
this mutation is particularly prevalent223 and 90% of those with the V210I mutation
have a negative FHx210. The additional finding of elderly asymptomatic relatives
being carriers of the mutation implies that the penetrance of this mutation is low.
Whilst disease has successfully transmitted to transgenic mice using brain tissue
from affected individuals242, no similar attempts have been made with samples from
unaffected carriers. Questions regarding penetrance create quandaries for clinicians
and families; if it is low then is pre-symptomatic genetic counselling justified? What
public health risks would an as-yet asymptomatic person with a low penetrance
mutation pose?
5. VI.r Q212P
The single previously published case of the Q212P mutation occurred in a
Caucasian N. American gentleman, who had an 8 year long illness characterized by
ataxia, incoordination, dysarthria and dysphagia in the absence of dementia. Amyloid
and abnormal PrP deposition were found at neuropathology, leading to the case being
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labelled as one of GSSS. In the present study 1 British woman in her fourth decade
was affected by this mutation, with a similar presentation comprising initial gait
disturbance followed by cerebellar and pyramidal signs and myoclonus. However
cognitive impairment did occur, appearing over a year later. At the end of the study
period she was still alive, over 6 years after symptom onset. As with the earlier case,
EEG and MRI have shown only non-specific abnormalities and atrophy. CSF
analysis demonstrated a negative 14-3-3 with an elevated SI00b. The possibility of
this mutation not being the cause of her illness was considered, but extensive
investigations have failed to demonstrate an alternative diagnosis. It is of interest that
the patient is homozygous for the mutation, although the FHx is negative and there is
no known history of consanguinity. This might suggest a low penetrance but
significant dc novo mutation rate (or concealed consanguinity); the finding of an
asymptomatic elderly carrier sibling of the N. American case supports this theory.
5.VII Diagnostic Criteria for Genetic Prion Disease
The current internationally agreed diagnostic criteria divide cases into those
with 'probable' gPD or 'definite' gPD. A probable diagnosis can be made if a patient
has a progressive neuropsychiatric disorder and a disease-specific mutation, or if
they meet diagnostic criteria for probable prion disease and have a first-degree
relative with definite or probable prion disease. In order to reach a definite diagnosis
there must be neuropathological evidence of prion disease and a pathogenic PRNP
mutation and a first-degree relative with definite or probable prion disease. These
criteria have been carefully drawn up to try and classify cases as accurately as
possible, but there are certain circumstances where applying them becomes difficult.
For example, in the present study, individuals were identified with definite prion
disease (but no PRNP genotyping) and a second-degree relative with definite gPD. In
one case the individual had 2 second-degree relatives with gPD. In these
circumstances it seems highly likely that the diagnosis is one of gPD, but the case is
not classifiable as such. An individual approach is needed in such circumstances to
judge the likelihood of such cases representing sporadic or genetic disease.
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The criteria also create the situation where an individual with definite prion
disease and a mutation that is well known to be pathogenic such as P102L or E200K
but with an uninformative FHx can be described as having only probable gPD,
implying a degree of diagnostic uncertainty that is probably not really present.
Difficulties also arise with novel mutations such as D167G; the single
reported individual with this mutation had previously been diagnosed with definite
sCJD, and without a FHx or other case reports it is impossible to know if this is a
pathogenic mutation or not. From a pragmatic point of view it seems sensible to
assume that this mutation is pathogenic until proven otherwise and to advise the
family appropriately. Transmission studies or transgenic animal work may prove
useful approaches to determining the nature of such novel mutations.
There is now a trend to classify cases according to PRNP haplotype rather
than splitting them into gCJD or GSSS. Given the clinicopathological heterogeneity
seen this is probably the correct approach. For example, whilst P102F-129M is said
to be prototypic mutation causing GSSS, cases may actually closely resemble sCJD
(to the point ofmeeting the criteria for a diagnosis of probable sCJD). The division
of cases into gCJD and GSSS is somewhat artificial, and as more novel mutations
with unusual presentations and neuropathological findings are described, it becomes
less and less useful. PRNP genotyping is also the only way to exclude a diagnosis of
gPD and should be offered to all patients and families affected by prion diseases to
try and minimise the risk ofmisdiagnosis.
5.VIII Limitations of This Work & Suggested Topics for Further Research
This thesis has reviewed data on individuals of gPD referred to the
NCJDRSFT over a 20 year period, with additional cases from epidemiological studies
covering the previous decade. Despite this, the number of cases remains small,
especially when each PRNP mutation is considered separately. This is an issue
inherent to the study of any rare disease, and one encountered by previous
researchers. The large number of PRNP mutations and the need to further sub-
classify them according to the polymorphic codon 129 residue makes accumulating
sufficient cases for statistical analysis very difficult. Interesting conclusions can still
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be drawn, but care must be taken to not read too much into trends within small
groups. Previous authors have amalgamated cases into groups according to various
criteria, for example comparing those meeting the diagnostic criteria for GSSS with
those with insertional mutations. Whilst this is an attractive approach, it is difficult to
know how meaningful it is to compare such groups. By far the commonest
insertional mutation in the UK is 6-OPRI, whilst the commonest cause of GSSS is
P102L. A comparison of patients with insertional mutations vs. GSSS may therefore
effectively be a comparison of 6-OPRI and P102L. It is preferable to classify cases
by PRNP haplotype, despite the constraints this puts upon sample size. International
collaborations such as the EuroCJD study are one way of overcoming this difficulty.
Detailed haplotype analysis was performed for the 4-OPRI group, with the
outcome that all were found to be homozygous for both methionine at codon 129,
and the previously described risk allele for sCJD, rsl029273C. Future work seeking
other such risk polymorphisms would be of great interest, especially looking for
factors at work in families where elderly, unaffected mutation carriers are found.
This would be of particular utility in seeking to explain why the E200K mutation in
Israeli Sephardic Jews appears to have a very high penetrance, whereas in other
ethnic groups including the UK population, it does not. International collaborations
such as the EuroCJD project have already yielded a great deal of useful data because
of their access to a large population of affected individuals, and further collaborative
work screening for other genetic factors which influence disease susceptibility and
clinicopathological phenotype could be very rewarding.
Performing genotyping for an autosomal dominant mutation which causes an
unbeatable, fatal condition is understandably controversial. Explaining complex
genetic issues to families coming to terms with a terminal diagnosis in a loved one is
challenging, and clinicians must endeavour to present unbiased advice in an
understandable and timely fashion. There may also be disagreement between family
members as to the best course of action, with older relatives sometimes being against
genetic testing whilst younger relatives who are considering starting their own family
may be keener to be fully informed. Balancing the best interests of the patient, their
family, and the desire to gain data for research is difficult. The involvement of
specialist genetic counselling services is desirable in such circumstances. Ethical
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considerations limit the volume of genetic testing performed, particularly on pre-
symptomatic, at-risk individuals. This may well change if significant developments
are made in the field of prion disease treatment, in which case more widespread
PRNP genotyping of all individuals with prion disease and their blood relatives could
be justified on clinical grounds. Until then the current policy ofmaking all families
aware of the risk of gPD masquerading as sCJD, and targeting genetic testing
specifically to those at higher risk based on the clinical picture and FHx is
appropriate. However this will undoubtedly continue to miss a (hopefully small)
number of cases of gPD.
5.VIX Conclusions
In summary, the clinico-pathological phenotype of gPD remains highly
diverse, and their diagnosis is often difficult. Whilst CSF analysis, MRI and EEG are
useful tools, the mainstay of diagnosis should be formal PRNP genotyping. Patients
and families should receive specialist genetic counselling, and care must be taken to
ensure that they are fully informed of the implications of a diagnosis of gPD before
testing is performed, particularly in pre-symptomatic individuals. Whilst the current,
internationally agreed diagnostic criteria are robust, they may require individual
interpretation in some cases. Finally, the terminology is now evolving towards
subdivision of cases by haplotype, as the terms gCJD and GSSS are not the exclusive
entities they were once thought to be. There seems to be a continuum of clinical and
pathological appearances on a spectrum between classical CJD and GSSS, which can
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Genetic factors are implicated in the aetiology of sporadic late-onset neurodegenerative diseases. Whether these genetic vari¬
ants are predominantly common or rare, and how multiple genetic factors interact with each other to cause disease is poorly
understood, inherited prion diseases are highly heterogeneous and may be clinically mistaken for sporadic Creutzfeldt-iakob
disease because of a negative family history. Here we report our investigation of patients from the UK with four extra octa-
peptide repeats, which suggest that the risk of clinical disease is increased by a combination of the mutation and a susceptibilty
haplotype on the wild-type chromosome. The predominant clinical syndrome is a progressive cortical dementia with pyramidal
signs, myoclonus and cerebellar abnormalities that closely resemble sporadic Creutzfeldt-Jakob disease. Autopsy shows per¬
pendicular deposits of prion protein in the molecular layer of the cerebellum, identity testing, PRNP microsatellite haplotyping
and genealogical work confirm no cryptic close family relationships and suggests multiple progenitor disease haplotypes. All
patients were homozygous for methionine at polymorphic codon 129. In addition, at a single nucleotide polymorphism upstream
of PRNP thought to confer susceptibility to sporadic Creutzfeldt-Jakob disease (rs1029273), all patients were homozygous for
the risk allele (combined P= 5.9 x 10 5). The haplotype identified may also be a risk factor in other partially penetrant inherited
prion diseases although it does not modify age of onset. Blood expression of PRNP in healthy individuals was modestly
higher in carriers of the risk haplotype. These findings may provide a precedent for understanding apparently sporadic
neurodegenerative diseases caused by rare high-risk mutations.
Keywords: inherited prion disease; octapeptide repeat insertion; Creutzfeldt-Jakob disease; epistasis
Abbreviations: CJD = Creutzfeldt-Jakob disease; OPRI = octapeptide repeat insertion
Received April 1, 2010. Revised March 2, 2011. Accepted March 4, 2011
© The Author (2011). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
1830 I Brain 2011: 134; 1829-1838 D. N. Kaski et at.
Introduction
Prions are lethal infectious pathogens, largely composed of an
abnormally folded host protein (Collinge, 2001). As one of
the prototypic protein misfolding disorders, prion diseases share
fundamental mechanisms with other neurodegenerative con¬
ditions. Human prion diseases may be divided into three cate¬
gories: acquired, inherited or unexplained—termed sporadic
Creutzfeldt-Jakob disease (CJD). Clinically, sporadic CJD and
inherited prion disease show remarkable diversity, being associ¬
ated with several subtypes and eponymous syndromes, and are
often misdiagnosed as a result. The aetiology and clinical hetero¬
geneity of sporadic neurodegenerative diseases are poorly
understood.
Inherited prion disease accounts for ~15% of human prion dis¬
eases, and are always associated with coding mutations in
the prion protein gene (PRNP) (Mead, 2006). Two types of patho¬
genic PRNP mutation exist: point mutations leading to an amino
acid substitution in the prion protein or the production of prema¬
ture stop codons; and alteration of the number of octapeptide
repeats. The normal prion protein octapeptide repeat region is
composed of a nonapeptide followed by a tandem repeat of
four copies of an octapeptide and lies between codons 51 and
91 (Kretzschmar et at., 1986). Insertions of up to nine extra,
and deletion of two, octapeptide repeats have been described in
patients.
Typically, octapeptide repeat insertion (OPRI)-associated prion
disease presents as a syndrome of slowly progressive multi¬
focal dementia accompanied by dyspraxia and cerebellar ataxia.
However, the clinicopathological phenotype, both within and
between OPRI families shows significant variability. Age of
onset varies from adolescence to old age, the clinical course
from several months to >15 years and the dominant clinical fea¬
tures may be psychiatric, cognitive, cerebellar or extrapyramidal
(Collinge et at., 1992; Laplanche et at., 1999; Moore et at.,
2001; Mead et at., 2006; Webb et at., 2008). This is partly
due to a coding polymorphism of PRNP codon 129 (Poulter
et at., 1992; Mead et at., 2006, 2007). Much of the clinical
heterogeneity remains unexplained however; candidate factors
include variation of modifier loci (Lloyd et at., 2001) and hetero¬
geneity of the misfolded prion protein itself (Wadsworth et at.,
2006).
In the first patient series of this mutation we report the clinical
phenotype, investigative findings, molecular genetic and neuro-
pathological features of all known UK patients with 4-OPRI. We
show that the clinical phenotype of 4-OPRI prion disease is distinct
from that seen in patients with 5- or 6-OPRI. For a genetically
determined disease, we found that a family history of early-onset
dementia was remarkably uncommon. To explain this, we provide
evidence that the mutation alone appears not to be sufficient
to consistently cause the disease: all UK patients were homozy¬
gous at two common polymorphisms, in and upstream of PRNP.
Our findings provide a precedent for the mechanisms of pene¬




Genomic DNA was extracted from peripheral blood using the Nucleon
Bioscience BACC2 DNA extraction kit. The entire open reading frame
of PRNP was assessed by direct sequencing from genomic DNA. The
size of insertions was confirmed by fractionation of amplicons from
polymerase chain reaction designed to amplify the octapeptide repeat
region by agarose gel electrophoresis. The exact nature of additional
repeat units was confirmed by a combination of subcloning and by
direct sequencing. Sequence data were analysed using allele discrim¬
ination assay Seqscape software. rs1029273 upstream of the PRNP
open reading frame (Mead ef al, 2001) was genotyped using
the Taqman 5' nuclease allele discrimination assay. For PRNP haplo-
type analysis, microsatellite markers D20S181, D20S193, D20S473,
D20S867, D20S889, D20S116, D20S482, D20S97, D20S895,
D20S849, D20S873, D20S95 and D20S194 were amplified. Data
were analysed using ABI GeneMapper software v4.0.
For relatedness testing, a subset of the Powerplex16 microsatellite
marker set (Promega) was utilized and processed in a similar manner
to PRNP microsatellites. This subset included microsatellite markers
VWA, D5S818, D13S317, D7S820, D16S539, TH01, TPOX,
CSF1PO, PENTA E and PENTA D. Following allele discrimination
assay GeneMapper software analysis to provide allele sizes (basepairs),
these data were subsequently converted to equivalent Powerplex16
allele sizes (numerical scores) for use in the ML-Relate program
(Kalinowski ef a/., 2006).
Samples
Samples were obtained for 10 patients (Table 1 and Supplementary
Material) with informed consent by the National Prion Clinic, London,
or the National CJD Surveillance Unit, Edinburgh.
The clinical, genetic, biochemical and neuropathological studies were
approved by the National Hospital for Neurology and Neurosurgery
and University College London Hospital research ethics committee. UK
control samples (566) were obtained from healthy blood donors.
Statistical analysis
Means, standard deviations (SDs), tests of normality, Mann-Whitney
U-test, binomial probability tests, linear regression and x2-tests were
performed using the Statistical Package for the Social Sciences package
(SPSS Inc.). Genetic association studies were performed with the use of
PLINK (Purcell et at., 2007).
Genealogical investigations
Family lineages were traced back to identify cause of death of parents
of affected individuals. Birth and death certificates were obtained from
the General Register Office via their website. Where records were not
available the original clinical notes, out-patient letters and medical re¬
cords were used. A family history of neuropsychiatric illness was con¬
sidered positive when there was early-onset dementia (age <65 years)
or a later-onset progressive dementia or behavioural disturbance in the
context of abnormal neurological signs leading to death, in keeping
with the clinical picture observed in this case series.
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Table 1 Clinical features
Patient Sex Age at Age at Duration Codon Symptoms at onset Pyramidal Extrapyramidal Myoclonus Chorea Cerebellar
onset death (days) 129 signs signs signs
(years) (years)
I M 56 56 59 MM Dementia, gait
disturbance, myoclonus,
drowsiness
No Yes Yes No No
II M 67 67 77 MM Deteriorating handwriting Yes No Yes No No
III M 47 53 2319 MM Impaired memory and
concentration
Yes Yes Yes No Yes
IV F 85 NA Alive MM Impaired memory No No No No No
V F 39 45 2160 MM Impaired memory and
concentration
No Yes No Yes No
VI M 58 58 73 MM Deteriorating handwriting No No Yes No Yes
VII F 65 66 414 MM Impaired memory and
anxiety
No Yes Yes No Yes
VIII M 70 73 1191 MM Impaired memory and
personality change
No Yes Yes Yes No
IX F 51 52 93 U Dizziness Yes No Yes Yes Yes
X F 53 59 1943 MM Dementia No No Yes No Yes
M = male; F = female; U = unknown, although identical twin of Patient X, and therefore highly likely to be 129MM.
Neuropathology
Tissue was fixed in 10% buffered formol saline followed by incubation
in 98% formic acid for 1 h. Following post-fixation for 24 h in 10%
buffered formol saline, the tissue samples were processed through
graded alcohols and paraffin wax embedded.
Paraffin sections were cut at a nominal thickness of 7 pm, boiled in a
low ionic strength Tris-ethylenediaminetetraacetic acid buffer, pH 7.8
for 20min, followed by 15min in 98% formic acid. Primary antibodies
used were anti-glial fibrillary acidic protein rabbit polyclonal anti-serum
(Dako), anti-prion protein monoclonal antibodies ICSM 35 (D-Gen
Ltd) and KG9 (TSE Resource Centre, Neuropathogenesis Division,
University of Edinburgh), anti-Tau AT8 (Dako) and anti-Beta-amyloid
(Dako). Antibodies were detected with the Ventana Medical Systems
Inc. immunostainer using a biotinylated universal IgG secondary anti¬
body (iView Biotinylated Ig; Ventana Medical Systems, Inc.) an avidin-
biotin horseradish peroxidase conjugate system (iView SA-HRP;
Ventana Medical Systems, Inc.) before development with 3,
3'-diaminobenzedine tetrachloride as the chromogen (iView DAB;
Ventana Medical Systems Inc.). Haematoxylin was used as the counter
stain. Haematoxylin and eosin staining of serial sections was performed
using conventional methods. Appropriate controls were used through¬
out (Wadsworth et at., 2008). At least eight blocks were analysed in
each case, including frontal, occipital and parietal cortices, temporal
cortex with hippocampus, basal ganglia, thalamus, cerebellum and
brainstem.
Expression analysis
Whole blood was drawn into ethylenediaminetetraacetic acid and
PAXgene™ tubes at a Donor Suite of the National Blood Service
with informed consent. DNA was extracted from ethylenediaminete¬
traacetic acid whole blood using the Nucleon BACC3 kit (GE
Healthcare). Samples were genotyped for PRNP codon 129
(rs1799990) and rs1029273 by allelic discrimination using the
SDS7500 (Applied Biosystems) system. Primer and probe sequences
are available on request. RNA was extracted from PAXgene tubes
using the PAXgene™ 96 Blood RNA kit (PreAnalytix). RNA (1 pg)
from each individual homozygous for the M129 allele was reverse
transcribed using Omniscript (Qiagen) with random hexamer priming.
PRNP transcript levels were measured using the SDS7500 by relative
quantification using the delta-delta-Ct method with two different
primer limited endogenous controls (P-actin and TATA box binding
protein) each duplexed seperately with PRNP (assay details on re¬
quest). The endogenous controls were selected for suitability using
geNorm (http://genomebiology.eom/2002/3/7/research/0034) to
minimize candidate endogenous gene variability in human whole
blood. Results of the relative quantities of the PRNP transcript
represent the normalization of real-time quantitative polymerase
chain reaction data by geometric averaging of relative quantities
calculated using the two internal reference genes.
Immunoblotting
Human brain (frontal cortex) was prepared as 10% w/v homogenates
in Dulbecco's sterile phosphate buffered saline lacking Ca2+ and Mg2*
ions and analysed after proteinase K digestion (12.5 or 50pg/ml final
protease concentration, 1 h, 37°C) by immunoblotting with anti-prion
protein monoclonal antibody 3F4 using high sensitivity enhanced
chemiluminescence as described previously (Wadsworth et al., 2001;
Hill et al., 2006).
Results
Clinical findings
The principle clinical features are shown in Table 1 and investiga¬
tions in Table 2. In summary, the predominant clinical syndrome
was a rapidly progressive cortical dementia with myoclonus, motor
and cerebellar signs resembling sporadic CJD. A pure cognitive
syndrome was apparent in one patient (Patient IV) in which
there had been a slowly progressive decline in episodic memory
over 7 years in the absence of neurological signs. This patient has
a moderate cortical dementia with early defects in episodic memory





EEG CT MRI Neuropathology
I NAa Typical Gross generalized
atrophy
Not done CJD
II No Typical Atrophy Not done CJD
III Nob Non-specifically abnormal Normal High signal in right caudate
head and temporal lobe
CJD
IV No Not done Not done Parietal and temporal lobe
atrophy
NA (patient alive)
V Yes Non-specifically abnormal Atrophy Not done Not done
VI No Non-specifically abnormal Not done Normal CJD
VII No Suggestive Atrophy Not done CJD
VIII No Non-specifically abnormal Mild atrophy Left chronic subdural
haematoma
CJD
IX Noc Non-specifically abnormal Atrophy Not done Not done
X Noc Normal Unknown Atrophy CJD
A family history was considered positive if there was a history of dementia in a parent with onset prior to the age of 65 years, or a late-onset neurodegenerative disease
associated with dementia and neurological signs consistent with inherited prion disease. For EEC, typical refers to classical findings associated with CJD.
NA = Not available,
a Family history was censored.
b Son of Patient IV; however, we cannot be certain that Patient IV has inherited prion disease as her clinical phenotype is consistent with Alzheimer's disease,
c Monozygotic twins, family history refers to parents.
and executive functions, clinically resembling Alzheimer's disease.
Memory deficits and more widespread cognitive decline were the
predominant features in Patients I, III, IV, VII, VIII and X. A par¬
ental history typical of inherited prion disease was only rarely seen
in our patient series.
Age at onset of disease was known for all patients and disease
duration was known for nine patients. Both showed considerable
variability, the youngest patient presenting in her late thirties and
the oldest aged 85 years (or possibly 70 years; see description of
living Patient IV in the Supplementary Material). The longest ill¬
ness duration was 77 months (Patient III) although Patient IV is
still alive aged 92 years, with a minimum disease duration of 7
years. The mean (SD) age of onset was 60 (12.97) years (range
39-85 years) with a median disease duration of 414 days (range
59-2319 days).
Biochemical (urea and electrolytes, liver function tests, serum
calcium, serum copper, serum angiotensin-converting enzyme,
and serum vitamin B12 and folate), haematological (full blood
count and erythrocyte sedimentation rate), serological (anti-
nuclear antibodies, rheumatoid factor, syphilis serology and
anti-cardiolipin antibodies) and thyroid function tests, when per¬
formed, were within normal limits. CSF examination was per¬
formed in six patients (Table 3). Protein 14-3-3 was consistently
positive in those tested (n = 4).
Genetic analysis
The complete PRNP open reading frame was sequenced in nine
patients. DNA was unavailable for Patient IX (the identical twin of
Patient X, monozygosity not genetically confirmed). All patients
tested were shown to have an additional four R2 repeats,
and to be homozygous for methionine at codon 129. No other
sequence variations were detected.
We genotyped PR/VP-linked and unlinked microsatellites to test:
(i) the number of separate ancestral occurrences of the 4-OPRI
mutation; and (ii) cryptic close kinship within our series.
Relatedness testing at unlinked microsatellites confirmed a mother-
son relationship between Patients III and IV (P = 6 x 10~6, max¬
imum likelihood of parent offspring 0.57). Other relatedness in
this patient series, closer than second degree, was excluded by
this analysis. For linked microsatellites, Patients II, VII and X
shared a haplotype of 2.5Mb, differing from the mother/son
and each other, at a single 3' marker (D20S194). Two further
patients, Patients I and VI, shared with the above five patients a
central core haplotype spanning ~1.2Mb (D20S889-D20S895).
Finally, Patients V and VIII demonstrated a shared 1 Mb haplotype
with those described above between D20S97 and D20S895 only,
although these two patients shared an extended haplotype of
2Mb (D20S181-D20S849). Overall our data were consistent
with multiple (at least two) ancestral occurrences of 4-OPRI in
the UK; however, we cannot exclude a single ancestral occurrence
several centuries in the past with time for recombination and
mutation events to disrupt the disease haplotype.
PRNP codon 129 (rs1799990) and rs1029273C (upstream of
PRNP) have been identified as risk factors for sporadic CJD
(Palmer et at., 1991; Mead et at., 2001; Vollmert et at., 2006;
Mead et at., 2009). Genotyping revealed homozygosity for codon
129MM (r5l799990AA) and rs1029273CC in all 4-OPRI patients.
At least one rs1029273C-129M haplotype would be expected in
each patient if the 4-OPRI mutations had all occurred on this
haplotype background. This assumption is conservative as our
microsatellite genotyping suggests that there may have been mul¬
tiple mutational events. Flowever, the haplotype of the wild-type
chromosome is independent of the presence of the mutation,
and the haplotypes seen on the unaffected chromosome were
not expected to be different from the control population. The
rs1029273C-129M haplotype occurs at a frequency of 0.339 in
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Table 3 CSF analysis
Patient Glucose
(mmol/l)
Protein (mg/ml) Cell counts CSF OCB Plasma OCB 14-3-3 S100b (ng/ml,
<0.38)
II 6.7 0.44 Normal Positive Positive Positive Not done
III 3.0 0.44 Normal Not done Not done Positive 2.42
VI 3.9 0.31 Normal Not done Not done Not done Not done
VII 4.4 0.25 Normal Not done Not done Positive 3.8
VIII Unknown Unknown Unknown Positive Not done Positive 0.44
IX 3.6 0.63 Normal Not done Not done Not done Not done
OCB - oligoclonal bands.
the control UK population (384/1132 UK control haplotypes). The
probability that all wild-type haplotypes would be rs1029273C-
129M is P= 5.9 x 10~5 (binomial probability). rs1029273C is usu¬
ally found on a 129M chromosome, but the significance of the
association of rs1029273C and 4-OPRI could not be accounted
for by an association driven by 129M alone (P = U.OO3, binomial
probability, of finding that all nine wild-type alleles were
rs1029293C, with the assumption that all patients were genotype
129MM). With the conservative assumption that Patient IV
had Alzheimer's disease rather than prion disease, these asso¬
ciations remain significant (for the rs1029273C-129M haplotype
P = 1.7 x 10~4, for rs1029273C independent of 129M P = 0.005).
We also compared the clinical phenotype of 4-OPRI with slight¬
ly larger insertional mutations. We did not compare 4-OPRI with
smaller insertions as these have been identified in healthy control
populations and are not clearly pathogenic (Beck et at., 2010).
OPRI length had a profound effect on mean age of onset with
5- and 6-OPRI having earlier ages of onset. Mean (SD) age at
onset in UK patients with 5-OPRI in those with codon 129MM
was 42.3 (12.4) years (range 26-63 years, n = 6) (Mead et at.,
2007). Mean (SD) age of onset in UK patients with 6-OPRI
in those with codon 129MM was 31.4 (5.7) years (range
20-49 years, n = 30) (Mead et at., 2006); P = 0.04 for comparison
between 4-OPRI and 5-OPRI, and P < 0.001 for 4-OPRI com¬
pared with 6-OPRI. The relationship between increasing size of
octapeptide repeat insertion, codon 129, and age of clinical onset
is shown in Fig. 1. Duration of disease was also significantly shorter
(P < 0.001) compared with patients with 6-OPRI. However, we
found no significant difference between 4- and 6-OPRI for a
number of clinical parameters, including myoclonus, cerebellar,
extrapyramidal or pyramidal signs.
We went on to consider the frequency and phenotypic effects
of rs1029273C-129M in other inherited prion diseases. Here we
tested samples from 144 individuals with various inherited prion
diseases (5-OPRI, n = 11; 6-OPRI, n = 51; P102L, n = 36; P105L,
n = 1; A117V, n = 12; D178N, n = 5; E200K, n = 26; and Q212P,
n = 2). None of the other inherited prion diseases had an absolute
association with the upstream risk factor; however, in the entire
series, rs1029273C was strongly associated with disease status
compared with healthy controls (odds ratio =1.62, P = 2.5 x
1CT4, x2-test, 1 degrees of freedom) with an increased frequency
of the risk allele in inherited prion diseases. This overall association
is potentially confounded by linkage between rs1029273C and
































Figure 1 Correlation between mean age of onset and the
number of OPRIs. Individual patient data shown (green, red and
dark blue points) with means (horizontal black bars) for 4-, 5-
and 6-OPRI, codon 129MM. Patients with a PRNP codon
129MV genotype are represented by yellow (5-OPRI) and light
blue (6-OPRI) points, this genotype was not observed for
4-OPRI.
mutation to be more frequent because of hitch-hiking. It is
known that the large UK kindred segregating a 6-OPRI mutation
occurs on an rs1029273C-129M haplotype; however, large UK
kindreds segregating P102L and A117V occur on
rs1029273T-129M and rs1029273T-129V haplotypes. The haplo¬
type background of other mutations is not known with certainty;
microsatellite haplotype analysis in P102L, E200K, D178N and
5-OPRI is most consistent with multiple ancestral events. As a
result, the mutation haplotype background has little overall
impact on the frequency of rs1029273C and adjusting for the
most probable background where known, had little effect on
the statistical association reported above.
We went on to consider the strength of the association of
rs1029273 in different inherited prion diseases, such as those
most similar to 4-OPRI on the basis of reduced penetrance and
a CJD-like clinical phenotype (e.g. 5-OPRI, E200K, D178N). In this
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analysis, we considered only 129MM individuals in cases and con¬
trols to exclude the possibility of an association being confounded
by hitch-hiking with codon 129, In these three inherited prion
diseases there were 47 rs1029273C alleles and 15 rs1029273T
alleles, compared with 288/188 in controls, respectively
(P = 0.019, x2-test, 1 degrees of freedom). A similar analysis in
the early-onset, highly penetrant inherited prion diseases (e.g.
6-OPRI, P102L, A117V) showed no significant associations inde¬
pendent of the codon 129 genotype. The rs1029273 genotype did
not have any effect on the age of onset of inherited prion disease
(for example, 6-OPRI, age of onset for rs1029273C = 33 years,
rs1029273T = 31 years; r? = 27), suggesting that in 4-OPRI, and
possibly other similar inherited prion diseases, the wild-type
chromosome determines the risk of a patient getting disease at
any age rather than modifying the age of onset of disease itself.
Electroencephalography
EEGs were performed in nine patients. Two showed characteristic
periodic complexes associated with sporadic CJD. One was 'highly
suggestive' of sporadic CJD and a further five were abnormal but
not suggestive of CJD. One was normal. Brief summaries of indi¬
vidual reports are provided in the appropriate patient histories
(Supplementary Material).
Neuroimaging
CT scans were performed on seven patients (Patients I, II, III, V,
VII, VIII, IX and X) and MRI on five (Patients III, IV, VI, VIII and
X). Findings varied from normal appearances to generalized cor¬
tical atrophy with cerebellar involvement, with one case having
right caudate head and temporal lobe high signal (appearances
considered suspicious but not diagnostic of CJD; Case III). In
one patient, a left-sided subdural haematoma was seen (Patient
VIII). Detailed information about sequences performed for some
patients was not available, and were often variable between pa¬
tients as scans were performed at different stages of magnetic
resonance technology.
Neuropathology
Seven patients had post-mortem examinations. Patients II, III and
VIII were examined in detail (refer to 'Materials and methods'
section). A brief summary of salient neuropathological features
for other patients with examined post-mortem is included in the
patient histories (Patients I, VI, VII and X); however, the three
described below are representative of the findings overall.
The macroscopic finding of a subdural haematoma was histolo¬
gically confirmed in Patient VIII, showing dura mater as well as
granulation tissue with intensive capillarization and haemosiderin
deposition. In all three cases examined in detail, there was mod¬
erate to severe spongiform degeneration in all neocortical areas,
often in a patchy distribution. This was associated with a moder¬
ate, focally severe neuronal loss with destruction of cortical grey
matter (Figs 2A and Supplementary Fig. 1A). In these areas, there
was also a severe proliferation of astrocytes, highlighted by glial
fibrillary acidic protein immunostaining. Prion protein
immunostaining showed a very delicate network of twisted prion
protein-positive structures, which were most likely axons and den¬
drites (Fig. 2B). Typical synaptic prion protein deposits were not
seen. Also, thin thread-like structures in the cortex and white
matter were labelled, probably corresponding to intra-axonal ab¬
normal prion protein (Fig. 2C and Supplementary Fig. 1B). There
was no synaptic pattern and no deposition of plaques anywhere in
the cortex. In contrast, the cerebellum showed features that are
distinct, and very different from the pathology in the neocortex:
there was no cerebellar spongiform degeneration in Case VIII, and
only moderate gliosis that was pronounced in the molecular layer.
Cases II and III showed moderate microvacuolar spongiform
change in the molecular layer (Supplementary Fig. 1C). Prion pro¬
tein immunostaining showed a very characteristic and unique pat¬
tern, where the staining appeared to extend along Purkinje
cell processes or was contained within Purkinje cell processes in
the molecular layer oriented perpendicularly to the surface. Small
rounded deposits were also present in the granular layer in Cases
II and III (Fig. 2F and G and Supplementary Fig. 1D). No amyloid
plaques were present in the cerebellum. There was also deposition
of hyperphosphorylated tau, which varied in shape and extent:
while the occipital cortex showed the most intense deposition of
hyperphosphorylated tau with formation of neuropil threads and
occasional intraneuronal tangles (Fig. 2E), all other cortical areas
showed much smaller, stub-like inclusions (Fig. 2D). The cerebel¬
lum was almost devoid of hyperphosphorylated tau structures,
with only occasional granular inclusions (Fig. 2H). No beta-amyloid
was seen in any of these areas.
Expression analysis
We hypothesized that the susceptibility effect of the rs1029273C-
129M haplotype was conferred by increased expression of
wild-type prion protein. We tested this by measuring PRNP ex¬
pression in whole blood against selected control genes. Healthy
UK blood donors (n = 145) were sampled, 51 were homozygous
for methionine at codon 129, 14/51 had rs1029273CC genotype,
24/51 were CT heterozygous and 13/51 were TT homozygous.
Normalized PRNP expression levels varied from 0.76 to 1.44 with
a mean of 1.14 (95% CI 1.02-1.26, P-0.03, f-test) in CC homo¬
zygous individuals relative to TT homozygous individuals, with CT
heterozygous individuals having intermediate levels of expression.
When individuals were ranked by PRNP expression, the top four
individuals with highest levels of relative PRNP expression were
rs1029273C-129M homozygous.
Prion protein immunoblotting
Frozen brain was available for analysis from Patients III, VI, VII
and VIII. Frontal cortex (grey matter) was prepared as 10% w/v
homogenate and analysed after limited digestion with proteinase K
by immunoblotting using anti-prion protein monoclonal antibody
3F4. All four patient brain samples showed prominent protease-
resistant PrPSc fragments in the molecular mass range of
~19-30kDa with no evidence for the generation of lower
molecular mass prion protein fragments or for the co-existence
of different PrPSc types within the same brain sample (Fig. 3).
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Figure 2 Pathology in Patient VIII with 4-OPRI. (A) Haematoxylin-eosin-stained section of the frontal cortex with severe spongiform
degeneration and neuronal loss. (B, C) Prion protein deposition occasionally forms small 'woollen' structures in the deep cortical layers,
and distinct, delicate labelling of axons is seen in the grey (C, arrows) and white matter. In the cortex, variable amounts of phosphorylated
tau were seen, which were scattered and sparse in the frontal and temporal (D), and more abundant in the occipital cortex (E). Prion
protein deposits form a striking, 'tigroid' pattern, which is oriented perpendicularly to the surface and is limited to the molecular layer
(F, G). Very rarely, there are also deposits of phosphorylated tau (H, arrow).
Previous analysis of brain from 4-OPRI Patients VI and VII to¬
gether with brain tissue from patients with 2- and 6-OPRI (Hill
et at., 2006) showed that the PrPSc types associated with these
OPRI mutations are apparently indistinguishable with respect to
glycoform ratios and fragment sizes from those observed in clas¬
sical CJD (Hill et al., 2003; Wadsworth et at., 2008). Consistent
with these findings, 4-OPRI Patient III propagated PrPSc with a
type 2 fragment size (Fig. 3) that was indistinguishable from type
2 PrPSc seen in 4-OPRI Patient VII (Fig. 3). 4-OPRI Patient VIII
propagated PrPSc with a type 3 fragment size (Fig. 3) that we
have previously only observed in a single PRNP codon 129 me¬
thionine homozygous patient with sporadic CJD (Hill et at.,
2003). The clear demonstration of the propagation of different
PrPSc types among patients with 4-OPRI provides a molecular
basis for phenotypic variability, although the small patient
cohort examined here precludes significant analysis. However,
in this context, it is interesting to note that Patient VI, who
propagated type 1 PrPSc, had a short clinical duration and that
this mirrors the association of type 1 PrPSc and short clinical
duration seen in sporadic CJD (Wadsworth et at., 1999; Hill
et at., 2003).
Discussion
We have presented the clinical, neuropathological and molecular
genetic analysis of 10 patients with the 4-OPRI mutation of PRNP.
All patients were homozygous for methionine at codon 129 and
for the previously described sporadic CJD risk allele, rs1029273C.
This statistically significant finding suggests that the risk of disease
conferred by the 4-OPRI mutation alone may be enhanced by the
wild-type chromosome. These additional factors being absent from
relatives could account for the reduced penetrance of the muta¬
tion indicated by a relatively low frequency of familial concurrence
of disease in these pedigrees. While this possibility might have
been confirmed by genetic testing of healthy elderly relatives of
4-OPRI probands, there would be major implications for the
families and this was not done. The sample of patients analysed
was necessarily small and therefore the statistical significance of
our genetic findings would not be robust to the addition of several
further patients with 4-OPRI with different genotypes at codon
129 and rs1029273.
The effect of heterozygosity of the polymorphic codon 129 of
PRNP on susceptibility to and/or incubation time is well
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Figure 3 Prion protein immunoblots in 4-OPRI and other
inherited prion diseases. PrPSc types in Patients III, VI, VII and
VIII. (A-C) Immunoblots of proteinase K digested brain
homogenate from patients with different PRNP OPRI mutations.
The size of OPRI mutation is designated below each immunoblot
together with PrPSc proteolytic fragment size [using the London
classification of PrPSc types (Hill et a!., 2003)] and PRNP codon
129 genotype, methionine (M) or valine (V). Immunoblots were
developed with anti-prion protein monoclonal antibody 3F4
using a chemiluminescent substrate.
documented in sporadic, acquired (Collinge et at., 1991; Palmer
et at., 1991) and some forms of inherited prion disease (Poulter
et at., 1992). In 5-OPRI, 6-OPRI, P102L, A117V and F198S, het¬
erozygosity at codon 129 is associated with an older clinical onset
compared with homozygosity (Dlouhy et at., 1992; Poulter et at.,
1992; Mead et at., 2007; Webb et at., 2008, 2009). Prion disease
susceptibility is thought to be conferred on a molecular level by
homotypic protein-protein interactions (Palmer et at., 1991) with
an important role for the degree to which the wild-type and
mutant prion proteins can adopt the same pathogenic conform¬
ations (Collinge, 1999; Hill and Collinge, 2003; Collinge and
Clarke, 2007). Given that 4-OPRI with 129MM has an older clin¬
ical onset than many other inherited prion diseases, it is reasonable
to predict that the age of onset of 4-OPRI with 129MV might lie
beyond the average human lifespan. This would therefore explain
the absence of patients with 129MV in our cohort. While this
explanation is plausible, it would also be possible that the presence
of the 129 V on the wild-type allele prevents the stable generation
of prions in 4-OPRI.
Our analyses support the concept of variable penetrance of the
4-OPRI mutation that is dependent upon more than just hom¬
ology between mutant and wild-type prion protein at codon
129. Additional factors upstream of PRNP presumably act by
altered expression of wild-type prion protein. Increased prion pro¬
tein expression has been known for many years to be a potent
susceptibility factor in transgenic mice (Bueler et at., 1993), and
we now report modestly increased expression of PRNP in blood
conferred by the risk haplotype. We assumed that the
rs1029273C-129M haplotype on the mutant chromosome was
shared between all patients because of common ancestry. This
conservative assumption was only partially supported by our
haplotype analysis, which was in fact most consistent with several
different mutational events. In this latter scenario, the observation
that all mutant alleles were also associated with the rs1029273C-
129M haplotype lends further support to the increased susceptibility
conferred by this haplotype.
Four-OPRIs are the smallest insertional mutations of PRNP that
are clearly pathogenic. Smaller (1-OPRI and 3-OPRI, but not
2-OPRI) insertions have been found incidentally and in healthy
control populations (Beck et at., 2010). Four- through 5- to
6-OPRI shows a dramatically earlier clinical onset. Insertional mu¬
tations larger than 5-OPRI show similar ages of clinical onset
(Mead et at., 2006). Thus, a correlation between insertion size
and clinical phenotype is clear over this short range, and not for
shorter or longer insertions. These clinical observations may form
the basis for an informed correlation between molecular properties
of mutant prion proteins and the consequences for the onset and
clinical phenotype of the human disease.
Epistasis was initially used by Bateson in 1909 to describe the
masking effect of an allele at one locus over a variant at another
locus. The term is now more broadly used to describe an inter¬
action between different loci, and has recently received a great
deal of interest in complex disease genetics. Epistasis has been
implicated in a number of human conditions, such as inflammatory
bowel disease (Cummings et al., 2007), colorectal cancer (Felix
et at., 2006) and among HLA class II alleles in human immune
responses (Lincoln et at., 2009). However, to our knowledge,
there are no examples of neurological diseases caused by a mu¬
tation associated with a common susceptibility haplotype. Our
4-OPRI inherited prion disease case series may thus provide a
useful precedent for understanding how a rare high-risk mutation
might typically manifest as an apparently sporadic neurodegenerative
disease.
The immunohistochemistry showed a distinct pattern from spor¬
adic CJD. There was very delicate staining of axons and dendrites,
rather than synaptic or uncommon plaque-forming deposits that
are seen in the sporadic form. The cerebellum in these patients
also showed prion protein deposits that seem to follow the den¬
drites of the Purkinje cells, in that they extend perpendicularly to
the surface, giving the cerebellum a 'tigroid' appearance. This ap¬
pearance is similar to previously reported cases with 4-OPRI, and
the pattern of cerebellar prion protein deposition is also seen in
cases with 5-OPRI (Mead et at., 2007) or 6-OPRI (Capellari et at.,
1997; King et at., 2003; Kovacs et at., 2007) but not that of
longer (8-OPRI) inserts, which show deposition of frequent amyl¬
oid plaques in the cerebellum and the forebrain (Laplanche etal.,
1999). In contrast to previous reports, we consistently observed
fine, thread-like intra-axonal prion protein deposits in Case VIII
and also in cases with 6-OPRI (Reiniger et at., 2010), most
likely due to a more sensitive detection method for abnormal
prion protein. Remarkably, there was frequent deposition of hyper-
phosphorylated tau in several cortical areas, even with a very subtle
involvement of the cerebellum as reported earlier (Reiniger et at.,
2010). Although this tau pathology may have arisen independent¬
ly from the prion disease, the role of the prion disease in triggering
hyperphosphorylation and a secondary tauopathy remains likely, in
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The demonstration that the PrP types seen in patients with
4-OPRI are apparently indistinguishable from those seen in pa¬
tients with sporadic CJD of the same codon 129 genotype appears
difficult to reconcile with the distinct pattern of prion protein
immunohistochemistry seen in 4-OPRI brain. However, in this
context, it is important to note that we probe PrPSc conformation
by looking at accessibility to scissile bonds cleaved by proteinase K
at the N-terminus of the protein. While the sensitivity of the
N-terminal third of PrP5c to cleavage by proteinase K does not
appear to be altered by a 4-OPRI mutation, this mutation may
confer distinct conformational preferences to the N-terminus,
which could influence the kinetics of replication or the clearance
of mutant PrPSc, thereby accounting for a distinct neuropatho-
logical phenotype. Methods other than protease digestion will
now be required to reveal conformational differences between
full-length PrPSc in patients with sporadic CJD and 4-OPRI.
In summary, we report evidence for a susceptibility haplotype
that may be an important determinant of penetrance in 4-OPRI
and possibly other similar inherited prion diseases. While the mo¬
lecular basis of the susceptibility allele is unknown, one possibility
is that increased risk is conferred by a combination of both hom¬
ology at codon 129 and higher levels of expression of PRNP. This
example may provide a valuable model for understanding other
sporadic neurodegenerative diseases.
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LETTER
Elevated phosphorylated tau
pT-181 in a possible PRNP codon
129 MV vCJD case
CASE REPORT
A 30-year-old man died of a progressive
neuropsychiatric illness of approximately
17 months'' duration with a clinical picture
strongly suggestive of variant Creutz-
feldt—Jakob disease (vCJD).1 His initial
symptoms, at the age of 28. were of
personality change with anxiety and irrita¬
bility. Lower abdominal and leg pain were
troublesome early symptoms. At about
12 months of illness, he developed tremor
and unsteadiness, leading to progressive
walking problems. Increasing social with¬
drawal and behavioural problems were
complicated by the development of
progressive memory and genera! cognitive
impairment. Visual hallucinations and
paranoid delusions occurred in the later
parts of his illness. During the course of his
illness, he developed the following neuro¬
logical signs: cognitive impairment, limb
and gait cerebellar ataxia, mild dysarthria
and mild pyramidal signs. Extensive neuro¬
logical investigations revealed no cause
other than prion disease, including consid¬
eration of a wide variety of inflammatory,
neoplastic, immunological and neurodegen¬
erative illnesses. The EEG showed diffuse
slow activity without periodic complexes.
The cerebral MR1 showed changes sugges¬
tive of vCJD but did not show the charac¬
teristic pulvinar sign.2 No tonsil biopsy or
neuropathological examination was
performed. Sequencing of the PRNP gene
showed no pathogenic mutation and
revealed the patient to be heterozygous
(methionine (M)/valine (V)) at codon 129
and heterozygous for the common synony¬
mous substitution at codon 117. The final
formal case classification of this patient was
of possible vCJD,° but the clinical opinion is
that this is very likely to have been the first
instance of vCJD in a PRNP codon 129 non-
MM individual.
Cerebrospinal fluid (CSF) analysis was
performed as part of the routine investiga¬
tions, no abnormalities were found in white
cell count, total protein or glucose concen¬
trations, and no bacteria were grown on
culture. In light of the normal white cell count
and lack of bacterial growth, the CSF sample
was considered to be sterile, and no further
investigations were carried out. CSF was sent
to the National CJD Surveillance Unit for the
analysis of 14-3-3 and other brain-specific
proteins. CSF 14-3-3 was detected using
western blotting with chemiluminescent
detection,45 while CSF S-100b,4 tau protein55
and tau protein phosphorylated at threonine
181 (pT-181) were measured using enzyme-
linked immunosorbent assays (ELISAs). The
results are shown in table 1.













Positive CSF 14-3-3 results and elevated
S-lOOb and tau protein concentrations have
been reported in both vCJD4 and sporadic
CJD (sCJD).5 Thus, these results are consis¬
tent with either diagnosis. However, pT-181
concentrations have been reported to be
raised only in vCJD and not in sCJD6; this
study did not investigate the influence of
PRNP codon 129 genotype on CSF pT-181
concentrations in sCJD. CSF pT-181
concentrations have been analysed by the
National CJD Surveillance Unit (NCJDSU)
in 64 neuropathologically proven and 43
clinically probable vCJD patients (57M:50F;
age at onset disease 30.3±9.9 years, range
14—63 years) and 108 neuropathologically
proven sCJD patients (58M:50F; age at onset
of disease 64.5±12.5 years, range
27—87 years). The PRNP codon 129 geno¬
type was available in 100 of the sCJD cases:
46 patients were MM, 37 were MV, and 17
were W. Ninety-two of the vCJD cases had
a PRNP codon 129 genotype analysis under¬
taken, and all were MM. The mean±SD CSF
pT-181 concentrations for vCJD and sCJD
were found to be 112.8±88.6 versus
49.3±28.4 pg/ml, p<0.0001 respectively.
The mean±SD CSF pT-181 concentration
for 65 disease control patients (38M:27F; age
at onset of disease 61.3±15 years, range
14—89 years) who were initially suspected of
having either vCJD or sCJD but who had
neuropathological evidence of an alternative
disease was found to be 40.9±31.0 pg/ml. Of
these patients, 31 had neurodegenerative
diseases such as Alzheimer's disease, Lewy
body dementia, frontotemporal dementia,
Parkinson's disease or Huntington's disease;
13 had malignant disease involving the
central nervous system such as paraneo¬
plastic syndrome or primary cerebral malig¬
nancies; six had cerebrovascular disease; six
had no neuropathological evidence of CJD,
but no alternative diagnosis could be made;
two had hypoxic brain injury, and there was
one case of each of the following: multiple
sclerosis, subacute panencephalitis, enceph¬
alitis, multifocal demyelination, vasculitis,,
progressive multifocal leucoencephalopathy
and normal pressure hydrocephalus. A refer¬
ence range for pT-181 of less than 120 pg/ml
was calculated using the mean+2.5xSD of
the pT-181 concentrations in these control
patients. Elevated CSF pT-181 levels were
found in 33 vCJD patients and in one patient
with sCJD. The sCJD patient was hetero¬
zygous (MV) at PRNP codon 129. Thus, the
CSF pT-181 concentration of 124 pg/ml
found in our patient is more in keeping with
a diagnosis of vCJD than of sCJD.
CSF brain-specific protein investigations
are not part of the formal diagnostic criteria
for vCJD, and while these results are not
conclusive, they support the diagnosis of
vCJD in this patient on the balance of
probability. Further investigations are under
way investigating the role phosphorylated
tau plays in the pathogenesis of vCJD and
whether phosphorylated tau can be
exploited to develop more specific diagnostic
CSF tests for vCJD.
AJE Green, MM Andrews, MT Bishop, JM
McKenzie, Y McCord, C Pennington, G Chohan,
RSG Knight
The National CJD Surveillance Unit, University of
Edinburgh, Western General Hospital, Edinburgh, UK
Correspondence to Dr Alison Green, The National CJD
Surveillance Unit, Western General Hospital, Crewe
Road, Edinburgh EH4 2XU, UK; Alison.Green@ed.ac.uk
Acknowledgements Surveillance of CJD is
dependent on the co-operation of neurologists and
neuropathologists throughout the UK. The authors are
particularly grateful to the relatives of the patients
for their co-operation and in particular to the relatives
of the patient reported in this case report for their
consent to publish.
Funding The CJD Surveillance Unit is funded by the
Department of Health and the Scottish Home Office
Department of Health.
Competing interests None.
Patient consent Obtained from the patient's family.
Ethics approval Ethics approval was provided by the
Multi-Centre Research Ethics Committee for Scotland
(REC reference number: 05/MRE00/67).
Provenance and peer review Not commissioned;
externally peer reviewed.
Received 1 June 2009
Revised 16 September 2009
Accepted 28 September 2009
J Neurol Neurosurg Psychiatry 2010; ■: 1.
doi:10.1136/jnnp.2009.183418
REFERENCES
1. Kashi D, Mead S, Hyare H, et al. Variant CJD in an
individual heterozygous for PRNP codon 129. Lancet
2009:374:2128.
2. Collie DA, Summers DM, Sellar RJ, ef al. Diagnosing
variant Creutzfeldt—Jakob disease with the pulvinar
sign: MR imaging findings in 86 neuropathologically
confirmed cases. Am J Neuroradiol 2003,24:1560—9.
3. http://www.cjd.ed.ac.Uk/criteria.htm#vCJD.
4. Green AJE, Thompson EJ. Stewart GE, et al.
The use of CSF 14-3-3 and other brain-specific
proteins in the diagnosis of variant Creutzfeldt—Jakob
disease. J Neurol Neurosurg Psych 2001.70 744—8.
5. Sanchez-Juan P, Green A, Ladogana A. et al. CSF
tests in the differential diagnosis of Creutzfeldt—Jakob
disease. Neurology 2006:67:637-43.
6. Goodall CA, Head MW, Everington D. et al. Raised
CSF phospho-tau concentrations in variant CJD:
diagnostic and pathological implications. J Neurol
Neurosurg Psych 2006:77:89—91.
Group Ltd under licence0/ 1
Downloaded from jnnp.bmj.com on September 23, 2010 - Published by group.bmj.com
The role of cerebrospinal fluid 14-3-3 and other
proteins in the diagnosis of sporadic
Creutzfeldt-Jakob disease in the UK: a 10-year
review
G Chohan, C Pennington, J M Mackenzie, et al.
J Neurol Neurosurg Psychiatry published online September 20, 2010
doi: 10.1136/jnnp.2009.197962
Updated information and services can be found at:
http://jnnp.bmj.com/content/early/2010/09/20/jnnp.2009.197962.full.html
These include:
References This article cites 16 articles, 8 of which can be accessed free at:
http://jnnp.bmj.eom/content/early/2010/09/20/jnnp.2009.197962.full.html#ref-list-1
P<P Published online September 20, 2010 in advance of the print journal.
Email alerting
service
Receive free email alerts when new articles cite this article. Sign up in the
box at the top right corner of the online article.
Notes
Advance online articles have been peer reviewed and accepted for publication but have not
yet appeared in the paper journal (edited, typeset versions may be posted when available
prior to final publication). Advance online articles are citable and establish publication
priority; they are indexed by PubMed from initial publication. Citations to Advance online
articles must include the digital object identifier (DOIs) and date of initial publication.
To order reprints of this article go to:
http://jnnp.bmj.com/cgi/reprintform
To subscribe to Journal ofNeurology, Neurosurgery & Psychiatry go to:
http://jnnp.bmj.com/subscriptions
Downloaded from jnnp.bmj.com on September 23, 2010 - Published by group.bmj.com
September 20, 2010 as 10.1136/jnnp.2009.
The role of cerebrospinal fluid 14-3-3 and other
proteins in the diagnosis of sporadic
Creutzfeldt—Jakob disease in the UK:
a 10-year review
G Chohan, C Pennington, J M Mackenzie, M Andrews, D Everington, R G
R S G Knight, A J E Green
The National CJD Surveillance








Crewe Road, Edinburgh EH4
2XU, UK;
alison.green@ed.ac.uk
Received 20 October 2009
Revised 21 April 2010
Accepted 31 May 2010
ABSTRACT
Background It is 10 years since the detection of
cerebrospinal fluid (CSF) 14-3-3 was included in the
diagnostic criteria for sporadic Creutzfeldt—Jakob
disease (sCJD) by the WHO. Since that time, other CSF
proteins, such as S100b and tau protein, have been
proposed as surrogate markers for sCJD. The authors
aimed to investigate the diagnostic value of each of
these three proteins.
Methods CSF samples collected from patients who
were referred to the National CJD Surveillance Unit as
suspected cases of sCJD during the period 1997—2007
were analysed for 14-3-3, S100b and tau protein. The
sensitivity, specificity, positive predictive value and
negative predictive value of each of these markers, either
alone or in combination for the diagnosis of sCJD, were
assessed. The impact of CSF 14-3-3 analysis on the case
classification of sCJD was investigated.
Results and discussion CSF 14-3-3 had the greatest
sensitivity (86%) when compared with tau protein (81%)
and S100b (65%). The combination of a positive CSF
14-3-3 or an elevated tau protein with a raised S100b had
the highest positive predictive power for sCJD. During the
study period, 100 patients were classified as probable
sCJD solely on the basis of the clinical features and
a positive CSF 14-3-3. The most sensitive marker for sCJD
was a positive CSF 14-3-3. The analysis of CSF 14-3-3
plays a crucial role in the case classification of sCJD.
INTRODUCTION
Creutzfeldt—Jakob disease belongs to a family of
fatal neurodegenerative diseases collectively known
as human transmissible spongiform encephalopa¬
thies. Sporadic CJD (sCJD) remains the most prev¬
alent form worldwide, with an annual incidence of
1.0—1.5/million/year.1 Human spongiform enceph¬
alopathies are characterised by the accumulation of
pathological prion protein (PrP) in the central
nervous tissue. The pathological isoform is termed
PrP
, and this differs from the normal cellular
isoform by its high content of fl-sheet structure and
partial resistance to protease digestion." Additional
histological changes identified include spongiosis,
neuronal loss and gliosis. Neuropathological studies
remain the only means of obtaining a definitive
diagnosis; the initial diagnosis however is still
dependent on the clinical phenotype, as defined by
the WHO criteria.3 Marked phenotypic heteroge¬
neity is well documented in all human prion
diseases, and in sCJD this observation is yet to be
explained. Early experimental transmission studies
on primates,4 subsequent epidemiological studies5 6
and isolated case reports have allowed diagnostic
criteria to be refined over the years; however early
diagnosis and in turn accurate surveillance remains
a challenge. Atypical forms of sCJD are well recog¬
nised, it has been postulated that such variation is
partially dependent on, or associated with, genetic
and molecular factors, PRNP codon 129 genotype
and PrP isotype respectively. The typical short
duration disease phenotype is linked to methionine
homozygosity and PrPSc type 1. The atypical and
rarer variants (those defined as having a long dura¬
tion of illness, young age of onset and unusual
clinical or pathological features) are linked to valine
homozygosity or heterozygosity at codon 129 and
PrPSc type 2.
The advent of novel diagnostic tests, specifically
the cerebrospinal fluid (CSF) 14-3-3 protein, has
also allowed improvements in classification over
the last decade. The 14-3-3 has a better diagnostic
utility than investigative tests such as the EEG.7 8
However, the sensitivity of CSF 14-3-3 has been
shown to vary, partially dependent on the genetic
and molecular influences described above.9 The
detection of CSF 14-3-3 remains a supportive tool
in the appropriate clinical context but as a solitary
test, independent of clinical phenotype, has little
value.
The major differential diagnoses of sCJD remain
those of other irreversible neurodegenerative
conditions; however a small proportion of patients
may have a potentially treatable condition. There¬
fore, CSF analyses, such as cell count and total
protein, are an important early investigation in
these patients, and CSF 14-3-3 is often performed
at this time. Many conditions associated with
acute neuronal damage may result in a positive CSF
14-3-3 and thereby reduce the specificity of CSF
14-3-3 for sCJD.8 Therefore, other brain-specific
proteins in the CSF may be of value as diagnostic
markers. These additional markers include the CSF
astrocytic marker SlOOb and the neuronal marker
tau, protein in isolation or in combination.
In this study, we aim to first review the sensi¬
tivity and specificity of each CSF protein in sCJD
and also review the potential role of a combination
of several markers to improve sensitivity and
specificity in the clinical diagnosis of sCJD. Second,
the impact of the CSF 14-3-3 on UK surveillance is
iM?1MfrWfeYf ^WSblishing Group Ltd under licence7 6
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of great importance and is therefore considered, specifically
reviewing the number of cases of probable sCJD classified on the
basis of CSF 14-3-3. In addition, those cases classified as a prob¬
able case of sCJD on the basis of a positive 14-3-3, but found to
have an alternative pathological diagnosis, are investigated. The
additional role of combining neuronal markers in order to
potentially exclude sCJD is reviewed.
MATERIALS AND METHODS
Patients
The National CJD Surveillance Unit (NCJDSU) was estab¬
lished in May 1990 to prospectively identify and record all
suspected cases of sCJD in the UK. The primary aim of the
programme was to detect any change in the epidemiology of
the disease that might be attributable to bovine spongiform
encephalopathy, and a distinct clinical—pathological pheno-
type was described in 1996 (variant CJD). Global surveillance
of CJD has continued within the UK, and active surveillance
has improved due to strong collaborations with the neurosci-
ence community. Patients are referred and, where possible,
visited. A detailed history of the current illness and past
medical history, including potential risk exposure, is under¬
taken. Each case is further investigated by clinical examination
and review of clinical investigations. Investigative tests which
are potentially supportive for a diagnosis of sCJD such as an
EEG and MRI are reviewed by a member of the NCJDSU. The
NCJDSU acts as a referral centre for CSF 14-3-3 analysis
throughout the UK.
During the period 1997 and 2007 inclusive, 245 cases of
neuropathologically confirmed sCJD10 (117 female, 128 male
aged 27—87 years (mean 65.8±9.7 years) at notification), 163
cases of clinically probable sCJD3 (82 female, 81 male aged
41—92 years (mean 68.0±9.8 years) at notification) and 171
disease control cases (86 females, 85 males aged 28—89 years
(mean 66.4 ±11.4 years) at notification) who had CSF 14-3-3
analysis were identified for this study. Cases classified as not
suffering from CJD (disease control cases) included those with
a pathologically proven alternative diagnosis or those provided
with an alternative clinical diagnosis by either the clinical team
or by a member of the NCJDSU (table 1).
CSF protein analysis
CSF samples are sent to the laboratory on dry ice and stored at
—80°C prior to analysis. For this study, CSF 14-3-3, SlOOb and
tau protein were analysed. Protein 14-3-3 in CSF was detected
by western blotting after SDS-polyacrylamide gel electropho¬
resis (SDS-PAGE) with chemiluminescent visualisation.11-13 A
positive, negative and two weak positive 14-3-3 controls were
included on each run. These were controls from patients with
neuropathologically confirmed sCJD (positive control) or from
patients with either a clinical or pathological diagnosis of an
alternative disease (negative and weak positive controls). The
relative immunoreactivity of positive, negative and weak posi¬
tive 14-3-3 CSF samples is given in figure 1. The blots were
independently assessed by two people (AJEG, MA, GC or CP),
and only positive CSF 14-3-3 results were used for case classifi¬
cation. CSF SlOOb was measured using a previously reported
sandwich enzyme-linked immunosorbant assay.11 A concentra¬
tion of <0.5 ng/ml was considered to be normal, while
a concentration of >1.0 ng/ml was considered to be diagnostic.
CSF tau protein was measured using an enzyme immunoassay
(Innotest hTAU-Ag, Innogenetics, Ghent. Belgium), according to
the manufacturer's recommendations. A concentration of
>1260 pg/m! was considered to be diagnostic.14 This assay
Table 1 Disease control cases (pathologically proven alternative
diagnosis or alternative clinical diagnosis)
Alternative pathological proven diagnosis No of cases
Alzheimer's disease 14
Biopsy/post-mortem showed no evidence of CJD 12*
Malignancy/paraneoplastic syndrome iot





Alzheimer's disease and ischaemic change 3
Alzheimer's disease and Lewy body dementia 3
Progressive multifocal leucoencephalopathy 1
Normal pressure hydrocephalus 1
f"ronto-temporal dementia 1
Corticostriatal degenerative disease 1
Demyelination 1
Alternative clinical diagnosis No of cases
Dementia (unknown aetiology) or clinically not CJD 22
Clinically improved with or without steroids 22
Alzheimer's disease 18
Cerebrovascular disease/cerebral vasculitus 9
Fronto-temporal dementia 7








Central pontine myelinolysis 1
Serotonin syndrome 1
*0ne patient clinically not thought to have had Creutzfeldt—Jakob disease (CJD) and post¬
mortem conducted but brain tissue not examined.
t One patient had a western blot for PrPSc which was negative; clinically this patient is
thought to have a paraneoplastic process.
measures total tau protein concentrations and as such measures
both normally phosphorylated tau protein and hyper-phos-
phorylated tau protein. Some CSF samples had insufficient
volume for all three analytes to be measured.
123456789
Figure 1 Western blotting illustrating the presence of positive, weak
positive and negative cerebrospinal fluid (CSF) 14-3-3. Lanes 1, 2 and 3
are positive for CSF 14-3-3; lanes 4, 5 and 6 are weakly positive for CSF
14-3-3; and lanes 7, 8 and 9 are negative for CSF 14-3-3. Lanes 1 and 2
are from two patients with sporadic Creutzfeldt—Jakob disease (sCJD),
lanes 3 and 4 are from patients who have had a stroke, and the remaining
lanes contain CSF samples from patients who do not have CJD.
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PRNP codon 129 genotype and PrP isotyping
PrP isotyping was performed on all suspected cases of prion
disease where fresh brain tissue was received by the NCJDSU.
Small quantities of cerebral cortex were homogenised and
treated with proteases, and the size and abundance of the three
PrPSl' glycoforms was determined by western blot analysis.15
Genotyping for polymorphism at codon 129 of the PRNP gene
was carried out on all available blood specimens. DNA was
extracted from blood using standard techniques and analysed
using the Helsinki method.16
Statistical analysis
A comparison of age by Mann—Whitney tests was carried out.
Descriptive statistics were calculated for the sCJD and control
patients. The sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV) and efficiency of each
marker and for combinations of markers were obtained. To
investigate the influence of the stage of disease on the sensitivity
of CSF 14-3-3 and tau protein, we divided the disease duration
for each patient into equal thirds. The stage in which the lumbar
puncture (LP) was performed was noted, and the sensitivity of
each marker for sCJD in each of the three stages was calculated.
RESULTS
The sensitivity, specificity, PPV, NPV and efficiency of each
neuronal marker for the diagnosis of neuropathologically
confirmed sCJD cases are shown in table 2. CSF 14-3-3 is the
most sensitive marker and has a higher sensitivity than CSF tau
protein, 86% and 81% respectively. CSF SI00b does not have
adequate sensitivity (65%) to be used as an isolated marker of
sCJD. The difference in sensitivity between CSF 14-3-3 and tau
protein is not influenced by the different numbers of cases
investigated for each analyte. The sensitivity of CSF 14-3-3 and r
protein calculated using those samples where both analytes were
measured is 85% and 81% respectively. The specificity of CSF
14-3-3 and tau protein in those samples where both analytes
were measured is 74% and 85% respectively.
The combination of a positive CSF 14-3-3 with either an
elevated SlOOb or an elevated tau protein increased the PPV of
14-3-3 from 83% to 94% or 91%, respectively (table 2. figure 2A, B).
Likewise the combination of an elevated tau protein and an
elevated SlOOb resulted in a higher PPV (95%) for sCJD when
compared with using each marker alone (table 2, figure 2C).
However, combining the tests either in pairs or taking all three
markers together resulted in a reduction in sensitivity and
a reduction in the efficiency of each marker. That is to say, the
ability of each marker to distinguish between those patients
with sCJD and those that present with symptoms similar to
sCJD but turn out to have an alternative diagnosis is reduced if
they are combined (table 2).
In the atypical subgroups, although the numbers are small,
CSF 14-3-3 is more sensitive than an elevated tau protein (table 3).
This finding is particularly noticeable in those patients who are
50 years old or younger at the onset of the disease. However, in
those sCJD cases that were negative for either CSF 14-3-3 or tau
protein, there did not seem to be any difference in the demo¬
graphics of the patients or any obvious effect of codon 129 and
PrPSc isotype. In the 14-3-3 negative group, there were 35 sCJD
cases (27—81 years (mean 62.0±10.9 years) at notification), and
in the tau protein negative group there were 41 sCJD cases
(44—81 years (mean 63.3±9.9 years) at notification). The disease
duration was also comparable: 2-54 months (mean 15.1 ±11.7
months) and 2—54 months (mean 14.4±12.2 months) respec¬
tively. These disease durations are much longer than those in
sCJD cases who are positive for CSF 14-3-3 (mean 6.6±6.8
months) or CSF t; protein (mean 6.5±6.6 months).
The effect of stage of disease on the sensitivity of CSF 14-3-3
and tau protein is shown in table 4. The time of the LP and the
date of the onset of disease were only available in 209 patients.
Only 7% of patients had an LP within the first stage of disease,
while 42% and 51% of patients had CSF samples taken in the
second and third stages of disease respectively. Both CSF 14-3-3
and tau protein show comparable sensitivity in the first two
stages of disease, but in the final stage of the disease CSF 14-3-3
is more sensitive than CSF tau protein.
During the study period, 21 patients had a weak positive CSF
14-3-3. Of the 21 patients with weak positive CSF 14-3-3 results,
nine patients had neuropathologically confirmed sCJD, while
the remaining 12 patients had Alzheimer's' disease (three), Lewy
body disease (two), no neuropathological evidence of CJD (two),
frontal lobe degeneration (one), epilepsy (one), multifocal
leucoencephalopathy (one) and angiotrophic lymphoma (one),
and no further information could be obtained on the final
diagnosis in the remaining patient.
The most specific individual marker was CSF SlOOb, but it
also had the poorest sensitivity which limits its use as an
isolated marker. CSF tau protein had a greater specificity than
CSF 14-3-3 protein (85% vs 74%). Analysis of the control cases
that had a positive CSF 14-3-3 and/or an elevated CSF tau
protein showed that the most prevalent diagnoses included
Alzheimer's disease, paraneoplastic syndrome and patients who
clinically improved without an alternative diagnosis (table 5).
Out of a total of 242 cases of sCJD which had both CSF 14-3-3
and SlOOb measured, only 10 had a negative 14-3-3 and a normal
SlOOb concentration of <0.5ng/ml. Likewise, out of 216 sCJD
cases that had both CSF tau protein and SlOOb measured, only
14 had concentrations of both markers within the normal range
(figure 3A, B).
The impact of CSF 14-3-3 on UK surveillance over the last
decade was assessed by examining the number of clinically
Table 2 Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and efficiency for each marker and combination of
cerebrospinal fluid markers in neuropathologically confirmed sporadic Creutzfeldt—Jakob disease (sCJD)
14-3-3 Tau S100b 14-3-3 and SlOOb Tau and SlOOb 14-3-3 and tau 14-3-3, tau and S100b
sCJD* 210/245 175/216 158/243 151/242 127/216 162/216 123/216
Not sCJD" 44/171 20/135 17/169 9/169 7/135 16/135 6/135
Sensitivity (%) 86 (81 to 90) 81 (75 to 86) 65 (59 to 71) 62 (57 to 69) 59 (52 to 65) 75 (69 to 81) 57 (50 to 64)
Specificity (%) 74 (67 to 81) 84 (78 to 91) 90 (84 to 94) 95 (90 to 98) 95 (90 to 98) 88 (81 to 93) 96 (91 to 98)
PPV (%) 83 (77 to 87) 90 (85 to 941 90 (85 to 94) 94 (90 to 97) 95 (90 to 98) 91 (86 to 95) 95 (90 to 98)
NPV (%) 78 (71 to 84) 74 (66 to 80) 64 (58 to 70) 64 (58 to 70) 59 (52 to 66) 69 (61 to 76) 58 (51 to 65)
Efficiency (%) 81 (77 to 85) 83 (78 to 86) 75 (71 to 79) 76 (72 to 80) 73 (68 to 77| 80 (75 to 84) 72 (67 to 76)
Figures in parentheses are 95% confidence limits.
*The figures given are the number of positive or negative results divided by the total number of samples investigated. Efficiency was defined as the number of positive and true negative results
divided by the total number of samples investigated.
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Figure 2 (A) Role of a positive 14-3-3
and a diagnostic SI00b in the diagnosis
of sporadic Creutzfeldt-Jakob disease
(sCJD). Positive 14-3-3: positive
predictive value (PPV)=83%. Positive
14-3-3 and S-1000b>1.0 ng/ml=94.
(B) Role of a positive 14-3-3 and an
elevated x protein in the diagnosis of
sCJD. Positive 14-3-3: PPV=83%.
Positive 14-3-3 and tau
protein>1260 pg/ml: PPV=91%.
(C) Role of a positive tau protein and an
elevated SI00b in the diagnosis of sCJD.
Positive tau protein: PPV=90%. Positive
tau protein and positive S-100b:
PPV=95%.
Positive 14-3-3: PPV = 83%
Positive 14-3-3 and S-100b >1 .Ong/ml: PPV = 94%
Positive 14-3-3: PPV = 83%
Positive 14-3-3 and tau protein >1260pg/ml: PPV = 91%
Positive tau protein: PPV = 90%
Positive tau protein and positive S-100b: PPV = 95%
probable cases classified as a result of a positive CSF alone. One
hundred and sixty-three probable cases that died without post¬
mortem examination were identified. No information regarding
whether an EEG had been performed was available in 25 cases.
Of the remaining 138 cases, three had no EEG performed, and
135 had an EEG reviewed by a senior member of the NCJDSU.
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Table 3 Effect of age at onset of disease, disease duration and PRNP
codon 129 genotype on the sensitivity of CSF 14-3-3 and tau protein
14-3-3 (%) Tau protein (%)
Table 5 Diagnoses in disease controls with positive cerebrospinal fluid
14-3-3 and elevated tau protein cases
<50 years at onset disease
£50 years at onset disease
>12 months' disease duration




12/17 (71%) (44 to 90)
198/228 (87%) (82 to 91)
23/41 (56%) (40 to 72)
184/199 (92%) (88 to 96)
106/121 (88%) (80 to 93)
32/44 (73%) (57 to 85)
27/29 (93%) (77 to 99)
10/16 (62%) (35 to 84)
165/200 (83%) (77 to 87)
21/39 (54%) (37 to 70)
151/175 (86%) (80 to 91)
92/108 (85%) (77 to 91)
26/39 (67%) (50 to 81)
24/27 (89%) (71 to 98)
Results are expressed as number of positives divided by total number investigated. Figures
in parentheses are the sensitivity of the individual marker in each subset of sCJO. The 95%
confidence limits are given in parentheses after the percentages.
Of these 135 patients, 38 had an EEC classified as highly
suggestive or typical and hence appropriate for use in classifica¬
tion. The remaining 97 were classified as probable with the aid
of a positive CSF 14-3-3 (72%). Therefore, over the study period,
at least 100 patients were classified as having probable sCJD
on the basis of CSF 14-3-3 alone. Sixty-nine patients initially
classified as probable sCJD on the basis of a positive 14-3-3
alone, with either an unsupportive or unobtainable EEC,
had subsequent post-mortem examination. Neuropathological
confirmation of sCJD was obtained in 66 of these cases. The
remaining three cases were misclassified as probable sCJD but
in fact had pathological confirmation of carcinomatosis of
the meninges (14-3-3 positive, SI00b 0.57 ng/ml, tau protein
3201 pg/ml) and Lewy body dementia (14-3-3 positive, SlOOb
0.57 ng/ml, tau protein 1170 pg/ml) and Alzheimer's disease
(14-3-3 positive, SlOOb 0.94 ng/ml, tau protein 1294 pg/ml).
This gives a misclassification rate of 4%.
DISCUSSION
It is 10 years since a positive CSF 14-3-3 was added to theWHO
diagnostic criteria for classifying probable sCJD. Since that time,
many studies have reported a poorer sensitivity and specificity of
CSF 14-3-3 than initially described, and have suggested that
other markers of neuronal damage such as tau protein perform
better. We have examined the diagnostic utility of CSF 14-3-3,
tau protein and SlOOb analysis in the investigation of patients
with suspected sCJD over a 10-year period. In addition, we have
examined the overall impact that the inclusion of a positive CSF
14-3-3 has made on the diagnosis sCJD since it was introduced
in 1997.
The sensitivity of a positive 14-3-3 in our study of sCJD is
86%, which is higher than that of tau protein (81%). The
difference in sensitivity is more marked in the atypical forms of
sCJD such as those who are younger than 50 years old at the
onset of disease. In these cases, the sensitivity of CSF 14-3-3 is
71% compared with 62% for CSF tau protein. This supports the
Table 4 Influence of time of cerebrospinal fluid sampling on
cerebrospinal fluid 14-3-3 and t protein positive results
Stage of disease 14-3-3 (%) Tau protein (%)
First stage (0-33% disease 9/14 (64%) (35 to 87) 10/14 (71%) (42 to 92)
duration)
Second stage (34-66% disease 73/88 (83%) (73 to 90) 72/88 (82%) (72 to 89)
duration)
Third stage (67-100% of disease 97/107 (91%) (83 to 95) 89/107 (83%) (75 to 90)
duration)
The time of the LP was calculated by expressing the time of LP from disease onset as
a percentage of the total disease duration. The patients were classified into three groups
depending on whether they had cerebrospinal fluid samples taken in the first, second or
third stage of the disease. Results are expressed as the number of positives over total
number investigated. The 95% confidence limits are given in parentheses after the
percentages.
Diagnosis (14-3-3 positive) Pathological (26) Clinical (18)
Alzheimer's disease 7* 2
Malignancy/paraneoplastic 5 1
Improved/no evidence of Creutzfeldt-Jakob 3t 7
disease
Encephalitis/limbic encephalitis 3 2
Lewy body dementia 1 0
Parkinson's disease 1 0
Cerebrovascular disease 0 2*
B cell lymphoma/cerebral lymphoma 3 0
Fronto-temporal dementia 0 1
Vasculitis 0 1
Central pontine myelinoiysis 0 1
Multifocal demyelination 1 0
Anoxic brain injury 1 0
Normal pressure hydrocephalus 1 0
Corticobasal degeneration 0 1
Diagnosis (t protein >1260 pg/ml) Pathological (12) Clinical (6)
Alzheimer's disease 3 1
Malignancy/paraneoplastic 3 0








Lewy body disease 1
Anoxic brain damage 1
•Three had evidence of additional cerebrovascular disease, and two also had evidence of
Lewy body dementia.
TOne did not have their brain examined.
T One had evidence of Alzheimer's disease.
findings of a larger European-wide study that found that
a positive CSF 14-3-3 was more sensitive than CSF tau protein in
atypical sCJD cases.9 CSF 14-3-3 is also more sensitive than CSF
tau protein in the final stage of disease. This is important as this
is the time at which the majority of CSF samples are taken.
A CSF SlOOb concentration of greater than 1.0 ng/ml increases
the PPV of a positive CSF 14-3-3 from 83% to 94%, and an
elevated CSF tau protein from 90% to 95%. CSF SlOOb is
routinely analysed by the NCJDSU for this reason. CSF SlOOb is
also useful in excluding disease, with a negative CSF 14-3-3 and
CSF SlOOb concentration of less than 0.5 ng/ml having a NPV of
88%. Normal concentrations of CSF tau protein and CSF SlOOb
concentration of less than 0.5 ng/ml have an NPV of 84%.
There are no differences in the age of onset of disease, disease
duration or codon 129 status of sCJD patients who are negative
for CSF 14-3-3 and those that are negative for CSF tau protein.
Therefore, it is unlikely that the additional measurement of CSF
tau protein will help improve the identification of CSF 14-3-3
negative sCJD cases.
Less than half the patients with weak positive CSF 14-3-3
results have sCJD, and this suggests that the diagnostic utility of
weak positive 14-3-3 results is limited. However, a repeat CSF
14-3-3 analysis in this group of patients may be of value if the
clinical circumstances warrant it.9
Elevated CSF tau protein has a better specificity for sCjD than
CSF 14-3-3 (84% vs 74%). This is a similar finding to a recently
published study where tau protein was felt to be the single best
marker for sCJD with a specificity of 90%.17 It is, however,
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Negative 14-3-3: NPV = 78%
Negative 14-3-3 and normal S100b: NPV = 88%




■ Not CJD (73)
. CJD (27)
' Not CJD (42)
Negative tou protein: NPV = 74%
Negative tau protein and normal S100b: NPV = 84%
Figure 3 (A) Role of a negative 14-3-3 and normal S100b in the
diagnosis of sporadic Creutzfeldt—Jakob disease (CJD). (B) Role of
a negative tau protein and a normal SI00b in excluding sporadic CJD.
NPV, negative predictive value.
important to note that the diagnostic test accuracy and the
differences reported by these various studies are partially
dependent on the cut-off concentration of tau protein used. A
universally agreed level for tau protein is not currently available.
The diagnoses in the non-CJD cases were similar for both tests.
It is unclear why CSF tau protein should be of greater specificity
than 14-3-3. The factors influencing the release of neuronal
proteins in CJD and other conditions are not fully understood.
Many studies have investigated the sensitivity of these two
markers for the diagnosis of sCJD, but very few have compared
their specificity. Indeed, specificity is highly dependent on the
population investigated, and therefore it is very difficult to
compare individual studies. However, the population investi¬
gated in this study is highly selected and consists of patients for
whom the preceding pretest probability of sCJD is high.
Box 1 Conclusions regarding the use of cerebrospinal fluid
14-3-3 and other markers in the diagnosis of sporadic
Creutzfeldt Jakob disease (sCJO)
Cerebrospinal fluid (CSF) 14-3-3 as a sole marker has the
highest sensitivity, particularly in the final stage of disease. As
a sole marker CSF tau protein has the greatest specificity.
A combination of CSF 14-3-3 and elevated SI00b or elevated
tau protein and SI00b has a greater positive predictive value
than CSF 14-3-3 alone
The combination of CSF 14-3-3 and tau protein in CSF 14-3-3
negative sCJD cases has not been shown to be of any
additional value, even in phenotypically atypical cases
The combination of a negative CSF 14-3-3 and S100b is of
value as a potential means of excluding sCJD
The differential diagnosis of sCJD in the 14-3-3 positive non-
CJD cases remains, as documented in previous studies
During the 10 years since its introduction, CSF 14-3-3 analysis
has enabled 100 patients in the UK with suspected sCJD who
died without a post-mortem and without supportive EEC data
to be classified as probable sCJD. During this time, only three
patients have been mis-classified as probable sCJD on the basis
of a positive CSF 14-3-3.
We conclude that within the UK population referred with
a clinical suspicion of sCJD to the NCJDSU over the last decade,
brain-derived proteins such as 14-3-3, SI00b and tau protein
have immense diagnostic value (see box 1). In our experience,
the combination of 14-3-3 and SlOOb remains the best predictor
of supporting or excluding sCJD as a diagnosis when employed
in an alogarithmic manner using 14-3-3 detection as the primary
screening marker before utilising the SlOOb results. The impor¬
tance of interpreting these results in the appropriate clinical
context, however, is vital, especially as the phenulypic hetero¬
geneity of sCJD remains wide.
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ARTICLE INFO ABSTRACT
The utility of cerebrospinal fluid (CSF) proteins such as 14-3-3, tau protein and S-lOOb as diagnostic
markers in the early stages of sporadic Creutzfeldt-Jakob disease (sCJD) is unclear. We examined the
diagnostic value of these CSF proteins in the early stages of sCJD (within 6 weeks of onset of symptoms).
Four groups of patients were compared: patients with probable or neuropathologically confirmed sCJD
with CSF taken within 6 weeks of onset ('sCJD< 6-week group', n = 47); patients with CSF taken within 6
weeks of disease onset but with a diagnosis other than CJD ('non-sCJD<6-week group', n = 21); patients
with neuropathologically proven sCJD where CSF was taken later than 6 weeks after onset ('sCJD>6-
week group', n = 206); patients with CSF taken later than 6 weeks after onset of symptoms but with a
diagnosis other than CJD ('non-sCJD> 6-week group', n = 166). The sensitivity and specificity of different
combinations of neuronal proteins were ascertained. The sensitivities of all three markers were similar
and ranged from 96% to 98%. The sensitivity of these markers was greater in the 'sCJD< 6-week group'
than in the 'sCJD> 6-week group'. This may be due to differences in the PRNPcodon 129 and PrP isotype
distribution between these groups. CSF tau protein had the greatest specificity (82%). We found all three
CSF protein markers to be highly sensitive in the early stages of sCJD, with CSF tau protein having the
greatest specificity and efficiency. Our findings indicate that CSF protein markers are effective tests in the
early stages of sCJD.
© 2009 Elsevier Ireland Ltd. All rights reserved.
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Sporadic Creutzfeldt-Jakob disease (sCJD) belongs to the family of
transmissible spongiform encephalopathies, or prion diseases. It
is a fatal neurodegenerative disease which is characterized by a
rapidly progressive dementia, cerebellar ataxia and myoclonus. This
progresses to akinetic mutism in the later stages [12]. Definitive
diagnosis depends on neuropathological examination of brain tis¬
sue taken either at autopsy or by brain biopsy. Diagnostic criteria
have been developed which allow for the classification of patients
as probable cases during life. These criteria require the presence
of typical clinical features and supportive investigations such as
EEG or the presence of the protein 14-3-3 in the cerebrospinal fluid
(CSF) [ 10]. The diagnosis of sCJD in the early stages can be difficult.
While CSF 14-3-3 has proved to be a useful diagnostic test for sCJD
since its inclusion into the WHO diagnostic criteria for probable
sCJD [3,5,10,13), there have been a number of reports suggesting
that CSF 14-3-3 may not be detectable in the early stages of dis¬
ease [6-8]. A recent study reported that CSF tau protein was more
sensitive than CSF 14-3-3 in early stages of sCJD [8], In this study
* Corresponding author. Tel.: +44 131 537 2125; fax: +44 131 343 1404.
E-mail address: catherine.pennington@ed.ac.uk (C. Pennington).
0304-3940/$ - see front matter © 2009 Elsevier Ireland Ltd. All rights reserved,
doi: 10.1016/j.neulet.2009.02.067
we compared the diagnostic value of CSF 14-3-3, tau protein and
S-IOOb in the early stages of sCJD
'Early stage' sCJD was defined as the period within 6 weeks
of symptom onset. This time point was chosen to enable a direct
comparison with a previously reported study [8]. The NCJDSU
database was reviewed and those patients for whom CSF sam¬
ples were taken within 6 weeks (42 days) of disease onset were
identified. Of these patients, 35 had neuropathologically confirmed
sCJD and 12 had probable sCJD based on clinical features and a
characteristic EEG pattern [11). One patient had had two CSF sam¬
ples sent within 6 weeks of disease onset; for the purposes of
this study the first sample was used. This group of patients was
designated the 'sCJD< 6-week group". The male: female ratio was
25:22; the median age at disease onset was 67 years (interquar¬
tile range 61-75 years); the median total disease duration was
56 days (interquartile range 47-76. The median time from disease
onset to lumbar puncture was 33 days (interquartile range 25-38
days).
Those patients who had a CSF sample taken within 6 weeks of
symptom onset, who had a final diagnosis other than CJD were des¬
ignated as the 'non-sCJD< 6-week group'. The male: female ratio
was 10:11; the median age at disease onset was 70 years (interquar-
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Table 1
The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and efficiency for each marker and combination ofCSF markers in the 'sCJD < 6-week
group'. Efficiency was defined as: true positives + true negatives/total no. tested.
CSFmarker 14-3-3 Tau S-lOOb 14-3-3 ancl Tau 14-3-3 and S-lOOb Tau and S-lOOb All three markers
sCJD < 6-week group N = 47 N-45 N« 46 N-45 N = 46 N~ 45 N-45
Non-sCJD < 6-week group N« 21 N-17 N-21 N-17 N~ 21 N- 17 17
Sensitivity (%) (95% Ci) 96(85, 99) 98(88.99.9) 98 (88, 99.9) 93(82,99) 93 (82.99) 95 (85. 99) 91 (79. 98)
Specificity (%) (95% CI) 67(43,85) 82 (56, 96) 29(11,52) 82 (57, 96) 76(53,92) 82 (57,96) 82 (57, 96)
PPV (%) (95% CI) 87 (74. 94) 93(82,99) 75(62,85) 93(82,99) 90 (77, 97) 96(85,99) 93(81,99)
NPV (%) (95% CI) 88(62, 98) 93 (68,99.9) 86(42,99.7) 82 (57. 96) 84(60. 97) 82 (57,96) 82(52,94)
Efficiency (%) 72 94 76 90 88 92 89
tile range 59-77 years). The median time from disease onset to
lumbar puncture was 20 clays (interquartile range 16-30 days).
Overall, 11 patients had neuropathological evidence of a diagno¬
sis other than CJD and these diagnoses were: Lewy Body disease
(LBD) (2); Parkinson's disease (2); Alzheimer's disease (AD) (1);
AD and cerebral arteriosclerosis (1); chronic limbic encephalitis
(1); anaplastic astrocytoma WHO grade 3(1): paraneoplastic syn¬
drome (1): viral or post-viral encephalopathy (1); inflammatory
changes on brain biopsy with no evidence of CJD (1). The remain¬
ing 10 patients had only clinical evidence of a diagnosis other than
CJD and these diagnoses were: encephalopathy of unknown origin
with spontaneous improvement (3); AD (1); LBD or AD (1); steroid
responsive encephalopathy (1); psychiatric disorder/or epilepsy
(1); mesothelioma and paraneoplastic syndrome (1); corticobasal
degeneration (1); central pontine myelinolysis(l).
A group of 206 patients with neuropathologically proven sCJD
where CSF was taken outwith 6 weeks of symptom onset was
identified and designated as the 'sCJD> 6-week group'. This group
was included in order to determine whether those patients who
underwent CSF analysis within 6 weeks of symptom onset could
be taken to be representative of the wider population of patients
with sCJD. The maletfemale ratio was 107:99; the median age at
disease onset was 66 years (interquartile range 60-72 years); the
median total disease duration was 179 days (interquartile range
107-288 days) (one patient left the UK after diagnosis and so
disease duration was unknown). The median time from disease
onset to lumbar puncture was 128 days (interquartile range 69-208
days).
A group of 166 patients had a CSF sample taken outwith 6 weeks
of symptom onset who had a final diagnosis other than CJD were
designated as the 'non-sCJD >6-week group'. The male: female ratio
was 86:80; the median age at disease onset was 66 years (interquar¬
tile range 58-75 years). The median time from disease onset to
lumbar puncture was 161 days (interquartile range 75-339 days).
Neuropathological examination was performed in 63 cases and
in 11 of these no neuropathological evidence of CJD was found
but no alternative diagnosis could be made. In the remaining 52
patients the diagnoses were: AD (18); LBD (8); intracerebral malig¬
nancy (7); paraneoplastic syndrome (6); cerebrovascular disease
(4); hypoxic brain injury (2) and one each of the following cortico-
strial-nigral degeneration, neuroaxonal dystrophy, normal pressure
hydrocephalus, multi-focal demyelination. vasculitis, frontotempo-
ral dementia and progressive multi-focal lecoencephalopathy. The
diagnosis of CJD was excluded in the remaining 103 patients for
reasons that included complete or partial recovery (33) or an alter¬
native diagnosis was made on clinical grounds or investigations
were suggestive of an alternative disorder. The diagnoses in this
group were: AD (17); frontotemporal dementia (7); cerebrovascular
disease (7); dementia of unknown origin (7); LBD (6); paraneoplas¬
tic syndrome (4); psychiatric disorder (3); Huntington's disease (3);
encephalitis (3); intracerebral malignancy (3); vasculitis (2); drug
toxicity (2) and one each of the following motor neurone disease;
cerebellar syndrome; multi-system atrophy, corticobasal degener¬
ation, tuberculosis and spinocerebellar ataxia.
Samples were initially frozen and transported to the NCJDSU
on dry-ice. Samples which were insufficient for analysis, had been
improperly stored or were bloodstained were not analysed. The 14-
3-3 immunoassay was carried out as previously described [3]. A
rabbit polyclonal anti-14-3-3-gamma or a mouse anti-14-3-3-beta
monoclonal antibody was used. Tau protein in CSF was anal¬
ysed using a previously described enzyme linked immunosorbant
assay (EL1SA) [9] according to the manufacturer's recommendations
(Innogenetics, Belgium). This assay measures both the normal and
hyperphosphorylated forms of CSF tau protein. Concentrations of
CSF tau protein of greater than 1260pg/ml were considered to be
abnormal [8].
CSF S-100b was measured using a previously described sand¬
wich EL1SA |2], Concentrations of CSF S-100b greater than or equal
to 0.50 ng/ml were considered to be abnormal.
Cenotyping for polymorphism at codon 129 of the PRNP gene
was carried out using a previously described method (4).
The sensitivity, specificity, positive predictive value (PPV), neg¬
ative predictive value (NPV) and efficiency for each marker and for
combinations of markers were calculated.
In the 'sCJD < 6-week group' the sensitivities ofall three markers
were similar and ranged from 96% to 98%. Sensitivities were lower in
the 'sCJD> 6-week group' than in the 'sCJD < 6-week group': 86% for
14-3-3 (p = 0.08), 78% for tau protein (p = 0.002) and 92% for S-lOOb
(p = 0.21). Combining the markers together resulted in a reduction
of sensitivity (Table 1).
There are, however, differences in the PRNP codon 129 and
PrP isotype distribution in the two groups of patients. Of the
31 patients in the 'sCJD< 6-week group' 30 were homozygous at
PRNP codon 129 and one was W at PRNP codon 129. In addi¬
tion all of those tested for prion protein isotype (n = 21) were
type 1. Among the 'sCJD > 6-week group' there was greater hetero¬
geneity in PRNP codon 129 distribution and prion protein isotype
(Table 2). Prion protein isotype testing was performed in 109 of
the 'sCJD > 6-week group' patients. Of these 54 (49.5%) were type 1.
41 (37.6%) were type 2 and 14 (12.8%) had both type 1 and type 2
present.
Among the 'sCJD group' the sensitivities of all three CSF tests
were lower among codon 129 heterozygotes (14-3-3 p = 0.03; tau
p = 0.08; S-lOOb p = 0.02). Within the MM homozygotes there was
no evidence that test sensitivities differed between the two groups
for 14-3-3 (p = 0.37) or S-100b (p = 0.69). However, there was still
evidence that tau was more sensitive among cases tested before
6 weeks than among those tested after 6 weeks (100% vs 80%.
p = 0.01).
All three tests' sensitivities were lowest in those with type 2
prion protein only and highest in those with type 1 only, though
the differences between type 1 and mixed type 1 /type 2 cases were
small (14-3-3, p = 0.06; tau, p = 0.19; S-100b, p = 0.04). When atten¬
tion was restricted to cases with type 1 prion protein only, a similar
pattern to that observed in MM cases was seen, with similar sen¬
sitivities before and after 6 weeks for 14-3-3 (90% vs 93%, p = 0.76)
and S-lOOb (95% vs 96%, p = 0.83) but a higher sensitivity before 6
weeks than after for tau (100% vs 85%, p = 0.07).
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Table 2
Sensitivity of CSF markers by time of test, codon 129 genotype and prion protein isotype.
CSF marker sensitivity (%) sCJD<6-week group codon 129 status sCJD> 6-week group codon 129 status
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Of all the markers investigated CSF tau protein had the highest
specificity before 6 weeks (82%) while CSF 14-3-3 had a speci¬
ficity of 67% (Table 1). Combining the markers did not improve the
specificity over that of CSF tau protein alone. There were three con¬
trol patientswho had an elevated CSF tau protein; two patients with
AD and one patient with an astrocytoma. All three of these patients
also had a positive CSF 14-3-3. An additional four patients had a pos¬
itive 14-3-3 and the diagnoses in these patients were encephalitis
(2), paraneoplastic syndrome (1) and central pontine myelinolysis
(1). The specificity for the 'sCJD> 6-week group' was 72% for CSF
14-3-3 and 84% for CSF tau protein. The specificity of both tests was
less in the 'sCJD < 6-week group' when compared with the 'sCJD > 6-
week group', although this difference was more marked with CSF
14-3-3 than with CSF tau protein.
CSF S-lOOb was a very sensitive marker for sCJD but had very
poor specificity before 6 weeks (Table 1). The combination of CSF
S-lOOb with either an elevated CSF tau protein or a positive CSF
14-3-3 did not improve the sensitivity of either marker. However
inclusion of an elevated CSF S-lOOb did improve the specificity of
CSF14-3-3.
We found CSF protein markers to be highly sensitive in the early
stages of sCJD. This is in contrast with the findings of other recent
studies [7,8]. The lower sensitivities found by other authors maybe
related to their inclusion of not only cases of sCJD but also patients
with iatrogenic and familial CjD. The sensitivity ofCSF protein mark¬
ers has been reported to be lower in cases of familial and iatrogenic
CJD [5]. This discrepancy highlights the importance of study design
when investigating these CSF proteins. Themostmeaningful results
come from studies where neuropathologically confirmed cases of
sCJD are used. In addition the most reliable and meaningful speci¬
ficity data is obtained by using control patients who are initially
suspected of having sCJD but are subsequently proven to have an
alternative diagnosis.
The patient characteristics in the 'sCJD< 6-week group' and the
'sCJD >6-week group' were markedly different, with a much higher
prevalence of the MM1 subtype in those patients presenting within
6 weeks of symptom onset. This finding mirrors those of earlier
reports of patients with the MMl subtype having a more dramatic
onset ofdisease and more rapid decline. This is likely to lead to such
patients being investigated more promptly than those with a more
insidious onset. CSF protein markers have been reported to be of
higher sensitivity in patients of the MM1 phenotype [5], There are
studies which have shown that the sensitivity of CSF 14-3-3 is not
affected by the timing of a lumbar puncture during disease course
[5,1 ]. Thus the difference in sensitivity between the 'sCJD < 6-week
group' and the 'sCJD> 6-week group' is probably due to the faster
rate of disease progression in the former group when compared to
the latter.
in this limited study we found CSF tau protein to have the
greatest specificity and efficiency in distinguishing sCJD from other
rapidly progressive neurodegenerative conditions. It is unclear why
CSF tau protein should be ofgreater specificity than 14-3-3. The fac¬
tors influencing the release of neuronal proteins in CJD and other
conditions are not fully understood.
Our study is limited by the small numbers of samples analysed
(although these are still greater than those in previous reports [7,8])
and in particular the fact that the 'non-sCJD< 6-week group' was
markedly smaller than either the 'sCJD< 6-week group' and the
'sCJD > 6-week group'.
Diagnostic tests which are reliable in the early stages of sCJD are
necessary for a number of reasons; to guide further investigations
and appropriate management, to inform patients and their families
regarding diagnosis and prognosis, and possibly in the future in
order to ensure prompt treatment. However these tests should be
performed only if a patient is likely to have sCJD on clinical grounds
otherwise the high levels of sensitivity and specificity for sCJD are
lost. Our findings show that CSF 14-3-3, S-lOOb and tau protein have
comparable sensitivity in the early stages of sCJD and are effective
tests in the early stages of sCJD.
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Abstract
Background: Genetic analysis of the human prion protein gene (PRNP) in suspect cases of Creutzfeldt-Jakob
disease (CJD) is necessary for accurate diagnosis and case classification. Previous publications on the genetic
variation at the PRNP locus have highlighted the presence of numerous polymorphisms, in addition to the well
recognised one at codon 129, with significant variability between geographically distinct populations. It is
therefore of interest to consider their influence on susceptibility or the clinico-pathological disease phenotype.
This study aimed to characterise the frequency and effect of PRNP open reading frame polymorphisms other than
codon 129 in both disease and control samples sourced from the United Kingdom population.
Methods: DNA was extracted from blood samples and genetic data obtained by full sequence analysis of the
prion protein gene or by restriction fragment length polymorphism analysis using restriction enzymes specific to
the gene polymorphism under investigation.
Results: 147 of 166 confirmed cases of variant CJD (vCJD) in the UK have had PRNP codon 129 genotyping and
all are methionine homozygous at codon 129; I 18 have had full PRNP gene sequencing. Of the latter, 5 cases have
shown other polymorphic loci: at codon 219 (2, 1.69%), at codon 202 (2, 1.69%), and a 24 bp deletion in the
octapeptide repeat region (I, 0.85%). E2I9K and D202D were not found in sporadic CJD (sCJD) cases and
therefore may represent genetic risk factors for vCJD.
Genetic analysis of 309 confirmed UK sCJD patients showed codon 129 genotype frequencies of MM: 59.5% (n
= 184), MV: 21.4% (n = 66), and W: 19.1 % (n — 59). Thirteen (4.2%) had the A117A polymorphism, one of which
also had the P68P polymorphism, four (1.3%) had a 24 bp deletion, and a single patient had a novel missense
variation at codon 167. As the phenotype of this latter case is similar to sCJD and in the absence of a family history
of CJD, it is unknown whether this is a form of genetic CJD, or simply a neutral polymorphism.
Conclusions: This analysis of PRNP genetic variation in UK CJD patients is the first to show a comprehensive
comparison with healthy individuals (n = 970) from the same population, who were genotyped for the three most
common variations (codon 129, codon I 17, and 24 bp deletion). These latter two genetic variations were equally
frequent in UK sCJD or vCJD cases and a normal (healthy blood donor) UK population.
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Background
At the time of this study, there were 166 confirmed cases
ofvCJD in the IJ K, and a further 44 patients in other coun¬
tries. (For current UK and worldwide figures see http://
www.cid.ed.ac.uk) The widely accepted hypothesis is that
vCJD was initially acquired through dietary infection with
bovine produce contaminated with the infectious agent of
bovine spongiform encephalopathy (BSE) [1,2]. Addi¬
tionally, secondary cases have resulted from blood trans¬
fusion [3,4]. The proposed agent (designated a 'prion')
has not been fully characterised but disease and infectivity
are generally associated with an abnormally folded form
(designated PrPSc) of the host encoded prion protein
(PrPc) [5j. Variant CJD shows marked differences in clin¬
ical presentation [6] and neuropathology [7] when com¬
pared with sporadic CJD (sCJD) which has a worldwide
distribution affecting approximately 1-2 cases per million
population per year and has an unknown aetiology. In
comparison to sCJD, vCJD typically occurs in younger
individuals (median ages of onset: 66 & 26 years respec¬
tively) and with a longer disease duration (median dura¬
tions: 4 and 14 months respectively). There are two other
forms ofCJD: genetic and iatrogenic. Genetic CJD (gCJD)
is an autosomal dominant inherited illness related to
underlying mutations of the prion protein gene (PRNP).
There are other genetic human prion diseases (Fatal
Familial Insomnia (FFI), and Gerstmann Straussler
Scheinker syndrome (GSS)) traditionally separated from
gCJD on clinico-pathological grounds, but which are
related by certain common core features and an underly¬
ing causal PRNP mutation. Iatrogenic CJD (iCJD) results
from the accidental person-to-person (medical or surgi¬
cal) transmission of other forms of CJD.
Genetic analysis of the sCJD and vCJD disease cohort has
an important role in accurate diagnostic classification,
especially as genetic prion disease cannot always be differ¬
entiated clinically from other forms of prion disease and
a family history is absent in up to about 50% of cases [8].
The gene coding for prion protein, PRNP, is a key target
for analysis. This gene is highly conserved between mam¬
malian species indicating an important biological role for
the prion protein, but PRNP shows significant variation at
the individual level in humans [9]. Over twenty missense
and nonsense mutations have been identified in the open
reading frame (ORF) that have been linked to genetic
prion disease phenotypes [10]. Other polymorphic sites
in PRNP (over twenty examples) that are not directly
linked to a disease phenotype have been identified
through analysis of suspected CJD cases and other popu¬
lations. These polymorphisms may have disease modulat¬
ing capacities and these effects may vary according to the
population under investigation. The conversion ofPrlx; to
PrPSc is thought to involve some form of oligomerisation
and the melting and refolding of the peptide chains. It is
therefore possible that any changes to the amino-acid
sequence could alter the thermodynamic stability of the
protein and affect the kinetics of structural conversions
[11].
The PRNP polymorphic residue at codon 129 (ATG-
methionine to GTG-valine, Ml29V) has been studied
extensively. Variation in the genotype frequencies occurs
according to geographical region. In most countries stud¬
ied, the MM and MV frequencies are approximately 40-
50% however there is a large difference seen in Japan
where the normal population frequencies are: MM 92%,
MV 8%, andW 0% [12]. Genotype data from other coun¬
tries suggest a gradual increase in MM genotype frequency
from West to East which may reflect the historical human
migrations [12]. It has been shown that Ml 29V may affect
susceptibility to prion diseases [13], the incubation
period in acquired forms [14,15] and the clinico-patho¬
logical phenotype [16]. Codon 129 homozygosity is con¬
sidered a risk factor for human prion disease: while ~40%
of the normal population is MM, ~70% of sCJD patients,
and all clinical vCJD patients tested to date have this gen¬
otype [17]. Homozygosity has also been shown to be a
risk factor, and reduces the incubation time, for both
human growth hormone associated iCJD [14] and kuru
[15] (an historical disease of the Fore linguistic tribe of
Papua New Guinea transmitted by endocannibalism). In
some circumstances, the genotype at codon 129 can deter¬
mine the disease phenotype for human genetic prion
cases associated with pathogenic mutations [16]. In addi¬
tion, variation in sCJD clinico-pathological phenotype
can be associated with specific genotypes [18].
The most significant finding with respect to codon 129
genotype and CJD is that all clinically probable and neu-
ropathoiogically confirmed cases of vCJD so far analysed
world-wide (n = 147 UK and 44 non-llK) have the MM
genotype and, therefore, this genotype is categorised as a
risk factor. However, there is evidence that other 129 gen¬
otypes are susceptible to BSE/vCJD infection and that they
may develop disease after a longer incubation period than
in MM individuals. It is hypothesised that MV and W
cases will occur in the future 119]. Fhere are four reports
of transmission of vCJD infection via blood transfusion
from blood donors who later developed vCJD [3,4,20,21],
In three instances, the recipients developed clinical vCJD
and all three were homozygous MM at codon 129. In the
fourth case, there was no clinical or neuropathological
evidence of vCJD in the recipient, but disease-related
abnormal prion protein was found in the spleen and a
lymph node. This individual was MV at codon 129 and
may represent subclinical infection in a non-MM individ¬
ual; it is impossible to know whether the individual
would have developed clinical vCJD if they had lived
longer [21], In addition, two of three samples in an anon-
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ymous appendix study in the IJK that were positive for
deposition of prion disease associated PrPSc were geno-
typed asW [22].
Variation in the DNA sequence of PRNP may be linked to
other genetic changes separate to the prion protein itself,
such as promoter elements or regions more distant to the
PRNP gene. To understand more fully the control mecha¬
nisms ofPRNP gene expression, such as promoter activity,
extensive studies have been undertaken to examine the
region of chromosome 20 adjacent to the PRNP locus [23-
26], Analysis of a 4.8 kb region around PRNP, identified 3
polymorphisms in areas that were predicted to control
gene expression [24].
This study involved the genetic analysis of CJD cases
referred to the National CJD Surveillance Unit during rou¬
tine UK surveillance and a specific project to determine




The Scottish Blood Donor controls (n = 778) were sup¬
plied as 0.5 ml aliquots of frozen whole blood by Dr lan
MacGregor (National Science Laboratory, Scottish
National Blood Transfusion Service) from samples taken
as part of a human prion disease study of blood markers
(covered by Multi-Centre Research Ethics Committee for
Scotland approval, reference MREC/02/10/46). There was
no ethical approval for full PRNP sequence analysis of
these samples.
DNA samples (UK DNA controls, n = 192) were pur¬
chased from the European Collection of Cell Cultures
(ECACC) originating from donors in the UK cities of
Oxford and Birmingham. (Catalogue references: HRC-1
and HRC-2.)
For the normal population data, the Scottish Blood
Donor and UK DNA controls were genotyped for poly¬
morphisms atMl 29V, and A117A, and the 24 bp deletion
in the N-terminus octapeptide repeat region (the three
most common polymorphic loci of PRNP). For the CJD
cases, we had PRNP sequence analysis data on 118 vCJD
and 309 sCJD patients.
Patient Samples
Patient blood samples were taken from individuals under
clinical review for suspected CJD, by venipuncture, into
citrate anticoagulant treated blood collection tubes. Once
received into the laboratory the blood was separated into
its major constituents as follows:
1. Whole blood was spun at 450 g for 10 minutes to
separate platelet rich plasma, buffy coat, and red
blood cells (RBC).
2. Platelets were removed from the plasma by two
washes in phosphate buffered saline (PBS) with cen-
trifugations at 16,000 g leaving platelet poor plasma.
This was stored at -80°C.
3. The buffy coat fraction was cleared of contaminat¬
ing platelets by centrifugation at 180 g for 10 minutes,
then the RBC were removed by lysis with distilled
water and centrifugation at 180 g for 10 minutes.
Finally the buffy coat fraction was washed in PBS then
centrifuged at 100 g for 10 minutes before storing at -
80 °C.
4. The RBC were washed twice with PBS, with centrif¬
ugation at 180 g for 10 minutes each time. RBC were
stored at -80°C as a 50% solution in PBS.
DNA Extraction
DNA from cases and controls was prepared from 200 pi of
frozen whole blood by cell lysis and column purification
using the DNA Blood Mini Kit (Qiagen, UK) and stored at
-20° C.
PCR-RFLP Analysis
Amplification of the PRNP gene sequence (NCB1 Acces¬
sion: AL133396) by the polymerase chain reaction (PGR)
involved forward primer (S'-TGATAC CATTGCTAT GCA
CrcATrC-3') anc( reverse primer (5'-C,AC ACC ACC ACT
AAA AGG GCT GCA G-3') at 5 pinoles each per reaction
(Eurofms MWG Operon, Germany), that are specific for a
956 bp sequence. Each reaction contained 2 mM MgCl2
(Qiagen, UK), 0.2 mM dNTPs (Promega, UK), and 1 Unit
ofTaq Polymerase (HotStarTaq, Qiagen, UK). The ther¬
mal cycling program included an annealing temperature
step-down from 65 °C to 60°C over ten cycles followed by
30 cycles at 60°C.
Confirmation of the codon 129 genotype was performed
by restriction enzyme digestion at 37°C with Nspl (New
England Biolabs, UK). This enzyme cleaves the amplicon
at PRNP codon 155 and at codon 129 only when the latter
sequence codes for valine (-GTG-). This allowed for dis¬
crimination of the three genotypes: MM, MV, and W by
agarose gel electrophoresis and ethidium bromide stain¬
ing, Figure 1. The presence of a 24 bp deletion in the
octapeptide repeat region could be observed from the
codon 129 genotyping agarose gel data due to an addi¬
tional band shift for the restriction enzyme digest prod¬
ucts. Codon 117 polymorphism genotype was
determined by restriction enzyme digestion of the same
PRNP PGR product with PvuII (New England Biolabs,
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A: Polymorphism M129V
Mw MV MM VV
B: Polymorphism A117A
Mw WT WT MUT
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Figure I
Detection of PRNP polymorphisms. Panels A and B: Genotyping by PCR amplification of PRNP and restriction enzyme
digest. (Mw: 100 bp molecular weight ladder (dark band 600 bp); MV, MM, W: codon 129 genotypes; WT: wild-type codon
I 17 genotype; MUT: heterozygous for codon I 17 polymorphism) Panels C, D, and E: Electropherograms for polymorphisms
detected by sequence analysis. (Arrows point to heterozygous base position.)
UK) at 37 °C. This enzyme cleaves the wild-type PCR
product and not the codon 117 variant. In samples heter¬
ozygous for the codon 117 polymorphism this enzyme
produces digest products of sizes 499 and 457 in addition
to the full length 956 bp PCR amplicon. (Figure 1)
Sequencing
If consent from the patient, or relative, had been obtained
for full genetic analysis then the PCR product was
sequenced by fluorescent dye-primer chemistry (Thermo
Sequenase Primer Cycle Sequencing Kit, Amersham Bio¬
sciences, UK) using an ALF-Express DNA Sequencer
(Amersham Biosciences, UK). PCR products were purified
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using a QIAquick PGR Purification Kit (Qiagen, UK) to
remove excess printers and other PCR reagents. Four Cy5
labelled sequencing primers were used to give at least 2-
fold coverage of the entire ORF (5'-AGG TGG CAC CCA
CAG 'FCA GT-3'; 5'-CTATGC ACT CATTCATEATG-3'; 5'-
CCT CAA GCT GGA AAA AGA TTA G-3'; 5'-CGA TAG TAA
GGGTGCTGATA-3'). Sequencing reaction products were
electrophoresed through ReproGel Long Read acrylamide
gels (Amersham Biosciences, UK). ALFwin Software
(Amersham Biosciences, UK) was used to align the
sequence data with a reference sequence and each codon
of the ORF was visually checked by two individuals. This
method allows for identification of novel polymorphisms
rather than only checking for known ORF sequence
changes. (Figure 1)
Statistical Analysis
Analysis was undertaken through the use of R (v2.9.1) (R
Development Core Team (2009). R: A language and envi¬
ronment for statistical computing. R Foundation for Sta¬
tistical Computing, Vienna, Austria. ISBN 3-900051-07-0.
URL: http://www.R-proiect.org).
Results
Variant CJD PRNP Sequence Data
Table 1 shows the results of PRNP gene sequence analysis
in vCJD cases where material and specific consent was
available. 147 confirmed cases were genotyped at codon
129 and all were methionine homozygotes (MM). Com¬
plete sequence analysis of the PRNP ORF was performed
for 118 cases and found five individuals with genetic var¬
iation. Two had a synonymous (silent) polymorphism at
codon 202 (GAC-aspartic acid to GAT-aspartic acid;
D202D), two had a non-synonymous change at codon
219 (GAG-glutamic acid to AAG-lysine; E219K), and one
had a 24 bp deletion (classified as DelR34 according to
[27]). The DelR34 and the two D202D patients fulfilled
the diagnostic criteria [28] for definite vC)D. The two
patients with E219K genotype did not have a post mortem
and were classified as probable vC)D. The E219K muta¬
tion has not been seen in white Caucasian populations
and has so far only been detected in populations from
Asian and the Pacific [29], The two individuals with the
E219K genotype found in this study were not of white
Caucasian origin (the specific ancestral origin is
unknown).
Sporadic CjD Sequence Data
Sequence variation for 309 confirmed sCJD patients is
shown in Table 2. Codon 129 genotyping produced allele
frequencies similar to that expected for this disease from
other studies [13,18] and to the overall figures published
by the UK National CJD Surveillance Unit (MM 63%, MV
19%, VV 18%; n = 647) (http://www.cid.ed.ac.uk: Annual
Report 2008). Complete sequence analysis on these
patients found thirteen with the silent polymorphism at
codon 117 (GCA-alanine to GCG-alanine; A117A), which
included one individual with an additional silent poly¬
morphism at codon 68 (P68P), and four cases with a 24
bp deletion in the octapeptide repeat region. Of these 17
patients 13 were classified as definite and four as probable
sCJD according to the diagnostic criteria. In addition, one
patient was found to have a non-synonymous polymor¬
phism at codon 167 (GAT-aspartic acid to GGT-glycine;
D167G). There was nothing in the clinical phenotype sug¬
gesting that this could be a causative mutation of gCJD
and the patient was classified as probable "sporadic CJD".
Neuropathological analysis confirmed sporadic CJD with
type 1 prion protein isoform present, and genetic analysis
showed methionine homozygosity at codon 129 ofPRNP.
Control Codon 129 Genotype Data
Codon 129 genotype frequencies are given in Table 2 for
samples from the UK DNA and Scottish Blood Donor
Table I: PRNP gene sequence variation in vCJD cases
Codon Number Tested Genotype Data
129 (Met/Val) 147 All cases MM
4 (blood transfusion associated infections) MM (n = 3)
MV (n = 1)*
2 (appendix tissue) W (n = 2)**
202 (Asp/Asp) 118 DD (n = 2)
219 (Glu/Lys) 1 18 EK (n = 2)
24 bp deletion 1 18 DelR34 (n = 1)
* Non-clinical, non-neuropathologically confirmed case
** From anonymous screening program for vCJD associated PrPSc deposition
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Table 2: PRNP gene sequence variation in sCJD cases and controls
PRNP Variation 309 sCJD Patients 192 UK DNA Controls 778 Scottish Blood Donor Controls
Codon 129 (Met/Val) MM (n = 184; 59.5%) MM (n = 90; 46.9%) MM (n = 337:43.3%)
MV (n = 66; 21.4%) MV (n = 87; 45.3%) MV (n = 344; 44.2%)
VV (n = 59; 19.1%) VV (n = 15: 7.8%) W (n = 97; 12.5%)
Codon I 17 (Ala/Ala) n = 13; 4.2%
(10.4% of MV/VV cases)
n = 9; 4.7%
(10.3% of MV/W cases)
n = 47; 6.0%
(10.7% of MV/W cases)
24 bp Deletion n = 4; 1.3%
Deletion Class
R34 (n = 3)
R3 (n = I)
n = I; 0.5%
Deletion Class
R2 (n = I)
n = 12; 1.5%
Deletion Class
R34 (n = 12)
Codon 167
(Asp/Gly)




PP (n = I; 0.32%) (no sequence data available) (no sequence data available)
controls. Together with the published Edinburgh/Belfast
blood donors, the figures are similar across the three
groups and combined (n = 1158) give the predicted UK
national genotype frequencies of 44.1% (MM), 44.5%
(MV), and 11.4% (W). As there is a significant difference
in age at onset between vCJD and sCJD, and that gender
may influence sCJD survival [30], the Scottish Blood
Donor data was stratified into four groups according to
age (17-30, 31-40, 41-50, and 51-69), Figure 2, and by
sex, Figure 3. Statistical analysis (Chi-Squared test) indi¬
cated that there were no age (p = 0.5774, 0.1270, and
0.4781) or gender (p = 0.2228, 0.9884, and 0.7527)
effects determined by genotype at codon 129, or 117, or
by the presence of a 24 bp deletion, respectively.
Statistical Comparison (Chi Squared Testing) of Control
and Case Data
Comparisons made between codon 129 genotype fre¬
quencies for sCJD, vCJD, and the two control groups
showed statistically significant differences (P < 0.001,
Table 3). There was no significant difference in genotype
between the two control groups. There was no selection
bias for the sequenced sCJD patients as there was no sig¬
nificant difference between that group and the larger
group of UK National C|D Surveillance Unit sCJD
patients that have been genotyped.
The frequencies ofA117A and 24 bp deletion were not sta¬
tistically different from the control data.
Analysis of the genotype frequencies of D202D and
E219K could not be done as theywere only found in vC)D
and not in the controls, as the latter were not sequenced.
Discussion
Analysis of PRNP in sCJD, vCJD and controls has high¬
lighted the clear primary role in disease susceptibility for
the codon 129 genotype and has provided a base-line for
the healthy population for future vCJD susceptibility pre¬
dictions. In addition, the presence of genetic variation
(D202D and E219K) in vCJD that is not seen in sCJD sug¬
gests possible additional risk factors. A novel non-synon¬
ymous polymorphism (D167C,) in a case of suspected
sC)D has also underlined the need for PRNP genetic
screening of patients.
For accurate diagnosis of the various forms ofhuman CJD,
and especially to identify inherited genetic forms, DNA
sequence analysis of the PRNP open reading frame (ORF)
is necessary. Aside from the detection of any pathogenic
mutations, this provides data on any polymorphic resi¬
dues present, important for full characterisation of non-
genetic cases [18]. The majority of non-pathogenic poly¬
morphisms are rare.
Codon 129 genotype frequency data show the clear differ¬
ence between CJD cases and controls with a reduction in
the frequency of MV (21.4%) for sCJD cases compared to
the controls (~45%), and 100% MM cases in vC)D. As the
control genotype frequencies were not found to vary by
age the case data is unlikely to be due to the significant dif¬
ference in average age at onset between vCJD and sC)D. If
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Figure 2
PRNP polymorphisms in Scottish Blood Donors. Codon 129 and PRNP polymorphism frequency in relation to age of







Codon 129 and sex of Scottish Blood Donors. Codon 129 genotype frequency in relation to sex of Scottish Blood
Donors (n = 778, male = 456 (solid bars), female = 322 (hatched bars)).
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Table 3: Statistical analysis of PRNP polymorphism frequencies
Chi-Squared Test •■ P value
Comparison Codon 129 Codon117 24 bp Deletion
Sequenced sCJD (n = 309) vs.
All NCJDSU sCJD cases (n = 647)
0.582 NA NA
UK DNA Controls (n = 192) vs.
Scottish Blood Donors (n = 778)
0.185 0.584 0.452*
Sequenced sCJD (n = 309) vs.
UK DNA Controls (n = 192)
<0.001 0.975 0.700*
Sequenced sCJD (n = 309) vs.
Scottish Blood Donors (n = 778)
<0.001 0.295 0.978*
Sequenced vCJD (n = 118) vs.
Scottish Blood Donors (n = 778)
<0.001 NA 0.861*
*: Chi-Squared approximation may be incorrect due to low numbers; NA: no comparison could be made
clinical vCJD continues to manifest only in MM genotype
individuals then the mathematical models for predicting
the total epidemic size can use the population MM fre¬
quency of 44.1% in the UK population, generated by this
study.
Other than Ml 29V the two most common PRNP variants
in Caucasian populations are: A117A (frequency ~5%),
and a 24 bp deletion in the repeat expansion region
(~1%). Full PRNP sequencing of 118 confirmed UK vCJD
patients found five with PRNP polymorphisms: two with
E219K, two with D202D, and one with a 24 bp deletion
(DelR34). The codon 117 polymorphism has not been
found, as this is linked to the valine allele at codon 129,
and all vCJD cases to date have been 129-MM.
D202D is a synonymous polymorphism and therefore
there is no resulting change in prion protein amino acid
sequence. No data are available on normal population
frequency and the only record of its appearance has been
in single French cases of sCJD and iCJD related to human
Growth Hormone treatment (Dr N Delasnerie-Laupretre -
personal communication). There are no structural
changes to the prion protein itself and so this DNA
sequence alteration would not directly affect protein fold¬
ing kinetics in a potentially disease causing manner. Mis-
sense DNA sequence change GAG (glutamic acid) to AAC
(asparagine) at this codon (D202N) is associated with a
disease phenotype of Gerstmann-Straussler-Scheinker
syndrome (GSS) a genetic form of human prion disease
[31]. The D202D change may be linked with a haplotype,
as yet undefined, that alters susceptibility via an alterna¬
tive route such as differential expression of PrP. This may
possibly be the reason why ~2% of tested vCJD cases have
been found with this polymorphism. Until control popu¬
lation frequencies are available this possibility remains
hypothetical.
E219K is a non-synonymous, missense mutation with a
change in amino acid and, therefore, the possibility of
protein structural differences which may be linked to an
increase in disease susceptibility. This polymorphism has
not been found inWestern European populations and has
only been investigated in detail, with regards to CJD, in
japan [32] and Korea [33] where approximately 12% and
8% respectively of the population carry the lysine (K)
allele. These studies indicated that E219K influenced the
clinical phenotype of GSS in cases with the P102L muta¬
tion [34], and found it was a protective factor to sCJD as
no confirmed cases of sCJD in Japan or Korea carry the
polymorphism. In the two vCJD cases found in our study
with E219K, there were no clinico-pathological differ¬
ences from the other vCJD cases. These patients were of
non-Caucasian origin, therefore their genetic ancestry
may originate from populations where E219K is more
common than the UK [29). There remains a possibility
that the presence of this polymorphism may increase sus¬
ceptibility to vCJD. A transgenic mouse model suggests
that the lysine (K) allele PrPcis more susceptible than the
glutamic acid (E) allele to conversion to PrPSc [35].
24 bp deletions were found in healthy individuals, sC)D,
and vCJD patients at similar frequencies. It is therefore
proposed that this genetic variation does not influence the
disease state or susceptibility, even though the PrP(;
formed is significantly different at the metal binding
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domain of the N-terminus, as shown by other studies
[36,371- Deletion of two 24 bp repeats in this region has
been linked to a familial form of C)D [38],
There have been no reported instances of the D167G sCJD
polymorphism associated with familial human prion dis¬
ease. Evidence for this event to be the cause of a genetic
form of CID in this patient is twofold:
1. The replacement of a large hydrophilic amino acid
for a small hydrophobic one may disturb the physical
properties of the prion protein and thus accelerate for¬
mation of the disease associated form (PrPSc).
2. Transgenic mouse studies propose that codon 167
may be in a region of the prion protein structure where
chaperone molecules bind and accelerate disease
transmission [39J.
Without the additional evidence of further affected mem¬
bers of the family with the mutation or data on a healthy
control population there is no direct proof of the associa¬
tion of D167G and CjD.
Conclusions
This study has produced genotype frequencies for the
most common PRNP genetic variants in the largest cohort
of healthy individuals from the UK so far published, and
in groups of patients with vC)D and sCJD. These data can
act as a benchmark for studying the genotype frequency
variation found in human prion disease in the UK. DNA
sequence analysis ofvC]D patients has revealed the extent
of genetic variation within this population to include
potential new risk factors, and sCJD analysis has uncov¬
ered a novel PRNP polymorphism.
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